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Outline of the thesis 
 
Bilirubin is an orange pigment that is produced by the breakdown of heme 
by heme oxygenase (HO). In daily clinical practice elevated bilirubin levels 
and the associated yellow discoloration of the skin (jaundice) are 
traditionally associated with diseases that either increase the supply of heme 
or impair the conjugation and subsequent excretion of bilirubin by the 
hepatobiliary tract. In biomedical research however there is also a long 
history on the potential health benefits of bilirubin. Likewise HO-activity is 
known for its versatile protective properties. HO is the rate-limiting enzyme 
in the breakdown of heme that by breaking down heme generates biliverdin, 
carbon monoxide and iron. Biliverdin is then directly converted to bilirubin 
by biliverdin reductase. Both bilirubin and HO-activity have been shown to 
possess important anti-oxidant and anti-inflammatory properties and 
consequently possible therapeutic potential in a variety of disorders, 
including metabolic syndrome (MetS), type 2 diabetes mellitus (T2DM), 
cardiovascular disease (CVD) and sepsis. Despite the overwhelming amount 
of promising preclinical and observational data, experimental human data 
are scarce. This thesis covers different human studies that focus on the 
translation of the promising preclinical therapeutic findings with bilirubin 
and HO in the context of MetS, T2DM, CVD and sepsis. 
Chapter one is a general introduction on the metabolic syndrome, type 2 
diabetes mellitus and cardiovascular disease. It discusses the central role of 
inflammation and oxidative stress, and the pathophysiology of insulin 
resistance and endothelial dysfunction. Besides, preclinical and 
observational data on the therapeutic potential of both bilirubin and HO-1 
activity are summarized for the scope of MetS, T2DM and CVD. It concludes 
with a short overview of the human pharmacology of HO-1 and bilirubin. 
The experimental studies that were performed are discussed in chapters two 
to six. In chapter two, we describe a translational controlled cross-over 
study in subjects with MetS. In this study 14 subjects with MetS were 
6  
 
treated with a heme arginate infusion on day 1 and 3. We evaluated the 
impact on parameters of HO-1 induction, endothelial function and insulin 
sensitivity. Chapter three includes the findings of an observational study in 
which we examined the relationship between basal plasma bilirubin 
concentrations and several measures of subclinical atherosclerosis in both 
the general study population of Nijmegen Biomedical Study (n=1463) and a 
subpopulation of subjects meeting MetS criteria (n=487). In chapter four, 
we describe a translational placebo-controlled cross-over study in 16 
subjects suffering from T2DM in which we evaluated the impact of a short 
term atazanavir-induced hyperbilirubinemia on endothelial function. 
Chapter five embraces the same model and aims at the evaluation of a 
short-term atazanavir-induced hyperbilirubinemia on the inflammatory 
response evoked by lipopolysaccharide (LPS) administration to healthy 
volunteers. Chapter six is directed to the re-introduction of bilirubin for 
human use. Supported by an overview of former studies on the human 
parenteral use of bilirubin, it discusses a pharmacokinetic and safety study 
in healthy volunteers on the intravenous and intra-arterial administration of 
bilirubin. 
Chapter seven includes the general discussion of our findings and 
associated future perspectives. Chapter eight summarizes the thesis. 
  
 Chapter 1 
 
General introduction 
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Metabolic syndrome (MetS), type 2 diabetes mellitus 
(T2DM) and cardiovascular disease 
 
MetS is by definition characterized by a combination of cardiovascular risk 
factors including overweight, hypertension, dyslipidemia, and insulin 
resistance (1). Due to the gradual development of a relative insulin deficit by 
both increasing insulin resistance and declining insulin production, subjects 
with MetS are at risk to develop overt hyperglycemia (2). In parallel, the 
clinical picture gradually develops from the MetS, in which glucose levels are 
hardly affected, to T2DM, in which both fasting and postprandial glucose 
levels are markedly elevated. Yet prior to the development of T2DM, subjects 
at risk can be identified by plasma glucose levels that exceed the normal 
range but do not meet T2DM criteria (3). Several names are used to describe 
this entity, including “intermediate hyperglycemia”, “prediabetes”, and “high-
risk state of developing diabetes”. Similar to MetS, hyperglycemia in T2DM is 
accompanied by additional cardiovascular risk factors, including obesity (in 
62% of cases), hypertension (77%), and dyslipidemia (74%) (4). 
The global health burden of MetS and T2DM is huge and increasing (5). The 
increasing global population, their growing prosperity and their consequent 
changes in life style and diet are contributing to an epidemic of obesity, 
which is the main risk factor of MetS and T2DM. For individuals aged 45 
years, recent data from a large prospective cohort study in the Netherlands 
demonstrate a remaining lifetime risk of 49% to develop prediabetes and 
31% to develop T2DM (6). Worldwide, conservative estimations of the 
International Diabetes Federation indicate an increase in subjects with 
diabetes from 366 million in 2011 to 552 million in 2030 (7).  
Every seven seconds, diabetes and its complications cause one death 
worldwide (5). The majority of morbidity and mortality associated with MetS 
and T2DM is caused by cardiovascular complications (8). Apart from the 
traditional risk factors that accompany MetS and T2DM, it should be 
mentioned that several other risk factors including physical inactivity, 
cigarette smoking, and a positive family history, substantially contribute to 
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the individual cardiovascular risk (9). In addition to the stimulation of 
lifestyle changes, current preventive strategies in the context of MetS and 
T2DM mainly focus on pharmacologic reduction of individual risk factors, 
including hypertension, hyperglycemia, and dyslipidemia. Indeed, long-term 
intensive multifactorial treatment has shown to reduce the risk of both 
macro- and microvascular incidents by about fifty percent (10). In 
accordance, a decline in excess mortality has been observed over the last 
decades in most (11-13), but not all observational studies (14). Nevertheless, 
the remaining risk is still doubled compared to subjects without T2DM (11, 
15). Intensification of treatment strategies for hypertension (16), 
hyperglycemia (17), and hypercholesterolemia (18) unfortunately do not 
improve cardiovascular outcome. For hyperglycemia in fact, lowering of the 
target level for glycosylated hemoglobin was even associated with an increase 
in overall mortality (17). In addition, early screening and immediate start of 
an intensive ten year treatment of cardiovascular risk factors did not show 
any additional improvement of cardiovascular outcome (19). 
In summary, current treatment strategies focus on changes in lifestyle and 
the treatment of individual risk factors. Unfortunately, this does not 
normalize the increased cardiovascular risk of subjects with T2DM, but 
decreases it by only 50%. Neither intensification nor earlier initiation of 
these approaches has led to a further reduction of cardiovascular risk. As 
such, there is a need for additional treatment strategies. 
 
 
The central role of inflammatory and oxidative stress 
in cardiovascular disease 
 
Obesity-related adipocyte dysfunction and consequent adipose inflammation 
are central in the development of MetS, T2DM and their cardiovascular 
complications (20). Though initially regarded simply as a chronic activation 
of the innate immune system, both the innate and the adaptive immune 
system appear to be involved (21). Their immunological interplay is complex 
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and beyond the scope of this introduction, but reviewed by others (21). In 
short, excess of nutrients trigger intra-cellular signaling cascades in 
adipocytes. This results in the activation of pro-inflammatory transcription 
factors such as NF-κB, c-Jun and p38 and culminates in the production of 
pro-inflammatory cytokines such as TNF-α and IL-1. Transcription factor 
activation is mediated by serine kinases such as IκB kinase (IKK), c-Jun N-
terminal kinase (JNK) and p38 MAP kinase (p38 MAPK). Reactive oxygen and 
nitrogen species (RONS) fulfil the role of second messenger in inflammatory 
intra-cellular signaling cascades (22, 23). Several studies have demonstrated 
an association between body mass index (BMI) and systemic levels of 
oxidative stress in humans (24, 25). In several animal models of obesity, 
adipose tissue appears to be the main source of oxidative stress (26). 
As free radicals, reactive oxygen and nitrogen species (RONS) are atoms, 
molecules or ions that possess an unpaired electron. Examples include 
superoxide anions (O2-), hydrogen peroxide (H2O2), hydroxyl radicals (OH˙), 
nitrogen oxide radicals (NO˙), and peroxynitrite (ONOO-). An important 
cellular source of free radical production are superoxide producing NADPH 
oxidases (NOXs). The NOX family consists of several isoforms, which are all 
dedicated to the production of superoxides (27). Free radicals can be also 
abundantly produced by nitric oxide synthase (NOS) (28). Under normal 
conditions, NOS produces nitric oxide (NO), which exerts many beneficial 
effects. Exposed to superoxides, however, NO is converted into the highly 
reactive ONOO- that interferes with BH4, a crucial co-factor of NOS. Upon 
this so-called uncoupling of NOS, the enzyme switches from production of 
NO to superoxides. As such, NOS amplifies the redox signaling by NOX. 
Notably, the production of RONS in MetS and T2DM may not be exclusively 
due to inflammatory activation of adipose tissue. Several additional triggers 
for ROS production have been proposed, including an oversupply of 
nutrients to the mitochondria and elevated levels of angiotensin II (AngII) 
and oxidized low-density lipoprotein (oxLDL) (29). 
Though important as second messengers in redox-sensitive signaling 
pathways, RONS easily react with proteins, lipids, carbohydrates and nucleic 
acids. Not surprisingly, cells have many mechanisms to protect themselves 
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against oxidative damage, including anti-oxidant enzymes such as heme 
oxygenase (HO), glutathione peroxidase, catalase, and superoxide dismutase, 
and anti-oxidants such as bilirubin, vitamin E, vitamin C, and glutathione. 
The expression of many anti-oxidant enzymes is regulated by transcription 
factor Nrf2 (30). In the unfortunate coincidence that protective anti-oxidatn 
systems are overwhelmed by high intracellular RONS levels, a so-called loss 
of redox balance may cause oxidative stress. The consequent cellular 
dysfunction contributes to several human diseases, including MetS, T2DM, 
and atherosclerosis.  
 
Measurement of oxidative stress in plasma 
Theoretically, the presence of oxidative stress can be measured in 
several ways (31, 32). The determination of plasma levels of free 
radicals itself is quite difficult given their highly reactive nature and 
consequent short half-life. Besides, levels of oxidants do not provide 
insight into the total redox balance. The same applies to anti-oxidant 
levels, although they can be measured more easily. In contrast, plasma 
levels of stable endproducts of oxidative stress do provide information 
with regard to the redox balance. Examples of such products are 
oxidized low density lipoprotein (oxLDL), F2-isoprostanes, and 
malondialdehyde (MDA), which is often measured by the  thiobarbituric 
acid reactive substances (TBARS) assay. TBARS and F2-isoprostanes 
stem from the peroxidation of lipids and phospholipid bound 
arachidonic acid, respectively. 
Another way to estimate the plasma redox state, is the assessment of 
total anti-oxidant capacity (TAC). Many assays of TAC have been 
developed, including the ferric-reducing ability of plasma (FRAP), as 
used in our studies. It should, however, be noted that TAC assays do 
not incorporate the activity of anti-oxidant enzymes or metal binding 
proteins, therefore, not all anti-oxidants and oxidants present in 
plasma determine the outcome (33). 
 
 
1
General introduction
12  
 
The FRAP assay 
Two of the studies described in this thesis have used the FRAP assay 
(34). In short, this method determines the net ability of plasma to 
convert Fe3+ to Fe2+. Due to complex formation with tripyridyltriazine 
(TPTZ), the reduction of Fe3+ to Fe2+ induces a blue coloring of the 
solution, which can be quantified spectrophotometrically. Anti-oxidants 
that influence the outcome of the FRAP assay include vitamin C, 
vitamin E, uric acid, and bilirubin. 
 
 
Insulin resistance 
 
Insulin resistance is a key feature of MetS and T2DM. Being the major 
regulator of energy metabolism, insulin orchestrates the use and storage of 
glucose and lipids. Binding of insulin to its receptor activates the release of 
several different insulin receptor substrates (IRS) and associated signaling 
cascades. A detailed discussion of the insulin signaling cascade is beyond 
the scope of this introduction, but has been provided by others (35). The 
same applies to an overview of all possible pathways involved in insulin 
resistance (36).  
The first association of inflammation and insulin resistance was based on 
the observation that administration of TNF-α increases glucose levels (37). 
Numerous experiments on the role of the immune system in the development 
of insulin resistance have been published since (38). In summary, exposure 
to TNF-α is accompanied by redox-sensitive activation of serine kinases in 
the natural negative feedback loop of the insulin signaling cascade. Due to 
consequent excessive inactivation of IRS proteins by these serine kinases, 
signaling is hampered and resistance to insulin occurs. The central role of 
serine kinases in the development of insulin resistance has been reviewed 
(29, 39). Like in adipose tissue, inflammatory activation of macrophages also 
induces insulin resistance in the liver. 
1
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Apart from TNF-α, any other factor that activates the inflammatory signaling 
pathways may contribute to the development of insulin resistance. For 
example, oxidative stress has been shown to cause insulin resistance in two 
different preclinical models (40). Apart from serine kinase-mediated 
inactivation of the IRS complexes, cytokines also appear to affect the gene 
expression of several proteins that are related to glucose metabolism. An 
important example is the reduced expression of GLUT-4 and PPAR-gamma 
upon the exposure to TNF-α. 
  
Measurement of insulin sensitivity 
The hyperinsulinemic glucose clamp technique is considered the gold 
standard amongst the various measures of insulin sensitivity (41, 42). 
Its rationale is based on the creation of a steady-state 
hyperinsulinemia by continuous infusion of supra-physiological 
amounts of insulin. As a result, hepatic glucose production will be 
suppressed and the uptake of glucose by skeletal muscle and adipose 
tissue increased. During the infusion of insulin, subjects are 
simultaneously treated with adjustable rates of glucose infusion to 
counteract the tendency towards hypoglycemia. Based on the concept 
that the amount of glucose required to maintain euglycemia directly 
relates to the biological impact of insulin, the individual insulin 
sensitivity is reflected by total glucose disposal normalized to body 
weight.  
Another frequently used measure of insulin sensitivity is the HOMA-IR, 
which relates to the ratio of fasting insulin and glucose levels in 
plasma (43). In contrast to the hyperinsulinemic glucose clamp 
technique, this relatively simple method reflects hepatic rather than 
peripheral insulin resistance. 
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Endothelial dysfunction 
 
Activation of the endothelium is a vital element of the normal inflammatory 
response. It enables the adjustment of blood flow, thrombocyte aggregation, 
and the migration of leukocytes. Nevertheless, inappropriate and chronic 
activation, often referred to as endothelial dysfunction, is associated with the 
development of cardiovascular disease (44-48). In fact, endothelial 
dysfunction is one of the earliest signs of cardiovascular detriment due to 
MetS and T2DM. As for insulin resistance, multiple pathogenic factors and 
pathways have been suggested (49, 50). For the context of this thesis, we will 
focus on the contribution of inflammation, oxidative stress, and the crucial 
role of NOS. 
Endothelial NOS (eNOS) is a key regulator of endothelial and thus vascular 
function (28). Probably the most important inducer of eNOS in nature is the 
natural shear stress produced by blood flow. Alternative triggers include 
acetylcholine, serotonin, bradykinin, adenosine, and vascular endothelial 
growth factor. Normally, eNOS exerts a silencing influence on the 
endothelium by the production of NO. Upon diffusion to the vascular lumen, 
NO diminishes endothelial adhesion of platelets and leukocytes. Diffusion to 
the opposite direction enables NO to inhibit proliferation of the adjacent 
vascular smooth muscle cells (VSMCs). NO also serves a role as potent 
vasodilator as it stimulates soluble guanylate cyclase (sGC) in VSMCs and 
the resulting rise in cyclic guanosine monophosphate (cGMP) causes 
relaxation. 
Although NO is regarded as the key regulator, several other factors are 
known to affect vasomotor activity. For example, vasodilating properties have 
been attributed to prostacyclin and important vasoconstrictors are 
endothelin, AngII, prostaglandin H2, thromboxane A2, and ROS.  
eNOS is crucial during inflammatory activation of the endothelium. As 
discussed before, ROS interfere with an essential co-factor of eNOS, BH4. 
This so-called uncoupling of eNOS impedes NO production and even favors 
ROS production. Due to this metamorphosis, eNOS perpetuates the 
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culminating oxidative stress. This triggers activation of pro-inflammatory 
signaling pathways and the associated switch in endothelial phenotype, 
including increased expression of endothelial adhesion molecules like ICAM-
1, VCAM-1, and E-selectin. Elevated levels of these molecules have been 
demonstrated in both MetS and T2DM (48, 51).  
Many different factors associated with MetS and T2DM are able to trigger 
chronic low-grade inflammatory activation of the endothelium. Nevertheless, 
the production of ROS and the associated uncoupling of eNOS appear to 
constitute an important final common pathway. Whereas some risk factors 
represent a signal that triggers the innate immune system (oxLDL and 
saturated fatty acids), other factors primarily stimulate ROS production with 
subsequent activation of the same inflammatory signaling cascades 
(hyperglycemia and AngII) (52). Besides, several components of 
atherosclerotic plaques, like fibronectin, hyaluronan, and heparin sulfate, 
normally act as signals of tissue damage and thus trigger the innate immune 
system as well (53). Interestingly, erythrocytes appear to be a source of free 
heme and iron in atherosclerotic plaques (54). Both substances oxidize lipids 
and thereby contribute to the pro-oxidant and pro-inflammatory 
environment found in atherosclerotic plaques. 
 
Measurement of endothelial activation and 
(subclinical) atherosclerosis 
Endothelial activation and the subsequent development of 
atherosclerosis can be measured at several levels. At first, 
inflammatory activation of the endothelium is associated with 
increased plasma levels of endothelial adhesion molecules, including 
Von Willebrand Factor (vWF), ICAM-1, VCAM-1, and E-selectin. In 
addition, endothelial activation can be demonstrated in humans by 
measuring forearm bloodflow with venous occlusion strain-gauge 
plethysmography, which exploits the fact that the uncoupling of eNOS 
hampers the NO-dependent vasodilator response to shear stress or 
acetylcholine. As stated, decreased vasodilator responses have been 
demonstrated in human endotoxemia and numerous reports have 
1
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documented an impaired vasodilator response in MetS and T2DM. 
Notably, an impaired vasodilator response has been associated with 
increased cardiovascular risk on the long term. As nearly all current 
treatment strategies that target the traditional cardiovascular risk 
factors have shown to improve endothelial function on the short term, 
plethysmography can be considered as a useful model to estimate 
long-term effects (49). It is ideally suited for short-term proof of 
principle investigations exploring new strategies in the treatment of 
cardiovascular disease. For this thesis, venous occlusion strain-gauge 
plethysmography was used to assess the forearm blood flow in 
response to the intra-arterial administration of acetylcholine. The 
vasodilator response to nitroglycerin, which is independent of 
endothelial function and therefore unaffected by therapies that 
enhance endothelial function, was used as a negative control. 
In addition to the assessment of endothelial function, the presence of 
subclinical atherosclerosis can be demonstrated by a variety of non-
invasive measurements. First, the carotid artery intima media 
thickness (IMT) can be assessed using ultrasound. Second, tonography 
is used to measure the change in diameter of arteries following a blood 
pressure wave. Pulse wave analysis (PWA), computed analysis of this 
change, yields several parameters of arterial stiffness including the 
augmentation index (AIx). In Arterial stiffness can be also estimated by 
the pulse wave velocity (PWV), the speed of the waves through the 
arterial system. Third, impairment of peripheral flow can be quantified 
by the ankle-brachial index (ABI) that represents the systolic blood 
pressure of the ankle divided by the systolic blood pressure of the arm. 
Atherosclerosis is associated with the presence of plaques, a decrease 
of ABI and an increase of plaque thickness, IMT, AIx, PWV and AIx. 
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Bilirubin 
 
Bilirubin is one of the end products of the breakdown of heme. Its molecular 
structure consists of an open chain of four pyrrole-like rings with several 
polar groups (figure 1.1). As all these polar groups are engaged in internal 
hydrogen bonding, bilirubin is hydrophobic by nature and as a result hardly 
soluble in plasma. As a result, nearly all bilirubin in plasma is bound to 
albumin and, to a lesser degree, to high density lipoproteins (55). As the 
hydrophobic character of bilirubin hinders excretion into bile, bilirubin is 
glucuronidated by the liver. This process is catalysed by UDP-
glucuronosyltransferase 1A1 (UGT1A1) and converts bilirubin in a 
hydrophilic conjugate (figure 1.1). 
 
  
Figure 1.1 Unconjugated and conjugated bilirubin 
 
Already in 1954, Von Bernhard reported bilirubin to stabilize vitamin A and 
to prevent the rapid oxidation of linoleic acid (56). In the same paper it was 
postulated that bile pigments could serve as natural anti-oxidants in vivo. 
Only in 1987, this hypothesis was revitalized by a pivotal paper 
demonstrating the anti-oxidant superiority of bilirubin over vitamin E (57). 
Based on the numerous papers that followed, bilirubin is currently well 
recognized for its strong anti-oxidant potential. In vitro, 10 nM bilirubin has 
been demonstrated to protect HeLa cells from cell death by a 10.000-fold 
excess of H2O2 (58). This raises the intriguing and still unanswered question 
of what the exact biochemical mechanism is that provides bilirubin with the 
capability to exert these impressive anti-oxidant effects (59). Several papers 
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have suggested a recycling mechanism in which the reaction of bilirubin and 
superoxides generates biliverdin, which is then reconverted into bilirubin by 
biliverdin reductase (BVR) (58, 60, 61). This hypothesis is attractive as it 
enables bilirubin to continuously act as an antioxidant, but has been 
questioned by others (62, 63). Interestingly, in vitro experiments have indeed 
demonstrated bilirubin to be both a substrate and a regulator of human 
cytochrome P450 2A6 (CYP2A6) (64). CYP2A6 may thereby act as a bilirubin 
oxidase by converting bilirubin to biliverdin, further fueling the theory on a 
recycling mechanism. Importantly, albumin binding does not eliminate the 
anti-oxidant capacity of bilirubin (65, 66). 
Bilirubin as a lipophilic compound particularly prevents lipid oxidation, 
which appears to complement the anti-oxidant activity of the hydrophilic 
tripeptide glutathione (67). Both conjugated and unconjugated bilirubin have 
been demonstrated to prevent LDL oxidation (68). Notably, unconjugated 
bilirubin appears to be almost 30 times more potent compared to an analog 
of vitamin E (69). Apart from the scavenging of free radicals, bilirubin also 
reduces oxidative stress by the inhibition of NOX, which is an important 
source of ROS in the vascular system (70). Suppression of cellular ROS 
production appears to be responsible for the anti-inflammatory effects of 
bilirubin through inhibition of VCAM-1-mediated leukocyte migration (71). 
Accordingly, bilirubin has been shown to suppress the activation of pro-
inflammatory genes and to restore eNOS expression by attenuating oxidative 
stress (72).  
 
 
Heme oxygenase 
 
Heme molecules consist of a heterocyclic organic ring with an iron atom in 
the ferrous (Fe2+) state in the centre (73). As a co-factor, heme is of vital 
importance for the so-called heme proteins. Members of this family have 
diverse biological functions and include hemoglobin, myoglobin, and 
cytochrome P450. If released from heme proteins, free heme is highly 
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cytotoxic due to oxidative and pro-inflammatory effects. To dampen these 
effects in plasma, free heme is primarily bound to hemopexin and has less 
affinity with other proteins, including albumin. 
  
 
Figure 1.2 Breakdown of heme 
 
 
HO is the rate-limiting enzyme in the process of heme catabolism and 
subsequent bilirubin formation (figure 1.2) (74). In three successive 
oxygenation reactions, the enzyme breaks down heme in equimolar amounts 
of carbon monoxide (CO), free iron (Fe2+) and biliverdin. Biliverdin is 
subsequently converted into bilirubin by biliverdin reductase (BVR) (74, 75). 
HO is highly conserved throughout evolution (76) and consists of two 
functional isoforms: HO-1, which is highly inducible and HO-2, which is 
constitutively active mainly in the vascular system and the testes. The basal 
expression of HO-1 is high in the liver and spleen and rather weak in other 
tissues, but can be up-regulated by an imbalance of the intracellular redox 
state due to a variety of pro-oxidative stimuli and other triggers, including 
heme (77), pro-inflammatory cytokines (78), and lipopolysaccharide (LPS) 
(79). 
HO-1 expression is mainly regulated at the transcription level and influenced 
by different signalling cascades and redox-dependent transcription factors 
(80). Key regulator of HO-1 expression is BACH1, which represses 
transcription by binding to the MARE site on the HO-1 promoter. In the 
Heme Biliverdin Bilirubin 
unconjugated 
HO 
CO+Fe2+ 
BVR 
HO : heme oxygena CO : carbon monoxi 
BVR : biliverdin reducta Fe : iron 
UGT 1A 1: UDP glucuronosyltransferas
Bilirubin 
conjugated 
UGT 1 A1 
Heme arginate Atazanavir 
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presence of elevated heme levels, BACH1 dissociates from the HO-1 
promoter thereby facilitating the binding of the activating transcription 
factors such as Nrf2, binding to the same MARE site (80). HO-1 induction 
can also be stimulated by inflammatory stress, in which BACH1/Bach1 
expression is reduced by binding of its mRNA to several microRNAs, 
including the TNF-α inducible miR-155 (81, 82). 
In humans, the extent of HO-1 induction upon stimulation is influenced by a 
(GT)n repeat polymorphism in the HO-1 promoter region (83). Studies on the 
frequency distribution of GT repeats in humans have demonstrated lengths 
varying from 12 to 40 repeats in a bimodal distribution with the main alleles 
being 23 and 30 repeats long. Based on preclinical studies, a length with 
less than 25 repeats is associated with increased HO-1 promoter activity and 
an increased response to various stimuli. Longer repeats have been 
associated with a higher risk of several diseases including cardiovascular 
disease (84) and T2DM (85). Additional research is, however, needed as both 
positive and negative studies on the association between (GT)n repeat 
polymorphism and disease have been published sofar (86). 
Interestingly, human HO-1 deficiency is extremely rare and has been 
reported only twice (87, 88). The symptoms reported include growth 
retardation, anemia, iron deposition, and increased vulnerability to oxidative 
stress and pro-inflammatory stimuli, which is comparable to the phenotype 
of HO-1 knockout mice (89). This underscores the protective nature of HO-1 
in normal physiology.  
Traditionally, the protective effects of HO-1 are attributed to the breakdown 
of cytotoxic heme and the resulting production of CO, Fe2+, biliverdin and 
bilirubin. It should be stated that this is an oversimplification. Under stress 
conditions for example, a truncated and enzymatically inactive part of the 
HO-1 protein can translocate to the nucleus where it influences the 
expression of other cytoprotective genes (90). HO-1 products nevertheless 
exhibit important biological actions, as already mentioned for bilirubin. 
CO is usually regarded as a highly toxic gas. In low concentrations, however, 
CO has many important and beneficial roles in cellular homeostasis as 
reviewed in detail by others (91, 92). In short, CO is able to influence the 
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activity of several heme proteins by binding to their heme group. CO binding 
to sGC and NOS stimulates the production of cyclic GMP and NO, 
respectively, whereas binding to NOX and mitochondrial cytochrome c 
oxidases inhibits the production of ROS. Interestingly, the biological effects 
of CO resemble those of NO in many ways and include vasodilation and the 
inhibition of trombocyte aggregation, leukocyte adhesion, and apoptosis. In 
contrast to NO, CO is more stable because it cannot react with ROS. 
Like CO, many beneficial properties have been attributed to the combination 
of biliverdin, BVR and bilirubin (93). Similar to bilirubin, biliverdin appears 
to have anti-oxidant and anti-inflammatory effects (94). A reasonable 
explanation may be the fast conversion of biliverdin to bilirubin in the 
presence of BVR. Nevertheless, biliverdin has been demonstrated to possess 
anti-oxidant and anti-inflammatory effects by itself. Besides, biliverdin is a 
potent inducer of BVR, of which cumulating data indicate its multiple 
protective roles in inflammation. In addition to the enzymatic generation of 
bilirubin, BVR has also been shown to act as a signalling kinase and 
transcription regulator (94). Fe2+ finally, is toxic in its free form but a potent 
inducer of the expression of ferritin, an iron scavenger with important anti-
oxidant effects (95). 
 
 
Preclinical and observational data on the therapeutic 
potential of bilirubin and HO-1 activity 
 
In view of the general role of oxidative stress and inflammation in human 
disease on the one hand and the powerful anti-oxidant and anti-
inflammatory capacity of bilirubin and HO-1 activity on the other, the 
plethora of preclinical studies on the therapeutic potential of bilirubin and 
HO-1 activity is not surprising. In addition, multiple observational studies 
have tried to quantify the impact of bilirubin levels and HO-1 activity on 
disease incidence and outcome in humans. 
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Preclinical data 
Several animal models of sepsis have proven the efficacy of HO-1 induction 
and the administration of its effector molecules. This is in line with in vitro 
data on the anti-oxidant and anti-inflammatory capacity of HO-1 and its 
effector molecules (96). In rodents for example, HO-1 induction improves the 
disease outcome upon administration of endotoxin (97). Likewise, HO-1 
induction ameliorates the clinical course after cecal ligation and puncture 
(CLP) procedure, i.e. perforation of the cecum allowing the release of fecal 
material and infection into the peritoneal cavity causing an aggravated 
immune response (97). Others have demonstrated that HO-1 induction 
protects against endotoxemia-related ileus (98) and CLP-related acute lung 
injury (99). In addition, the administration of the CO-releasing molecules 
(97), biliverdin (100, 101) and bilirubin (102, 103) have shown to reduce the 
burden of disease in preclinical sepsis models. 
HO-1 induction and its effector molecules appear also effective in the 
treatment of insulin resistance in animal experiments (104). Illustrative is 
the invariable reduction of insulin resistance in different models of obesity 
and T2DM upon HO-1 induction (105-109). This improvement is associated 
with a decrease in glucose levels and a paradoxical rise in insulin levels. In 
addition, HO-1 stimulates the expression of PPAR-γ (110) and vice-versa 
(111) and is associated with increased adiponectin levels (108), which are 
known to interact with PPAR-γ as well. The effects on adiponectin and PPAR-
γ possibly contribute to the finding that HO-1 induction causes a reduction 
in body weight and of subcutaneous and visceral adipose tissue (108, 112, 
113). Chronic HO-1 induction with cobalt porphyrin in obese mice resulted 
in weight reduction, which seemed to be related to increased metabolism 
and locomotor activity (114). In addition to HO-1 induction, biliverdin, which 
in vivo is rapidly converted to bilirubin, attenuated the development of 
hyperglycemia in a mouse model of T2DM (115). Likewise, the 
administration of bilirubin improves insulin sensitivity and reduces 
hyperglycemia in obese mice (116). 
Finally, as reviewed by others, the increase in either bilirubin level or HO-1 
activity has been demonstrated to ameliorate vascular dysfunction in a 
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variety of animal models (93, 117, 118). In rats with streptozotocin-induced 
diabetes, HO-1 activity appeared to protect against diabetes-related vascular 
insults (109, 119) and administration of biliverdin protected endothelial 
function (120). Besides, HO-1 induction reduces the size of atherosclerotic 
plaques in both hyperlipidemic rats and LDL-receptor knockout mice (121, 
122). HO-1 induction and intraperitoneal administration of bilirubin also 
improved endothelial function in high-fat fed LDL receptor knockout mice 
(72). Interestingly, the HO-1 activity appeared to support the bioavailability 
of endothelial NO by the modulation of eNOS expression and activity, by the 
prevention of NO inactivation, and by the substitution for a loss of NO effects 
(123). Recent experiments have elucidated a central role for bilirubin in the 
preservation of NO bioavailability and the improvement of endothelial 
function observed after HO-1 induction in diabetic mice (124).  
 
Observational data 
Several epidemiological studies have been published on the clinical relevance 
and thus the therapeutic potential of the modulation of bilirubin levels and 
HO-1 activity. These studies focused on possible associations between the 
incidence and clinical course of a variety of diseases on the one hand and 
either plasma bilirubin levels or markers of HO-1 activity on the other. 
Besides, associations with genetic polymorphisms that influence bilirubin 
levels or HO-1 activity have been studied. Important examples include the 
UGT1A1 polymorphism associated with Gilberts syndrome and the GT 
repeat polymorphism in the promoter region of HO-1, which is known to 
influence the inducibility of HO-1. 
Observational studies have consistently found an association between 
insulin resistance and both the HO system and bilirubin. Elevated HO-1 
plasma levels were observed in subjects suffering from T2DM (125). Besides, 
impaired inducibility of HO-1 by a long GT repeat in the HO-1 promoter 
region was related to an increased risk of developing T2DM (85). In addition, 
bilirubin plasma levels have been inversely associated with the risk to 
develop both MetS (126, 127) and T2DM (128). In accordance, the Gilbert 
syndrome protects against MetS (129). Using Mendelian randomization, 
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causality of the statistically significant association between bilirubin 
concentrations and new-onset T2DM was suggested recently (130).  
Multiple epidemiological studies have examined the relationship of bilirubin 
plasma concentration with cardiovascular morbidity and mortality. These 
studies were pooled in two independent meta-analyses that both 
demonstrate a significant inverse association between bilirubin levels and 
cardiovascular disease outcome, independent of established cardiovascular 
risk factors (131, 132). On average, a 2-fold increase of plasma bilirubin 
concentration is associated with a 10% reduction of cardiovascular risk 
(132). For subjects with the Gilbert syndrome, improvement of endothelial 
function and lower levels of oxidative stress were found (133), along with less 
T2DM-related complications (134) and only a third of the usual 
cardiovascular mortality risk (135, 136). Despite the findings on the 
beneficial impact of bilirubin in preclinical experiments, the causality of the 
inverse association between bilirubin concentrations and cardiovascular 
disease has been questioned by two large genetic studies using Mendelian 
randomization (137, 138). For the (GT)n polymorphism in the HO-1 promoter 
region, both positive and negative studies have been published on the 
relationship with cardiovascular disease (139). 
To conclude, numerous preclinical experiments on HO-1 induction and 
hyperbilirubinemia have demonstrated therapeutic efficacy in a variety of 
diseases including sepsis, MetS, T2DM, and CVD. Although the majority of 
observational data suggests clinical relevance, these data are questioned by 
others. Translational studies are obviously needed to provide definite 
certainty on the therapeutic value of HO-1 induction and hyperbilirubinemia 
in daily clinical practice. 
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Human pharmacology of HO-1 and bilirubin 
 
HO-1 
Several commonly used drugs, including statins, aspirin and losartan, and 
other medicinal substances, like curcumin, have shown to induce HO-1 in 
vitro or in animals (93). As these substances have more modes of action, it is 
difficult to ascribe possible treatment effects solely to HO-1. 
Metalloporphyrins, such as heme, heme arginate, and cobalt protoporphyrin 
(CoPP), are much more selective and therefore frequently used in animal 
experiments. Heme arginate can be used safely in humans (140). The drug is 
a stable reaction product of hemin and L-arginine and is dissolved in a 
mixture of propyleneglycol, ethanol, and water (141). In Europe, heme 
arginate is registered for human use in patients suffering from acute 
porphyria. It restores the negative feedback on porphyrin formation and 
thereby diminishes the symptoms associated with the accumulation of 
porphyrins (142). In the United States, hemin is used for the same indication 
(143). Both heme arginate and hemin have been reported to induce HO-1 in 
humans (140, 144). According to both papers, regularly prescribed doses of 
heme arginate and hemin increase HO-1 expression substantially, lasting for 
at least 48 hours after administration. Plasma heme levels on the other hand 
were reported to return to near normal levels within the same time frame. 
Interestingly, individual number of GTn repeats in the promoter region were 
only modestly related to differences in the extent of HO-1 induction (140).  
With regard to the pharmacological inhibition of HO-1 in humans, no 
substances are available in Europe. In the Unites States, tin mesoporphyrin 
(SnMP) is registered for compassionate use in neonates in order to inhibit 
bilirubin production in case of severe hyperbilirubinemia (145). SnMP 
inhibits HO-1 activity at the enzymatic level through competion with heme. 
Interestingly, however, SnMP simultaneously induces the transcription of 
HO-1 by binding to Bach1 (146). 
  
1
General introduction
26  
 
Bilirubin 
Theoretically, bilirubin plasma levels can be elevated by three 
pharmacological means: (1) stimulation of endogenous bilirubin production, 
(2) inhibition of bilirubin clearance, and (3) administration of exogenous 
bilirubin. All three methods have been applied in the studies described in 
this thesis and will therefore be discussed. 
 
Stimulation of endogenous bilirubin production 
Bilirubin production can be stimulated by either increasing the supply of 
heme or the induction of HO-1 activity. Experimental treatment with heme 
arginate combines both strategies as discussed previously. Apart from the 
production of bilirubin, however, heme arginate treatment also increases the 
levels of HO-1 transcripts, CO, Fe2+ and, ferritin through the subsequent 
induction by Fe2+. As discussed, HO-1 microRNA, HO-1 protein, CO, and 
ferritin, all have beneficial effects under circumstances of oxidative stress 
and inflammation. Theoretically this offers a therapeutic advantage over 
strategies that exclusively elevate bilirubin levels. However, the involvement 
of other possible mediators hampers the interpretation of studies that aim to 
assess the exclusive impact of bilirubin instead of HO-1. 
 
Inhibition of bilirubin clearance 
A second strategy to elevate bilirubin levels is the inhibition of bilirubin 
clearance, which is an active process mediated by several proteins in the 
liver. Amongst these are carrier proteins like the sinusoidal membrane 
OATP1B transporters (147). The most obvious pharmacological target for 
induction of hyperbilirubinemia is inhibition of UGT1A1, which is involved in 
the glucuronidation of bilirubin. Interestingly, this principle is quite common 
in nature, since about 5 to 10 percent of the general population carries a 
UTG1A1 mutation, which reduces its activity to 30% of normal (148). An 
experimental pharmacological counterpart of this so-called Gilbert syndrome 
can be achieved by treatment with the antiviral drug atazanavir (149, 150). 
Atazanavir is a protease inhibitor used for the treatment of HIV and well-
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known for its potency to cause mild hyperbilirubinemia by reversible 
inhibition of UGT1A1. Atazanavir has been authorized for the European 
market, is administered orally, and causes a quite steady increased bilirubin 
level. Atazanavir is therefore ideally suited for trials aiming at a therapeutic 
benefit of mild hyperbilirubinemia, although it remains difficult to 
distinguish the effects of bilirubin from atazanavir itself. Without additional 
control data, it will be impossible to ascribe an observed effect simply and 
solely to bilirubin. Secondly, the use of atazanavir does not enable to study a 
dose-response relationship over a wide range of bilirubin concentrations. 
 
Administration of endogenous bilirubin 
The only study design that will truly clarify the exclusive therapeutic effect of 
bilirubin includes the administration of exogenous bilirubin. Bilirubin 
cannot be administered orally due to its low bioavailability, but there are 
numerous human studies in which bilirubin was administerd parenterally. 
Yet in the 1920s, Von Bergmann and his student Eilbott were the first to 
publish on the preparation and intravenous administration of bilirubin to 
humans in the search for a liver function test (151, 152). Several studies on 
the clearance of bilirubin in different subjects and under various conditions 
have been published since (153-157). The first human studies on the 
therapeutic use of bilirubin were published in 1938. Triggered by the clinical 
observation that arthritis-related symptoms seemed to abate during an 
intercurrent jaundice, Thompson and Wyatt treated ten of their patients with 
repeated injections of both bilirubin and bile acids and reported a 
diminution of pain and swelling in all but one of the subjects (158). Another 
pioneer in the therapeutic use of bilirubin was Philip Hench, later Nobel 
prize winner for the discovery of cortisone and its applicability in arthritis 
(159). Hench unfortunately observed much less improvement of the 
complaints associated with arthritis (160). Few others tried to replicate the 
findings of both Thompson and Hench and reported their results in an 
addendum to the original paper of Thompson and Wyatt (158). Two years 
later, in 1940, Hench listed all available data on the therapeutic use of 
bilirubin as experimental therapy for arthritis in a review paper, which is 
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still worth reading (161). To the best of our knowledge, no reports on the 
therapeutic human use of bilirubin have been published since then. 
However, publications on human pharmacokinetics of bilirubin continued to 
appear up to the late 1960s (162, 163).  
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Abstract 
 
This translational randomized and vehicle-controlled cross-over study was 
performed to assess the impact of heme arginate (HA) treatment on heme 
oxygenase-1 (HO-1) induction, endothelial function and insulin sensitivity in 
subjects with the metabolic syndrome (n=14). Both treatment periods 
consisted of 5 days. HA or vehicle (L-arginine) was administered 
intravenously on days 1 and 3. Forearm blood flow in response to 
acetylcholine and nitroglycerine was measured by venous occlusion 
plethysmography (day 3), insulin sensitivity by a hyperinsulinemic clamp 
procedure (day 5). HA did not improve endothelial function or insulin 
sensitivity but significantly reduced the vasodilator response to NTG 
(p<0.01). These negative findings are in contrast with preclinical data, which 
may be due to short-term and limited HO-1 induction as well as interference 
by markedly elevated plasma heme levels observed after HA treatment 
(p<0.01). Future studies should pay attention to the delicate balance 
between sufficient dosing and timely normalization of plasma heme levels. 
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Introduction 
 
Heme oxygenase (HO) is the rate-limiting enzyme in the breakdown of heme 
into free iron, carbon monoxide and biliverdin (1). Biliverdin is then rapidly 
converted into the antioxidant bilirubin by biliverdin reductase. An 
overwhelming amount of preclinical evidence on the anti-oxidant and anti-
inflammatory effects of the inducible isoform HO-1 has fuelled speculations 
about the therapeutic use of HO-1 induction in human medicine (2). As the 
metabolic syndrome (MetS), type 2 diabetes mellitus, and cardiovascular 
disease are all associated with the presence of oxidative stress and chronic 
low grade inflammation (3-5), these conditions constitute an important area 
for research on the clinical use of HO-1 induction as a novel therapeutic 
strategy. Indeed, many preclinical experiments on HO-1 induction show 
promising results in models for MetS and type 2 diabetes mellitus (6). HO-1 
induction ameliorates MetS in obese mice (7), improves insulin sensitivity in 
insulin-resistant rats (8), reduces retroperitoneal adiposity and 
hyperglycemia in Zucker diabetic fatty rats (9) and protects against 
endothelial dysfunction in high-fat-fed LDL-receptor knockout mice (10). 
Interestingly, recent data challenge the supposed beneficial role of HO-1 and 
conversely suggest that in obese settings HO-1 functioning may be 
disturbed, and, may even fuel insulin resistance (11). 
Both hemin and heme arginate (HA) have been reported to induce HO-1 
expression in healthy volunteers (12, 13). Besides, short-term HA treatment 
has been demonstrated to ameliorate experimental ischemia-reperfusion 
injury in healthy volunteers (14). For the MetS, type 2 diabetes mellitus or 
cardiovascular disease, translational data on the impact of HO-1 are 
currently lacking. We therefore aimed to induce HO-1 by a short-term HA 
treatment and subsequently assess its effect on insulin sensitivity and 
endothelial function in subjects suffering from the MetS. 
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Materials and methods 
 
Study population 
Recruited subjects who met the MetS criteria (15) were invited to an 
additional and more extensive screening visit. Participants had to be at least 
18 and no older than 70 years of age and were not allowed to have a positive 
history of drug abuse, active smoking, type 2 diabetes, or cardiovascular 
disease. In addition, subjects were prohibited from using vasoactive 
medication, statins, aspirin, and anti-oxidant vitamin supplements, as these 
drugs could influence both HO-1 activity and endothelial function. Subjects 
with clinical evidence of cardiac or pulmonary disease or with biochemical 
evidence of renal or hepatic abnormalities (results exceeding twice the upper 
limit of normal range) were excluded. Finally, subjects with unconjugated 
hyperbilirubinemia (total bilirubin level > 10 μmol/l) were excluded to avoid 
participation of subjects with the Gilbert syndrome. All subjects gave written 
informed consent prior to the first screening visit. The study protocol was 
approved by the local Medical Research Ethics Committee and consistent 
with the Declaration of Helsinki.  
 
Study design 
In a randomized order and with a wash-out period of at least seven weeks in 
between, subjects received both a treatment with HA (Normosang®, Orphan 
Europe, France; 3 mg/kg with a maximum of 250 mg per dose) and a control 
treatment with equimolar amounts of L-arginine (3,2 mg/kg with a 
maximum of 267 mg per dose) to correct for a potential unintended impact of 
the release of L-arginine  upon HA infusion. The time schedule of both 
treatment periods is provided in Figure 2.1. In brief, the study medication 
was administered intravenously on days 1 and 3 of both treatment periods. 
Prior to the infusion on day 3, we assessed forearm blood flow (FBF). On day 
5 of each treatment period, we took a fat biopsy and performed an 
euglycemic hyperinsulinemic clamp to assess insulin sensitivity. During all 
visits, venous blood was drawn. Hematological parameters were assessed 
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using an ADVIA 120 Hemalog (Bayer Diagnostic, Tarrytown, N.Y., USA) and 
clinical chemistry parameters including bilirubin and ferritin were 
determined using an Aeroset (Abbott Laboratories, Abbott Park, IL, U.S.A.). 
In addition, plasma samples were stored at -80° C for additional 
measurements including the ferric reducing ability of plasma (FRAP) assay 
and plasma heme levels. A subcutaneous fat biopsy was taken under local 
anesthesia (2% Lidocaine HCl) after an overnight fast. Adipose tissue was 
aspired from the lateral aspect of the hypogastrium, inferior to the umbilicus 
using a Hepafix Luer Lock syringe (Braun, Melsungen, Germany) and a 2.10 
x 80 mm Braun Medical Sterican needle. The adipose tissue was washed 
using a 0.9% saline solution, snap frozen and stored at -80° C until further 
analysis. 
 
 
 
Figure 2.1 Study overview 
HA: heme arginate bolus infusion; LA: L-arginine bolus infusion; Lab: hematology, 
chemistry and parameters of HO activity; FBF: assessment of endothelial function; 
Fat: fat biopsy; Clamp: hyperinsulinemic euglycemic clamp.   
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Markers of the HO-1 system 
HO-1 was determined on multiple levels including mRNA (peripheral blood 
and adipose tissue) and  protein (plasma). In addition, we assessed plasma 
levels of the HO-1 substrate heme, the HO-1 activity product bilirubin and 
the iron scavenger ferritin. Finally, plasma anti-oxidant capacity was 
assessed by means of the ferric reducing ability of plasma (FRAP) assay. For 
the isolation of total RNA from peripheral blood, we used the PAXgene Blood 
mRNA kit (Qiagen Benelux B.V., Venlo, The Netherlands). Samples were 
handled according to the manufacturers protocol. From adipose tissue, we 
extracted total RNA using TRIzol Reagent (Life Technologies Europe B.V., 
Bleiswijk, The Netherlands). RNA concentrations were determined using the 
NanoDrop 2000 Spectrophotometer (NanoDrop Products, Wilmington, DE, 
USA). cDNA synthesis was performed using the iScript cDNA Synthesis kit 
(Bio-Rad Laboratories B.V., Veenendaal, The Netherlands). Real-time PCR 
was performed using the iQ SYBR Green Supermix (Bio-Rad Laboratories 
B.V., Veenendaal, The Netherlands) and the CFX Real-Time System and 
C1000 Thermal Cycler (Bio-Rad Laboratories B.V., Veenendaal, The 
Netherlands). Expression of the heme oxygenase-1 (HO-1) gene was 
normalized to acidic ribosomal phosphoprotein P0 (ARP) gene expression 
levels. Primer sequences were: ARP, CACCATTGAAATCCTGAGTGATGT 
(sense), TGACAAGCCCAAAGGAGAAG (antisense); HO-1, 
TTTCAGAAGGGCCAGGTG (sense), AGACTGGGCTCTCCTTGTTG (antisense) 
(Biolegio B.V., Nijmegen, The Netherlands). HO-1 protein content of plasma 
was determined using the Immuno Set HO-1 (human) ELISA development kit 
(Enzo Life Sciences BVBA, Antwerp, Belgium). To assess plasma heme levels, 
20 μl pure DMSO and subsequently 160 μl of a mixture of 250 μl HCl (37%) 
into 10 ml of acetone was added to 20 μl of plasma. After cooling on ice for 
two minutes, the sample was centrifuged. Next, the supernatant was 
analyzed by reversed-phase high performance liquid chromatography. The 
mobile phase comprised of Solvent A (44% methanol, 56% 0.1 M ammonium 
phosphate buffer pH 3.4, v/v) and Solvent B (100% methanol, v/v) using the 
following gradient: Solvent B, 0% at t0 to 100% at 14 minutes; then isocratic 
to 15 minutes; down to 0% at 16 minutes and isocratic to 21 minutes. The 
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UV detector was set at a wavelength of 400 nm. The gradient separation of 
heme was performed on a GraceSmart RP18 column, 150 x 4,6 mm i.d., 5 
μm particle size at a column temperature of 60º C. The FRAP assay was 
performed according to the method of Benzie and Strain (16). FRAP values 
were obtained using a seven-point calibration curve of known amounts of 
Fe2+ and expressed in μmol Fe2+/l. 
 
Endothelial function 
Subjects were instructed to refrain from caffeinated foods and beverages on 
the day prior to the flow experiments. After overnight fasting, flow 
experiments were performed using venous occlusion plethysmography as 
described previously (17). In brief, FBF was assessed during the successive 
administration of three increasing doses of acetylcholine (0.5, 2 and 8 μg 
min-1 dl-1 of forearm tissue), and nitroglycerin (0.25, 0.5 and 1.0 μg min-1 dl-
1).  
 
Insulin sensitivity 
Insulin sensitivity was measured by a 120 minutes hyperinsulinemic 
euglycemic clamp procedure. These experiments were also performed in the 
morning after overnight fasting with the subjects in supine position in a 
quiet temperature-controlled room. Glucose and insulin were administered 
in an antecubital vein. Insulin (Novorapid, NovoNordisk, Denmark; diluted in 
0.9% saline to a concentration of 1 U/ml with the addition of 2 ml of the 
subject’s blood per 50 ml) was infused at a constant rate of 60 mU min-1 m-2 
body surface area (360 pmol min-1 m-2). The plasma glucose level was 
monitored at 5 minute intervals by sampling of arterialized blood from a 
cannulated vein on the dorsum of the controlateral hand, which was placed 
in a warm-air box (18). Glucose concentrations were measured using a 
Biosen C_line GP+ (EKF-diagnostic, Barleben, Germany). Plasma glucose 
was clamped at a level of 5.0 mmol/l by variable infusion of a 20% glucose 
solution. Insulin sensitivity (M-value) was calculated from the average 
glucose infusion rate (μmol/min) between 90 and 120 minutes of the 
euglycemic clamp, divided by body weight (kg). 
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Statistical analyses 
Statistical analysis was performed using the SPSS (version 16.0) and SAS 
(version 8.2) software package. Paired-samples t-test was used to compare 
Gaussian distributed data. For analysis of the FBF measurements, the last 
five flows of each dose were used. Prior to analysis, logarithmic 
transformation was performed to obtain a Gaussian distribution. The flow 
data were then averaged per dose and subsequently analyzed in a mixed 
linear model with random factor subjects and fixed factors treatment and 
dose. The log-transformed data used for statistical analysis are presented in 
Table 2.3. The data discussed in the text are medians instead of averages of 
the original flow data to approximate the effect of logarithmic transformation. 
Statistical significance was accepted at the 95% confidence level (P≤0.05). 
 
 
Results 
 
A summary of the screening, participation and drop out of subjects is 
provided in Figure 2.2. Sixty-three obese non-smoking subjects with a 
negative history of cardiovascular disease were recruited through local 
advertisements and gave written informed consent for participation. Sixteen 
of these subjects met the MetS criteria as well as the additional criteria of 
our protocol. One of these subjects decided to withdraw informed consent 
prior to the actual enrollment in the cross-over study. Of the fifteen subjects 
that did participate in the study, one experienced a severe headache several 
hours after the first administration of HA. Additional examinations including 
head CT scan did not reveal any abnormality. Because of the severity of the 
headache, we nevertheless decided to refrain from the second infusion of HA 
and terminate the participation of this subject. The results of the remaining 
fourteen subjects are presented. 
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Figure 2.2 Diagram illustrating the screening, participation and drop out of 
subjects 
 
Subject characteristics 
Characteristics of the final study population are shown in Table 2.1. This 
population consisted of eight males and six females with an average age of 
50.4 years and an average body mass index of 34.6 kg/m2. All subjects met 
the MetS criteria with regard to elevated waist circumference and 
hypertension (15). Three of fourteen subjects demonstrated an elevated 
plasma level of fasting glucose. Two subjects were using corticosteroids 
chronically for psoriasis (topical application) and chronic obstructive 
pulmonary disease (inhalation) respectively. In both subjects, no dose 
adjustments were made during participation. A third subject was using 
small amounts of topical corticosteroids for eczema during the first day of 
his HA treatment. None of the remaining subjects suffered from active 
(auto)inflammatory disease during participation. Three subjects were using 
non-steroidal anti-inflammatory drugs on demand for musculoskeletal pain 
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and on our request refrained from taking these drugs during the 
experiments. 
 
Table 2.1 Characteristics of study population (n = 14) 
Sex 8 men, 6 women 
Age (years) 50 (13; 25 – 69) 
BMI  (kg/m2) 35 (5; 29 – 44) 
Waist circumference 116 (12; 96 – 129) 
SBP (mm Hg) 145 (14; 131 – 168) 
DBP (mm Hg) 89 (8; 72 – 100) 
Fasting glucose 5.3 (0.4; 4.5 – 6.0) 
Triglycerides (mmol/l) 2.35 (0.99; 0.89 – 
HDL cholesterol 1.1 (0.2; 0.77 – 
Data are given as mean (SD; range) 
 
Markers of the HO-1 system 
The outcome on the different markers of HO-1 induction is shown in table 
2.2. Apart from baseline, these measures were determined 48 hours after the 
first and 48 hours after the second dose of both HA and control. The data 
discussed concern the data following HA treatment compared to the data 
following control treatment at the same time point. The plasma heme levels 
were elevated significantly after HA infusion compared to control. On HO-1 
mRNA level, fat biopsies demonstrated a significant but modest increase 
(1.27 fold increase of mRNA level, P=0.03) after HA treatment, whereas no 
difference on mRNA levels was observed in the peripheral blood. On HO-1 
protein level, the HO-1 plasma level increased upon the first HA infusion. 
Upon the second infusion, no difference was found. On the level of HO-
effector molecules, plasma ferritin levels increased after both HA infusions, 
but plasma bilirubin levels remained unaffected. Finally, HA infusion did not 
alter the anti-oxidant capacity of plasma as measured by the FRAP assay. 
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Table 2.2 Impact of heme arginate compared to control treatment at day 3 
(48 hours after the first dose) and day 5 (48 hours after the second dose) on 
primary end points and markers of HO-1 induction 
 Day 3    Day 5   
 HA  LA  
P-
value 
 HA  LA  
P-
value 
Plasma heme level 
(μmol/l) 
11.7 
(0.95) 
 
6.6 
(0.84) 
 <0.01  
20.7 
(1.87) 
 
6.0 
(0.89) 
 <0.01 
Markers of HO-1 
induction 
           
 HO-1 mRNA level            
  adipose tissue (ΔCT)       
5.32 
(0.20) 
 
5.67 
(0.18) 
 0.03 
  blood (ΔCT)       
4.03 
(0.20) 
 
4.37 
(0.16) 
 0.23 
 HO-1 protein level            
  plasma (μg/l) 
9.0 
(0.85) 
 
4.0 
(0.53) 
 <0.01  
4.1 
(0.63) 
 
4.7 
(0.62) 
 0.55 
 HO-1 effector molecules            
  ferritin (μg/l) 
184 
(41) 
 
159 
(37) 
 <0.01  
178 
(37) 
 
150 
(40) 
 <0.01 
  bilirubin (μmol/l) 
7.86 
(0.54) 
 
8.36 
(0.57) 
 0.25  
7.08 
(0.68) 
 
7.43 
(0.65) 
 0.21 
Therapeutic effect            
 FRAP (μmol Fe2+/l) 
1155 
(48) 
 
1182 
(44) 
 0.28  
1207 
(53) 
 
1224 
(66) 
 0.54 
 Insulin sensitivity            
  M-value (μmol min-1 kg-1)      
7.1 
(0.72) 
 
7.3 
(0.82) 
 0.54 
Data are given as mean (SEM). HA, heme arginate; LA, arginine; FRAP, ferric 
reducing ability of plasma. Reported P-values are the result of paired t-tests. 
 
Adverse events 
Headache was reported during HA treatment in seven cases and during 
control treatment in five cases. Nearly all subjects reported their headache 
upon the first but not the second infusion of either HA or control. Only one 
subject experienced headache upon both the first and second infusion of 
2
HO-1 induction in MetS
50  
 
control treatment. In time, two cases of headache were closely related to the 
administration of HA. In one of these cases, participation was ended for the 
severity of the headache. The other subject continued participation and did 
not experience headache upon the second infusion of HA. Besides, phlebitis 
was noted after HA infusion in three cases and after the control infusion in a 
single case. 
 
Vascular and metabolic effects 
The results of the FBF experiments are depicted in Table 2.3. Baseline flow 
after control treatment was comparable to baseline flow after HA treatment 
(2,2 and 2,4 ml min-1 dl-1 tissue in the intervention arm and 1.8 and 2.2 ml 
min-1 dl-1 in the control arm respectively). During the FBF experiments mean 
arterial blood pressure was not significantly influenced by HA treatment 
compared to control (103 mm Hg versus 108 mm Hg respectively, NS). Intra-
arterial infusion of acetylcholine induced an increase in FBF at all three 
doses after both control and HA treatment. The extent of this response was 
not affected by pretreatment with HA. On average, a non-significant increase 
of 11% (95% CI: -10 to 36%) was observed in the response to the three doses 
of acetylcholine. At the highest dose of acetylcholine, 8 μg min-1 dl-1, FBF 
amounted to median levels of 20.3 and 23.5 ml min-1 dl-1 following control 
and HA respectively. 
Intra-arterial infusion of nitroglycerin induced an increase of FBF at all 
dosages. Pretreatment with HA led to a significant diminution of the 
vasodilator response to nitroglycerin when compared to control. On average, 
a significant decrease of -7% (95% CI: -11 to -3%) was observed in the 
response to the three doses of nitroglycerin. At the highest dose of 
nitroglycerin, 1.0 μg min-1 dl-1, FBF amounted to median levels of 10.6 and 
9.7 ml min-1 dl-1 following control and HA treatment, respectively. 
Regarding insulin sensitivity, no difference was observed (Table 2.2). The 
average M-values after treatment with HA and control mounted to 7.1 and 
7.3 μmol min-1 kg-1, respectively (NS). Post hoc analysis yielded similar 
findings for a subgroup with the highest insulin resistance (the seven 
subjects with the lowest M values after control treatment) and a subgroup 
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with the most prominent HO-1 induction (the seven subjects with the 
highest increase in HO-1 mRNA level in the adipose tissue). 
 
Table 2.3 Forearm blood flow data after logarithmic transformation 
 Heme arginate Control P-value 
Baseline 0.35 (0.07) 0.31 (0.06) 
0.34 
ACh 1 0.82 (0.09) 0.82 (0.06) 
ACh 2 1.12 (0.07) 1.03 (0.07) 
ACh 3 1.34 (0.07) 1.28 (0.05) 
    
Baseline 0.30 (0.07) 0.32 (0.05) 
< 0.0001 
NTG 1 0.87 (0.03) 0.90 (0.03) 
NTG 2 0.94 (0.03) 0.98 (0.03) 
NTG 3 0.98 (0.03) 1.01 (0.03) 
ACh1-3, acetylcholine dosage of 0.5, 2.0 and 8.0 μg min-1 dl-1 respectively; NTG1-3, 
nitroglycerin dosage of 0.25, 0.50 and 1.0 μg min-1 dl-1 respectively. In parenthesis 
standard errors of the mean. 
 
 
Discussion 
 
This is the first translational study to evaluate the impact of HA 
administration on HO-1 induction, insulin sensitivity and endothelial 
function in subjects suffering from the MetS. For years, an accumulation of 
preclinical data strongly suggested therapeutic benefit of HO-1 induction for 
both insulin resistance and endothelial dysfunction (2).  In contrast to the 
observed efficacy of HO-1 induction by chronic HA treatment in preclinical 
experiments, short term HA treatment in human subjects suffering from the 
MetS did not improve insulin sensitivity and endothelial function compared 
to control treatment with L-arginine. Several comments should be made. 
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HO-1 in metabolic disease 
Noteworthy, the dogma of metabolic protection by HO-1 has been challenged 
recently (11). Insulin-resistant obese subjects demonstrate increased HO-1 
expression in liver and visceral fat compartments compared to insulin-
sensitive obese subjects. In addition, hepatocyte HO-1 appears to promote 
insulin resistance in genetic gain- and loss-of-function models, and 
macrophage HO-1 knockout mice appear to be protected against metabolic 
disease upon a high fat diet. Finally, cellular assays support a pro-
inflammatory role for HO-1 in the development of metabolic disease. This 
discrepancy with previous preclinical studies on HO-1 induction is striking 
and urges to a re-evaluation of data and further research. One of the 
explanations put forward is the limited specificity of metalloprotoporphyrins 
used for HO-1 induction including cobalt protoporphyrin (CoPP), heme and 
hemin (11, 19). As a result, the net positive effects of metalloprotoporphyrins 
reported from preclinical experiments may be related to other mechanisms 
than HO-1 induction per se. However, this theory seems inconsistent with 
the observed abrogation of protection by metalloprotoporphyrins when HO-
activity is co-inhibited (8). Moreover, it does not explain the observed 
beneficial effects of HO-effector molecules like bilirubin in models of the 
MetS and diabetes (17, 20). An alternate explanation is a possible 
dysregulation of the HO-1 system by factors involved in the MetS, causing a 
switch from the well-known anti-inflammatory profile to the recently 
recognized pro-inflammatory role (21). Underlying mechanisms are to be 
clarified and might include a differential induction by pathological stimuli, 
alterations in posttranslational regulation or changes in the subcellular 
translocation of HO-1 (21). In conclusion, HO-1 appears to act as a double 
edged sword having both protective and injurious effects in the development 
of the MetS. 
 
Study design 
Our experiments are amongst the first studies to the therapeutic efficacy of 
HO-1 induction in human disease. Consequently little is known of the 
optimal design of translational experiments on the supposed beneficial 
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impact of HO-1 induction in man. As a result, we cannot exclude that either 
the observed low level or the duration of HO-1 induction obtained by our 
short-term HA treatment is insufficient in view of the lack of therapeutic 
efficacy. 
The short-term design of our experiments originated from promising data 
provided by two papers demonstrating significant experimental HO-1 
induction in healthy volunteers (12, 13). Significant increases of HO-1 mRNA 
plasma level, HO-1 protein plasma level and ex vivo HO-activity in 
leukocytes were reported 48 hours after a single bolus infusion of either HA 
(13) or hemin (12). The HA dosage applied in our study (3 mg/kg) equals the 
highest of three HA dosages applied in the first study and the single hemin 
dosage applied in the second study. Endothelial function and insulin 
sensitivity, our main outcome parameters, were assessed 48 hours after the 
administration of HA, parallel to the reported HO-1 induction in both 
studies. Suggesting effectiveness of short term HA treatment in human 
translational models on the therapeutic value of HO-1 induction, others have 
demonstrated an amelioration of ischemia reperfusion injury in healthy 
volunteers 24 hours after a single dosage of HA of only 1 mg/kg (14). For 
insulin sensitivity however, it should be noted that a chronic treatment with 
HO-1 inducers for 4 to 8 weeks was used in animal experiments 
demonstrating an improvement of glucose metabolism (7-9, 22). Likewise, a 
long term experiment might have been more effective in subjects suffering 
from the MetS. In clinical practice however, HA is registered for short term 
use only with a maximum of four days for acute porphyria attacks (23). 
Chronic once weekly use has been reported in individual porphyria cases 
(23), but no data are available on the extent of HO-1 induction associated 
with a chronic once weekly HA treatment regimen in man. Finally, chronic 
weekly HA treatment is associated with serious vascular side effects 
involving the disappearance of the superficial venous system and the need of 
an indwelling venous access (23). Although more promising based on 
preclinical experiments, we therefore felt that it was inappropriate to perform 
a long term experiment and overleap a short term design with less safety 
concerns and proven efficacy in terms of HO-1 induction. 
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The impact of HA treatment on markers of HO-1 induction observed in our 
subjects is limited. It is currently unclear however whether the extent of HO-
1 induction observed in translational studies relates to the intended clinical 
effect of treatment with metalloprotoporphyrins. Besides, the selection of 
appropriate markers of HO-1 induction is complicated by the differential 
impact of HO-1 activity on various tissues. As stated HO-1 activity in the 
liver and in visceral fat has been shown to aggravate instead of ameliorate 
the MetS (11). Finally, we have recently demonstrated that HO-1 induction 
by lipopolysaccharide in human cells differs from that in widely used 
experimental animal models (24). Potential inter-species differences and cell-
type specific responses therefore necessitate caution in the adoption of 
markers of HO-1 induction from animal to human experiments. In search for 
an appropriate marker of HO-1 induction and for the central role of adipose 
tissue in the MetS (4), we included the measurement of HO-1 mRNA in 
subcutaneous adipose tissue. However, the relevance of this marker too is 
challenged by recent data demonstrating that overexpression of HO-1 in 
adipocytes does not protect against insulin resistance (25). 
 
Elevated heme levels 
Assessing endothelial function, we observed an unexpected reduced 
response to nitroglycerin 48 hours after HA infusion. In theory, this reduced 
response might be related to changes in blood pressure. In animal 
experiments, lowering of blood pressure upon chronic HO-1 induction has 
been reported in obese mice (7). However, we did not observe significant 
changes of blood pressure after short term HA treatment compared to 
control. In addition, baseline blood flow was unaltered by HA treatment. In 
our opinion, the reduced response to nitroglycerin is more likely related to 
the elevated plasma levels of heme (11.7 μmol/l on average) at the time we 
performed forearm plethysmography. The heme levels found at this point of 
time, 48 hours after the first administration of HA, correspond to heme levels 
reported by others (13). Although long-term dosing of nitroglycerin involves 
complex effects (26), short term high dosing as used in our study is 
associated with the release of nitric oxide (NO) (27). Whereas HO-1 induction 
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is expected to increase the bioavailability of NO (28), elevated heme levels 
have been demonstrated to trigger the opposite by scavenging NO (29). In 
fact, heme levels exceeding 6 μmol/l have been demonstrated to lower the 
vasodilator response to sodium nitroprusside, an NO donor, by as much as 
80 percent (29). In addition, excess of heme is associated with increased 
oxidative and inflammatory stress and endothelial activation in mouse 
models of hemolytic diseases (30, 31). Scavenging of free heme by the 
administration of hemopexin markedly attenuates the observed endothelial 
toxicity induced by heme (30). In contrast to our design, animal experiments 
on HO-1 induction in a model of endothelial dysfunction involved a 
pretreatment HA without exposure to heme during the subsequent in vitro 
assessment of endothelial function (10). As for the vasodilator response to 
nitroglycerin, the elevated heme levels may have masked a beneficial impact 
of HA treatment on the NO dependent vasodilator response to acetylcholine, 
our marker of endothelial function. Likewise, the pro-inflammatory and pro-
oxidant effects of heme (31) may have counteracted a beneficial impact of 
HO-1 induction on insulin resistance. In our opinion, our data on 
nitroglycerin therefore reveal an important and general message with regard 
to the possible adverse effects of elevated heme levels upon the use of HA for 
translational studies on HO-1 induction. The pharmacokinetics of 
intravenously administered HA have been published in the past (32) and 
should be addressed specifically during the design of future experiments. 
 
Side effects 
We observed several well-known side effects of HA, including headache and 
phlebitis, despite the adherence to the instructions of the manufacturer. 
Both side effects were reported previously by others (12-14). Notably, 
headache was also observed during control treatment and occurred almost 
exclusively upon the first infusion of HA and control, prior to the assessment 
of forearm blood flow. Therefore, alternative causes including abstinence 
from caffeine must be considered (33). Phlebitis has been associated with 
both hemin and HA (23). For the use of hemin, others have been able to 
avoid phlebitis through the dilution in albumin instead of saline (12). Future 
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research should determine whether this strategy suits for HA and affects the 
efficacy of HA. 
 
Limitations 
Limitations of the study include the lack of a healthy control group in our 
protocol. As a result, we cannot substantiate the assumed presence of 
impaired insulin sensitivity and endothelial dysfunction in our MetS 
population at baseline. Second, our study population was characterized by a 
certain degree of diversity in terms of gender and age. Despite the use of a 
cross-over design, gender or age related differences in therapeutic efficacy of 
HO-1 induction within our study population may have flattened the results. 
Finally, our control treatment consisted of equimolar amounts of L-arginine 
for the fact that the administration of HA is accompanied by the release of 
equimolar amounts of arginate, a well-known substrate of NO. Though in 
our opinion more appropriate than true placebo, we cannot exclude small 
differences in pharmacological profile between L-arginine administered in 
solution and L-arginate administered as part of HA. 
 
In conclusion, short term HA treatment only marginally induces HO-1 
expression and does not improve insulin sensitivity nor endothelial function 
in subjects suffering from the MetS. This is in contrast with promising 
results from preclinical studies. Novel studies should unravel the various 
mechanisms by which HO-1 activity and metalloporphyrins affect MetS. In 
addition, chronic once weekly HA regimens should be examined for their 
potency to induce HO-1 and subsequently their efficacy on clinical 
endpoints. Finally, the design of translational experiments should be 
calculated on the delicate balance associated with the use of HA and strive 
for a dosage that is sufficiently high to achieve clinical efficacy and at the 
same time sufficiently low to avoid elevated heme levels by the time 
endpoints are assessed. 
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Abstract 
 
Bilirubin is one of the most powerful antioxidants in the human 
body.Observational data, animal experiments and limited translational 
research suggest that bilirubin is able to ameliorate the development of 
cardiovascular disease.  The objective of the present study was to assess the 
impact of plasma bilirubin levels on measurements of subclinical 
atherosclerosis in the general population. 
We measured bilirubin levels in stored plasma from the Nijmegen Biomedical 
Study, a large population-based study in which non-invasive measurements 
of atherosclerosis were performed in 1517 individuals. The outcome of the 
non-invasive measurements of atherosclerosis in the highest quartile of 
bilirubin was compared with that in the lowest quartile. This procedure was 
repeated for a subpopulation of subjects with the metabolic syndrome. In 
addition, both sexes were analyzed separately.  
For the highest bilirubin quartile, we observed a 3.2% (95%CI: 1.4 to 5.0%) 
higher ankle brachial index at rest and an 8.6% (95%CI: 4.7 to 12.7%) 
higher ankle brachial index after exercise compared to the lowest bilirubin 
quartile. Adjustment for traditional cardiovascular risk factors hardly 
interfered with the findings on the ankle brachial index. Separate analysis of 
subjects with the metabolic syndrome yielded similar results compared to 
the general population. The association between plasma bilirubin levels and 
ankle brachial index in women appeared less pronounced, and equality of 
impact in men and women cannot be excluded in view of the wide confidence 
intervals. 
Our data demonstrate an inverse association between plasma bilirubin levels 
and ABI that is unaffected by the coexistence of the metabolic syndrome, 
adding further support to bilirubin reducing the risk of atherosclerosis. 
Additional research is needed to proof causality and subsequently explore 
the additional value of therapeutic strategies aimed at raising plasma 
bilirubin levels in daily practice.  
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Introduction 
 
Bilirubin is one of the effector molecules of the cytoprotective enzyme heme 
oxygenase and is well-known for its powerful antioxidant capacity (1). Since 
oxidative stress is thought to play a fundamental role in the development of 
atherosclerosis (2), both preclinical and observational studies have explored 
the impact of bilirubin on cardiovascular disease. 
Preclinical data demonstrate a direct beneficial impact of bilirubin on 
cardiovascular disease. Interestingly, physiological or only mildly elevated 
bilirubin levels protect against in vitro oxidation of low density lipoproteins 
(LDL) (3, 4). Bilirubin additionally inhibits the activation of NADPH oxidase 
(5), which is an important source of reactive oxygen species (ROS) in 
atherosclerosis (2). Moreover, hyperbilirubinemia has been demonstrated to 
reduce balloon injury-induced neointima formation in rats (6) and to 
attenuate the development of angiotensin II-dependent hypertension in mice 
(7). In agreement with these findings, several animal experiments have 
demonstrated the amelioration of cardiovascular disease by the induction of 
heme oxygenase activity (8). 
In line with preclinical data, a log-linear inverse association between plasma 
levels of total bilirubin and the risk of cardiovascular disease has been 
demonstrated in a large meta-analysis of 12 population-based prospective 
studies (9). This association was independent of established risk factors of 
cardiovascular disease and appeared strong in men but non-significant in 
women without evidence of significant effect modification by sex. Therapeutic 
exploitation of bilirubin has been suggested for the prevention of 
cardiovascular disease in humans (10). Illustrating the potential of such 
strategies, we previously showed that the vascular function and serum anti-
oxidant capacity of subjects with type 2 diabetes mellitus is improved by a 
short-term treatment with the bilirubin-increasing drug atazanavir (11).  
In view of the general assumption that bilirubin exerts its beneficial impact 
through its anti-oxidant properties, one might hypothesize that the inverse 
association caused by this beneficial anti-oxidant impact is more 
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pronounced in the context of coexisting pro-oxidant cardiovascular risk 
factors. The metabolic syndrome (MetS) unites several cardiovascular risk 
factors that are associated with increased ROS production (2, 12). Though 
thoroughly studied in the general population and several high-risk 
populations, data with respect to the impact of plasma bilirubin levels on 
subclinical markers of cardiovascular disease are scarce in the setting of the 
MetS. For obese subjects who underwent cardiac catheterization to exclude 
coronary artery disease, a small observational study has demonstrated that 
the plasma bilirubin level was correlated to coronary endothelial function (r 
= 0.38, p = 0.02) (13). In normal weight subjects no correlation was found, 
but the power of these data is limited by the small number of subjects 
included (36 overweight and 71 normal weight). In both the presence and the 
absence of type 2 diabetes mellitus, others did demonstrate plasma bilirubin 
levels to be negatively associated with the carotid artery intima media 
thickness (14).  
The Nijmegen Biomedical Study (NBS) is a Dutch population-based survey. 
Within this population we previously determined the impact of the MetS and 
its individual traits on subclinical atherosclerosis, as measured with six 
different Non-Invasive Measurements of (subclinical) Atherosclerosis (NIMA) 
(15). The objective of the present study was to assess the impact of bilirubin 
levels on these different measurements of subclinical atherosclerosis in the 
general population. Second, we evaluated the impact of bilirubin in the 
presence of multiple other cardiovascular risk factors as presented in the 
metabolic syndrome. Finally, we performed an additional analysis for both 
sexes separately. 
 
 
Subjects and Methods 
 
The NBS is a population-based survey as described before (16). Participants 
aged 50 – 70 years were additionally invited to undergo assessments 
including pulse wave velocity (PWV), augmentation index (AIx), carotid 
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intima-media thickness (IMT), the presence and thickness of carotid plaques 
and the ankle-brachial index (ABI) after rest and exercise. Fasting venous 
blood samples were collected. Subjects were asked to fill out a questionnaire 
about their previous history of vascular disease, medicine use, smoking 
habits and exercise habits. If used, lipid-lowering medication was 
discontinued for four weeks prior to the measurements. The original study 
protocol was in accordance with the Declaration of Helsinki and approved by 
the Medical Ethics committee of the Radboud University Medical Center 
(Radboudumc). All participants provided written informed consent. 
 
Clinical evaluation and biochemical analysis  
Systolic and diastolic blood pressure were measured using an oscillometric 
sphygmanometer (Criticon model 1846; Criticon Inc., Tampa, FL). Waist 
circumference was measured at the level of the umbilicus. Weight and height 
were measured and body mass index (BMI) was calculated as body weight 
(kilograms) divided by the square of height (meters). Venous blood was drawn 
and plasma total cholesterol, high-density lipoprotein cholesterol (HDL-c), 
serum triglycerides (TG), and glucose concentrations were determined using 
commercially available enzymatic reagents (AEROSET System; Abbott, 
Chicago IL). Low-density lipoprotein cholesterol levels were calculated 
according to the Friedewald method (17). To enable future assessments, 
fasting plasma and serum samples were stored at -80 degrees Celsius. The 
total bilirubin levels were measured in plasma 22 to 55 months after storage. 
Commercially available enzymatic reagents were used (AEROSET System; 
Abbott, Chicago IL).  
 
Experimental protocol  
All NIMA were performed after an overnight fast or in the afternoon 6 h after 
a standardized breakfast. Participants were asked to abstain from caffeinated 
products and not to smoke for at least 12 h before the visit. All 
measurements were taken in supine position after at least 10 min rest in a 
temperature-controlled room (23 – 24 °C) and performed by well-trained and 
certified sonographers according to highly standardized protocols. Detailed 
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descriptions of methods including reproducibility data have been published 
previously (15, 18). In short, the NIMA provide information on arterial 
stiffness (PWV and AIx), thickness of the arterial wall (IMT, presence of 
plaque and plaque thickness) and peripheral flow (ABI at rest and after 
exercise). Peripheral arterial pressure waveforms were recorded by 
applanation tonometry at the radial artery and AIx was calculated, using the 
commercially available SphygmoCor system version 7.1 (Atcor Medical, 
Sydney, Australia). Subsequently the waveforms of the right carotid and left 
femoral arteries were recorded, the travelled distance was measured, and 
PWV was calculated. AIx was acquired in 1369 subjects (90.9%) and PWV in 
1479 subjects (98.2%). Carotid IMT was determined using an AU5 
Ultrasound machine (Esaote Biomedica, Genova, Italy) with a 7.5 MHz 
linear-array transducer. The mean IMT was calculated from the mean of all 
four measured segments: far wall left, near wall left, far wall right and near 
wall right. The mean far wall IMT was acquired in 1494 subjects (99.2%), 
and mean near wall IMT in 1478 subjects (98.1%). Subsequently, the 
presence of plaque and plaque thickness in the common carotid, internal 
carotid, or external carotid artery or in the entire common carotid artery, 
including the carotid bulbus were measured. The presence of plaque was 
defined as focal thickening of the vascular wall of at least 1.5× the mean 
IMT. Blood pressures at both arms and ankles were measured and the ABI 
was calculated at rest (ABI at rest) and after exercise (ABI-ex). In total 1502 
measurements of ABI at rest (99.7%) and 1469 measurements of ABI-ex 
(97.5%) were suitable for analysis. 
 
Definition of the MetS 
In 2009, a joint interim statement redefining the MetS was published (12). 
Criteria from this statement were adopted and define MetS as the presence of 
at least three of the following five criteria: 1. fasting glucose  5.6 mmol/L 
(100 mg/dL) or drug treatment of elevated glucose; 2. abdominal obesity 
characterized by a waist circumference  102 cm in men and  88 cm in 
women (European thresholds); 3. TG level  1.7 mmol/L (150 mg/dl) or drug 
treatment of elevated triglycerides; 4. HDL-c level < 1.04 mmol/L (40 mg/dL) 
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in men and < 1.29 mmol/L (50 mg/dL) in women or use drug treatment for 
reduced HDL-c; or 5. blood pressure  130/85 mm Hg or antihypertensive 
drug treatment in a patient with a history of hypertension.   
 
Statistical analysis 
Subjects with missing plasma samples were excluded from analysis. We 
determined quartiles of plasma bilirubin level.  Subjects with bilirubin levels 
below the detection limit (5 μmol/L) were categorized in the lowest quartile. 
Tables uniformly present data of the (depicted subgroup of) subjects within 
the lowest and highest bilirubin quartiles of the entire study population. In 
table 3.1, the clinical and biochemical characteristics are presented as 
means followed by the SD for continuous variables and as N followed by the 
percentage for dichotomous variables. Test for trend analysis was performed 
over the four quartiles. To assess associations of plasma bilirubin level with 
the NIMA, we used multivariable logistic regression for dichotomous 
variables and multivariable linear regression for continuous variables. In 
case of skewed data, logarithmic transformation was applied. Models were 
adjusted for 1. age and gender, and 2. age, gender, waist circumference, 
pack years, pulse pressure and plasma levels of HDL cholesterol and fasting 
glucose. The lowest bilirubin quartile was treated as reference group. Data 
from the highest bilirubin quartile are presented as percentage difference 
compared to this reference group followed by the 95% CI. Table 3.2a 
presents the results of both the primary analysis on the entire population 
and the additional analysis for the subgroup of subjects meeting the MetS 
criteria. Finally, we repeated the analysis for both genders separately. 
Results are shown in table 3.2b. STATA 11.0 (StataCorp LP, TX, USA) was 
used to perform the analysis. 
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Results 
 
In total 1517 participants from the NBS were included in the initial study on 
non-invasive measurement of subclinical atherosclerosis. Eleven of these 
subjects were excluded because of non-adherence to the study protocol (for 
example when they did not fast or had been smoking just before the NIMA 
measurements). From the remaining 1506 subjects, 1464 stored plasma 
samples were available for the determination of bilirubin levels. One of these 
samples demonstrated a marked hyperbilirubinemia of 111 μmol/L. In 
retrospect, the corresponding subject had been treated for 
choledocholithiasis shortly after participation to the NBS. This subject was 
therefore removed from analysis. 
Group characteristics per lowest and highest quartile of the bilirubin plasma 
level are summarized in Table 3.1. Compared to the lowest quartile, the 
highest quartile contained a smaller proportion of current smokers and on 
average a lower BMI in both men (P=0.07 and P<0.01, respectively) and 
women (P<0.01 and P=0.07, respectively). In men, fasting glucose and the 
incidence of the MetS were also lower in the highest quartile compared to the 
lowest quartile (P=0.04 and P=0.10, respectively). 
The impact of plasma bilirubin level on the outcomes of the NIMA is 
presented in table 3.2a. With adjustment for age and gender (model 1), 
subjects within the highest bilirubin quartile demonstrate a 3.2% (95%CI: 
1.4;5.0%) higher ABI at rest and an 8.6% (95%CI: 4.7;12.75) higher ABI-ex 
compared to the lowest bilirubin quartile. With additional adjustment for 
traditional cardiovascular risk factors (model 2) this association persists with 
a 1.9% (95%CI: 0.2;3.6%) higher ABI at rest and a 5.4% (95%CI: 1.7;9.2%) 
higher ABI-ex. For other NIMA measurements no clear associations were 
found. 
Of the total group, 489 subjects fulfilled the MetS criteria (264 men, 225 
women). Analysis of this subgroup revealed similar trends on ABI compared 
to the population at large (table 3.2a). Subjects in the highest bilirubin 
quartile of the MetS population demonstrated a trend to an increase of 3.4% 
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(95%CI: -0.3;7.3%) on ABI at rest and 7.6% (95%CI: -0.3;16.1%) on ABI-ex 
compared to those in the lowest bilirubin quartile. No differences were 
shown for PWV, Aix, IMT and both the presence and thickness of carotid 
plaques. 
Data of the analyses by gender are presented in table 3.2b. The associations 
between bilirubin levels and ABI seem less pronounced in women compared 
to men, but confidence intervals are large. 
 
 
Discussion 
 
In line with other studies, our data demonstrate a clear inverse relationship 
between bilirubin plasma levels and the ABI at rest and after exercise. If 
present at all, the reliability of the estimated effect size of the relationship 
between bilirubin plasma levels and other NIMA is limited due to wide 
confidence intervals that include the null value. The ABI is a powerful 
indicator of cardiovascular risk as a low index (≤ 0.90) doubles the 10-year 
risk of total mortality, cardiovascular mortality and major coronary events 
(19). Our results on the ABI fit with the findings by others and extend these 
findings with regard to the MetS. In a large population-based cohort, a 6% 
reduction in the odds of a low ABI (≤ 0.90) for each 0.1 mg/dL increase in 
bilirubin level was demonstrated (20). A similar correlation with ABI was 
found both in subjects with T2DM (21) and in subjects with cardiac disease 
(22). Previously, our group reported on the individual traits of the MetS and 
their association with NIMA within the same population (15). Interestingly 
and in line with other observations (9, 23, 24), the impact of bilirubin we 
demonstrated on the ABI equals the impact of traditional cardiovascular risk 
factors found in our previous study.  
As stated, individual NIMA other than ABI at rest and after exercise do not 
demonstrate a clear association with plasma bilirubin level. However, effect 
estimations of NIMA in general still tend towards a beneficial association 
with bilirubin levels. As our study population is a sample from the general 
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population and therefore characterized by a relatively low incidence of 
atherosclerotic disease, a lack of power may have contributed to the absence 
of a clear association between bilirubin levels and NIMA other than ABI. 
Only few other studies also failed to demonstrate an association between 
plasma bilirubin level and atherosclerotic disease (25-28), but these findings 
are outweighed by many studies including meta-analyses that have yielded a 
clear inverse correlation between bilirubin levels and (measures of) 
cardiovascular disease (9, 14, 20, 21, 29-32).  
Assuming that part of the beneficial impact of bilirubin arises from its 
antioxidant effect and the inhibition of NADPH oxidase, we postulated that 
people exposed to increased levels of oxidative stress, such as MetS patients, 
benefit extra from the protective antioxidant effects of bilirubin. Although 
many studies have demonstrated an association between plasma bilirubin 
level and cardiovascular risk in healthy and high-risk populations before, 
only few made a direct comparison between the impact in the general 
population and the MetS subpopulation. As the MetS subgroup yielded 
similar associations between bilirubin level and ABI compared to the 
population at large, we found no evidence that the beneficial impact of 
bilirubin is potentiated by the presence of traditional cardiovascular risk 
factors. This is consistent with the findings of a large meta-analysis 
demonstrating a persistent association between bilirubin plasma levels and 
cardiovascular disease across subpopulations.(9) For subclinical measures 
of cardiovascular disease, carotid artery intima media thickness has been 
also reported to be negatively correlated to plasma bilirubin levels in both 
the presence and the absence of type 2 diabetes mellitus (14). Others found 
a correlation between bilirubin levels and coronary endothelial function in 
overweight, but not in normal weight, subjects that underwent a coronary 
angiography. This may however be related to a lack of power by the limited 
number of normal weight subjects (13).  
Several reports have mentioned a weaker association or even the absence of 
an association between plasma bilirubin levels and atherosclerosis amongst 
women (23, 33-35). Other papers exclusively reported on a male population 
(24, 36, 37), including a large meta-analysis on bilirubin and cardiovascular 
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disease (29). More recently, others did include women in a large meta-
analysis on the association between plasma bilirubin levels and 
cardiovascular disease (9). They observed a significant log-linear relationship 
in men, which was  non-significant in women without evidence of effect 
modification by sex. In our population, bilirubin levels appeared to have a 
larger impact on ABI in men compared to women. However, because of the 
overlap of confidence intervals, we cannot rule out that the association in 
women in fact equals the association in men.  
Several limitations of our study should be addressed. First, the observational 
character does not permit conclusions on causality. Though supported by a 
genetic study within the Framingham population that demonstrated only a 
third of the cardiovascular risk in subjects with a lifelong mild 
hyperbilirubinemia due to the Gilbert syndrome (38), causality was 
questioned by a nested case referent study that could not establish an 
association between the risk of myocardial infarction and the same genetic 
variation (39). Although the authors did observe lower plasma bilirubin 
levels in cases, they conclude that the association with the risk of 
myocardial infarction should be due to confounding. Their data may have 
been influenced by the short observation period, the exclusion of subjects 
with a prior myocardial infarction or stroke and a survival bias due to the 
high average age at baseline (40). However, two publications have indeed 
added substantial evidence against causality (41, 42). Both papers made use 
of Mendelian randomization. The first could not establish an effect of the 
Gilbert polymorphism on the incidence of ischemic heart disease in three 
studies and a meta-analysis, including the two studies in the Gilbert 
syndrome mentioned before (41). The second evaluated the effect of the 
Gilbert polymorphism on several markers of subclinical atherosclerosis and 
was unable to demonstrate an impact of the Gilbert syndrome on PWV or 
IMT (42). Notably, this study did reveal an association with the cold pressor 
test and the brachial artery diameter. In addition, animal experiments 
support a causal relationship as experimental hyperbilirubinemia appeared 
to improve vascular function (7). Moreover, we recently translated these 
findings to humans. Hyperbilirubinemia induced by a short-term atazanavir 
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treatment improved vascular function in subjects suffering from T2DM (11). 
Notably, the Mendelian randomization studies should be interpreted with 
caution as they may have been confounded by false assumptions with regard 
to linearity of the association or the absence of both pleiotropy and linkage 
disequilibrium of the UGT1A1 gene (43). Additional Mendelian randomization 
studies should be awaited and further (translational) research is needed to 
make a definitive judgment on causality. 
Second, the original study protocol was not designed for determining 
bilirubin levels and did therefore not provide instructions to minimize light 
exposure during handling of the samples. Although the plasma samples were 
treated identically and stored within hours, prolonged light exposure may 
have lowered the bilirubin levels in varying degrees and therefore weakened 
our results. 
 
 
Conclusion 
 
Our data demonstrate an association between plasma bilirubin levels and 
ABI and suggest that this association is neither affected by the co-existence 
of traditional cardiovascular risk factors, nor MetS. Induction of mild 
hyperbilirubinemia may prevent the development of cardiovascular disease. 
However, future studies should provide proof of causality and quantify the 
additional value of such therapeutic strategies in daily practice. 
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Abstract 
 
In type 2 diabetes mellitus (T2DM), oxidative stress gives rise to endothelial 
dysfunction. Bilirubin, a powerful endogenous anti-oxidant, significantly 
attenuates endothelial dysfunction in preclinical experiments. The Gilbert 
syndrome is accompanied by a mild and lifelong hyperbilirubinemia and 
associated with only a third of the usual cardiovascular mortality risk. The 
hyperbilirubinemia caused by atazanavir treatment closely resembles the 
Gilbert syndrome. We thus hypothesized that treatment with atazanavir 
would ameliorate oxidative stress and vascular inflammation and improve 
endothelial function in T2DM. 
In a double blind placebo-controlled crossover design, we induced a 
moderate hyperbilirubinemia by a three day atazanavir treatment in sixteen 
subjects suffering from T2DM. On the fourth day, endothelial function was 
assessed by venous occlusion plethysmography. Endothelium-dependent 
and endothelium-independent vasodilation were assessed by intra-arterial 
infusion of acetylcholine and nitroglycerin respectively. Atazanavir treatment 
induced an increase in average bilirubin levels from 7 μmol/L (0.4 mg/dL) to 
64 μmol/L (3.8 mg/dL). A significant improvement of plasma antioxidant 
capacity (P<0.001) and endothelium-dependent vasodilation (P=0.036) and a 
decrease of plasma von Willebrand factor (P=0.052) were observed. 
Experimental hyperbilirubinemia is associated with a significant 
improvement of endothelial function in T2DM.  
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Introduction 
 
For years, bilirubin has been recognized as a powerful anti-oxidant in the 
human body (1, 2). As atherosclerosis is characterized by a chronic state of 
low grade inflammation (3) and oxidative stress of the vascular wall (4), its 
development may be delayed by bilirubin. Preclinical data strongly support 
this hypothesis. Several in vitro experiments for example have demonstrated 
protection against low density lipoprotein (LDL) oxidation by physiological or 
only mildly elevated bilirubin levels (5, 6). Moreover, bilirubin attenuates the 
pro-inflammatory response of vascular endothelial cells to oxidized LDL and 
tumor necrosis factor-α (7). Most importantly, parenteral treatment with 
bilirubin ameliorated the endothelium-dependent vasodilator response of 
thoracic aortic rings of LDL receptor knock-out mice on a high fat diet (7). In 
line with these robust preclinical data, multiple observational studies have 
demonstrated an inverse relation between bilirubin levels and cardiovascular 
disease in humans (8, 9). Striking in this respect, is the fact that subjects 
with a mild lifelong hyperbilirubinemia due to the Gilbert syndrome carry 
only one third of the cardiovascular mortality risk compared to subjects 
without the syndrome (10).  
 
Figure 4.1 Breakdown of heme 
HO: heme oxygenase; CO: carbon monoxide; Fe: iron; BVR: biliverdin reductase; 
UGT1A1: UDP glucuronosyl transferase (UGT1A1). 
 
As shown in figure 4.1, bilirubin is one of the effector molecules of the 
cytoprotective enzyme heme oxygenase (11). Prior to its excretion into the 
bile, it is conjugated by UDP glucuronosyl transferase 1A1 (UGT1A1). In the 
Gilbert syndrome, the conjugation and thus excretion of bilirubin is 
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hampered as a result of an inactivating TA-repeat polymorphism in the 
promoter region of the gene coding for UGT1A1 (12). As reported recently, 
this polymorphism contributes substantially to the variability in bilirubin 
levels (13). Not surprisingly, UGT1A1 has been suggested as an interesting 
drug target for the prevention of cardiovascular disease (14). Atazanavir is an 
HIV-1 protease inhibitor licensed for the treatment of HIV infections and is 
known to inhibit UGT1A1 activity (15). As such, treatment with atazanavir 
closely resembles the Gilbert syndrome. 
Subjects suffering from type 2 diabetes mellitus (T2DM) are particularly 
prone to the detrimental consequences of cardiovascular disease. 
Endothelial dysfunction can be demonstrated even early in the disease and 
is thought to be crucial in the development of atherosclerosis (16). As the 
prevalence of diabetes is increasing worldwide and is expected to double to 
366 million subjects during the next two decades (17), the prevention of 
cardiovascular disease in this population is of utmost importance. Parallel to 
the above mentioned observational data, the Gilbert syndrome has been 
associated with a significantly lower risk of cardiovascular disease in 
subjects with T2DM (18).  
Despite the strong evidence derived from preclinical and observational data, 
human experiments exploring the beneficial effect of bilirubin on 
cardiovascular disease have, to the best of our knowledge, not been 
published so far. The aim of this double blind placebo-controlled crossover 
study was to prove the hypothesis that elevation of the serum bilirubin level 
by experimental inhibition of UGT1A1 activity would be accompanied by an 
improvement of endothelial function in subjects suffering from T2DM. 
 
 
Methods 
 
Subjects with T2DM were recruited through local advertising and were not 
allowed to have a positive history of smoking, drug abuse or macrovascular 
complications of diabetes. Subjects had to be at least 18 and no older than 
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70 years of age. The body mass index was allowed to range from 18 to 35 
kg/m2. All hyperglycemia treatment regimens including diet, oral medication 
and insulin therapy were accepted. Subjects were prohibited from using 
vasoactive medication, aspirin or anti-oxidant vitamin supplements, as these 
drugs could influence endothelial function. To avoid pharmacokinetic 
interactions with atazanavir, any use of gastric acid suppressive medication 
and statins was discontinued during participation starting four weeks prior 
to the first treatment period. Subjects were enrolled only if they accepted 
such treatment interruption during participation. All subjects gave written 
informed consent prior to the screening visit. Subjects with clinical evidence 
of cardiac or pulmonary disease and subjects with laboratory evidence of 
renal or hepatic abnormalities were excluded. Finally, subjects were 
genetically tested for the presence of the Gilbert syndrome and excluded if 
positive. The study protocol was approved by the local Medical Research 
Ethics Committee and consistent with the Declaration of Helsinki.  
In a double blind and randomized crossover study, subjects received a three 
day atazanavir treatment (Reyataz®, Bristol-Myers Squibb BV, Woerden, the 
Netherlands) and a three day placebo treatment with a wash out period of at 
least three weeks in between. To amplify the level of hyperbilirubinemia, the 
regular dose regimen of atazanavir in HIV patients (either 400 mg once daily 
or 300 mg boosted with ritonavir 100 mg once daily) was modified to an 
alternative regimen of 300 mg twice daily to be taken with food. If reflected 
by the area under the curve, the exposure to atazanavir caused by this dose 
regimen does not exceed the exposure associated with both regular dose 
regimens (19). On the fourth day of both treatment periods, forearm blood 
flow (FBF) was assessed by venous occlusion strain gauge plethysmography. 
A time schedule of these flow assessments is provided in figure 4.2. 
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Figure 4.2 Schedule of flow assessments 
ACh: acetylcholine; NTG: nitroglycerin; S: saline. Dosages are depicted as 
μg/min/dL forearm volume. 
 
All experiments were performed in the morning after an overnight fast in a 
temperature-controlled room (23° C) with the subjects in supine position. If 
needed, dose adjustments of hypoglycaemic agents were recommended 
during the evening and early morning prior to the assessments. Capillary 
glucose levels were monitored. The brachial artery of the non-dominant arm 
was cannulated with a 27-gauge needle (kindly supplied by B. Braun 
Medical BV, Oss, the Netherlands) for intra-arterial administration of saline, 
acetylcholine (Miochol, Thea Pharma NV, Zoetermeer, the Netherlands) and 
nitroglycerine (Nitropohl, Pohl-Boskamp, Hoofddorp, the Netherlands). FBF 
was assessed during the successive administration of three increasing doses 
of acetylcholine (0.5, 2 and 8 μg/min/dL of forearm tissue) and nitroglycerin 
(0.125, 0.25 and 0.5 μg/min/dL). Both series were preceded by a 30 minute 
pause and started with the assessment of baseline FBF during saline 
infusion. Each dose was administered during five minutes. FBF was 
recorded simultaneously on both the infusion and the control arm by venous 
occlusion plethysmography using mercury-in-silastic strain gauges 
(Hokanson EC4, Hokanson, Inc., Washington, USA). The upper arm cuffs 
were inflated using a rapid cuff inflator (Hokanson E-20, DE Hokanson). 
Wrist cuffs were inflated to 220 mm Hg during each series. Immediately after 
completion of FBF assessments, blood pressure in supine position was 
assessed with an aneroid sphygmomanometer. 
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Prior to the experiment, venous blood was drawn. Hematological parameters 
were assessed using an ADVIA 120 Hemalog (Bayer Diagnostic, Tarrytown, 
N.Y., USA) and chemical parameters including bilirubin levels were 
determined using an Aeroset (Abbott Laboratories, Abbott Park, IL, U.S.A.). 
In addition, plasma samples were stored at -80° C for determination of 
atazanavir plasma levels, anti-oxidant capacity and biomarkers of vascular 
inflammation. Atazanavir plasma levels were determined using a 
modification of a validated HPLC method with UV detection as published 
previously (20). Plasma anti-oxidant capacity was assessed by means of the 
ferric reducing ability of plasma (FRAP) assay, according to the method of 
Benzie and Strain (21). FRAP values were obtained using a seven-point 
calibration curve of known amounts of Fe2+ and expressed in mmol Fe2+/L. 
The concentrations of soluble vascular cell adhesion molecule-1 (sVCAM-1) 
and soluble intercellular adhesion molecule-1 (sICAM-1) were determined by 
a multiplex assay (Bio-plex cytokine assay, BioRad, Hercules, CA, USA at 
Luminex 100, Luminex Corporation, the Netherlands). The concentration of 
von Willebrand factor (vWF) was determined by ELISA (Progen biotechnik, 
Heidelberg, Germany and R&D systems, Minneapolis, U.S.A). To enable the 
determination of bilirubin levels after deblinding of the study one additional 
lithium heparin plasma sample was stored at -80°C in a brown Eppendorf 
tube. 
Statistical analysis was performed using the SPSS (version 16.0) and SAS 
(version 8.2) software package. Paired-samples t-test was used to compare 
Gaussian distributed data. For analysis of the forearm blood flow 
measurements, the last five flows of each dose were used. Prior to analysis, 
logarithmic transformation was performed to obtain a Gaussian distribution. 
The flow data were then averaged per dose and subsequently analyzed in a 
mixed linear model with random factor subjects and fixed factors treatment 
and dose. In a post hoc analysis, the atazanavir level, the bilirubin level 
following atazanavir treatment, the baseline level of glycated hemoglobin and 
the duration since diagnosis were included in the model, in order to explore 
a possible impact of these factors on the degree of therapeutic response. 
Flow data are presented in three ways. Figure 4.3 displays the original data 
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in terms of percentage from baseline. The log-transformed data used for 
analysis are presented in table 4.3. The data discussed in the text are 
medians instead of averages of the original flow data to approximate the 
effect of logarithmic transformation. Statistical significance was accepted at 
the 95% confidence level (P ≤ 0.05). 
 
 
Results 
 
Eighteen non-smoking subjects with T2DM and a negative history for 
cardiovascular disease were recruited and gave written informed consent. 
Two of them were excluded during screening, one because of a genetically 
confirmed Gilbert syndrome and the other because of an observed tendency 
towards vasovagal collapse, which would have interfered with the 
assessment of FBF. Based on a data review following completion of the 
study, one of the sixteen participating subjects was excluded because of a 
highly inaccurate intake of study medication as well as an exceptionally low 
quality of the forearm blood flow assessments. This decision was made prior 
to the deblinding procedure. Based on post hoc analysis, inclusion of this 
subject would have resulted in a higher level of significance. The results 
presented concern those of the remaining 15 subjects.  
Characteristics of the study population are shown in table 4.1. We have 
examined six males and nine females with an average body mass index of 28 
kg/m2. The mean history of diabetes was 5.9 years, the average glycated 
hemoglobin level 6.8 percent. Three subjects were treated with a diet only. 
The other twelve subjects were treated with either mono or combination 
therapy containing a biguanide, sulphonylurea or insulin. Nine of fifteen 
subjects were taking statins on inclusion and agreed with interruption 
during participation. As a result of the exclusion criteria, none of the 
subjects was using aspirin or anti-hypertensive medication. 
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Table 4.1 Characteristics of study population (n = 15) 
Sex 6 men, 9 women 
Age (years) 61 (6, 51 – 70) 
BMI  (kg/m2) 28 (4, 18 – 35) 
HbA1c (%) 6.8 (1.1, 5.5 – 9.8) 
Treatment regimen 3 diet only 
  10 metformin 
  7 SU 
  2 insulin 
  9 statin 
Data are given as mean (SD, range), frequency of treatment regimens are given as 
number of subjects. BMI, body mass index; HbA1c, average glycated hemoglobin; 
SU, sulphonyl urea derivates.  
 
 
Table 4.2 Laboratory results after atazanavir and placebo treatment  
 placebo atazanavir P-value 
Bilirubin (μmol/L) 7 (1) 64 (21) < 0.01 
Glucose (mmol/L) 8.4 (0.6) 8.5 (0.7) 0.78 
LDL (mmol/L) 3.7 (0.2) 3.6 (0.2) 0.61 
FRAP (mmol Fe2+/L) 1.26 (0.06) 1.66 (0.07) < 0.001 
vWF  (U/mL) 1.46  (0.13) 1.18  (0.12) 0.05  
sVCAM-1 (pg/mL) 183 (10) 191  (8) 0.14  
sICAM-1 (pg/mL) 158 (7) 153  (7) 0.37  
Data are given as mean (SEM). LDL, low-density lipoprotein; FRAP, ferric reducing 
ability of plasma; vWF, von Willebrand factor; sVCAM-1, soluble vascular cell 
adhesion molecule-1; sICAM-1, soluble interstitial cellular adhesion molecule-1. 
Reported P-values are the result of paired t-tests. 
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Total bilirubin levels after placebo and atazanavir treatment are shown in 
table 4.2. The average bilirubin level following placebo treatment amounted 
to 7 μmol/L (0.4 mg/dL). As anticipated, the three day course of UGT1A1 
inhibition resulted in significantly elevated bilirubin levels with an average of 
64 μmol/L (3.8 mg/dL) and a range of 35 to 110 μmol/L (2.1 to 6.4 mg/dL). 
Due to the short term of the atazanavir treatment, significant tissue 
accumulation and thus clinically perceptible jaundice did not occur except in 
one case. In this subject, jaundice arose on day four after completion of the 
FBF assessments. 
When compared with placebo, a significant improvement of anti-oxidant 
capacity was observed following atazanavir treatment (P < 0.001). In 
addition, atazanavir treatment was associated with a decrease in plasma 
vWF (P = 0.052). Plasma levels of sVCAM-1 and sICAM-1 were not affected. 
Atazanavir treatment did not influence the plasma levels of fasting glucose 
and low density lipoprotein cholesterol.  
The results of FBF experiments are depicted in table 4.3 and figure 4.3. 
Baseline flow after placebo treatment was comparable to baseline flow after 
atazanavir treatment (1.8 and 1.5 mL/min/dL tissue in the intervention arm 
and 1.6 and 1.7 mL/min/dL in the control arm respectively). Neither 
acetylcholine infusion nor nitroglycerin infusion affected the blood flow of the 
contralateral forearm (data not shown). 
 
Table 4.3 Forearm blood flow data after logarithmic transformation 
 placebo atazanavir P-value 
Baseline 0.25 (0.04) 0.18 (0.05) 
0.036 ACh 1 0.75 (0.07) 0.78 (0.07) 
ACh 2 1.01 (0.06) 1.05 (0.06) 
ACh 3 1.25 (0.06) 1.33 (0.04) 
    
Baseline 0.25 (0.05) 0.21 (0.04) 
0.404 NTG 1 0.64 (0.04) 0.64 (0.04) 
NTG 2 0.72 (0.05) 0.73 (0.04) 
NTG 3 0.85 (0.04) 0.81 (0.04) 
ACh1-3, acetylcholine dosage of 0.5, 2.0 and 8.0 μg/min/dL respectively; NTG1-3, 
nitroglycerin dosage of 0.125, 0.250 and 0.500 μg/min/dL respectively. In 
parenthesis standard errors of the mean.  
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Figure 4.3 Forearm blood flow 
FBF in response to the three increasing dosages of acetylcholine and nitroglycerin, 
depicted as percentage from baseline. Black columns represent placebo treatment, 
white columns atazanavir treatment. Error bars indicate standard errors of the 
mean. Statistical analysis was performed on the log-transformed data depicted in 
table 4.3. 
 
 
Intra arterial infusion of acetylcholine induced an increase in FBF at all 
three doses after both placebo and atazanavir treatment. Compared to 
placebo, atazanavir treatment was accompanied by a significantly enhanced 
vasodilator response to acetylcholine. At the highest acetylcholine dose, 8 
μg/min/dL, FBF amounted to median levels of 19.9 and 21.9 mL/min/dL 
following placebo and atazanavir treatment respectively. Statistical analysis 
on the log-transformed flow data of all three acetylcholine dosages revealed a 
relative increase of 12 percent without relevant differences between the three 
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acetylcholine dosages. The improvement of acetylcholine response was not 
influenced by the atazanavir level, the bilirubin level following atazanavir 
treatment, the glycated hemoglobin level at baseline or the duration of 
diabetes prior to inclusion (based on post hoc analysis). 
Intra-arterial infusion of nitroglycerin also induced a significant increase of 
FBF at all dosages. Contrary to acetylcholine, the extent of vasodilator 
response to nitroglycerin was not influenced by our intervention with 
atazanavir. At the highest nitroglycerin dose, 0.5 μg/min/dL, FBF amounted 
to median levels of 7.3 and 7.1 mL/min/dL following placebo and atazanavir 
treatment respectively. 
 
 
Discussion 
 
A multitude of preclinical and observational studies have credited bilirubin 
with the potential to prevent cardiovascular disease. To our knowledge, this 
is the first study addressing the concept of experimental hyperbilirubinemia 
in humans. Our findings demonstrate, that even a three day atazanavir 
treatment improves endothelial function in subjects with T2DM. 
Endothelial dysfunction is strongly related to the development of 
atherosclerosis and the resulting cardiovascular risk (22). Central in the 
pathogenesis of endothelial dysfunction is the decreased availability of 
endothelial nitric oxide (NO) (23). One of the key factors leading to limited NO 
availability is the increase of intracellular oxidative stress. A substantial part 
of the production of reactive oxygen species (ROS) is supposed to stem from 
NADPH oxidase activity (24). 
Addressing the mechanistic importance of oxidative stress, several groups 
have studied the effect of anti-oxidant treatment strategies among which 
intra-arterial infusion of ascorbate. Underscoring the fundamental role of 
oxidative stress, improvement of endothelial function following parenteral 
administration of ascorbate was observed in subjects suffering from various 
conditions like hypercholesterolemia (25), hypertension (26) and both 
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insulin-independent (27) and insulin-dependent diabetes mellitus (28). 
Bilirubin is a powerful endogenous anti-oxidant and its clinical relevance is 
highly suggested by the results of preclinical and observational studies. As 
such, artificial elevation of the serum bilirubin level might be an attractive 
and for the long term workable approach for the prevention of cardiovascular 
disease (14, 29). Our current data on the significant improvement of 
antioxidant capacity and endothelial function observed after a three day 
atazanavir treatment, strongly support the potential of this strategy. 
Biomarkers of vascular inflammation like vWF, sVCAM-1 and sICAM-1, have 
shown to be related to the risk of cardiovascular complications in T2DM (30). 
Besides, bilirubin has been shown to attenuate H2O2-induced endothelial 
leukocyte rolling and adhesion in vivo (31). The observed trend towards a 
decrease of serum vWF is in line with the observed improvement of 
endothelial function and may reflect a decrease of vascular inflammation in 
our subjects. The limited size of our study population and the short duration 
of atazanavir treatment may account for the fact that sVCAM-1 and sICAM-1 
did not alter. 
Several limitations should be addressed as they may have influenced the 
outcome of our study. At first, there are no data available on the bilirubin 
levels needed to obtain maximally protective anti-oxidant effects in vivo in 
humans. In our design, we opted for a short term exposure aiming at 
moderately elevated bilirubin levels. The three day treatment regimen 
resulted in a mean bilirubin level of 64 μmol/L (3.8 mg/dL). As we did not 
observe a relation between bilirubin levels and the vasodilator response to 
acetylcholine, this may indicate that we reached the plateau of the 
concentration – effect curve. Considering the relatively low bilirubin levels 
and the still marked cardiovascular protection observed in subjects with the 
Gilbert syndrome, long term treatment regimens aiming at bilirubin levels in 
the subclinical range may be sufficient as well. This would favor long term 
application of a lower dose of atazanavir as our current regimen would 
definitely cause an unacceptable degree of jaundice during prolonged 
treatment. Further research is needed to address this topic. 
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Secondly, atazanavir itself may have a direct beneficial impact on endothelial 
function. In a previous study, 400 mg of atazanavir once daily did not 
influence endothelial function in healthy volunteers (32). In our study 
however, we administered a different dose. Moreover, we included patients 
with T2DM instead of healthy subjects. Therefore, we do not know whether 
our dose regimen of 300 mg twice daily might affect endothelial function in 
healthy subjects. Besides, bilirubin is obviously not the only substance 
conjugated by UGT1A1. It is likely therefore, that the Gilbert syndrome and 
atazanavir treatment affect plasma levels of substances other than bilirubin. 
Theoretically, such substances as well as atazanavir itself could cause the 
observed improvement of vascular function ascribed to bilirubin. 
Nevertheless, UGT1A1 inhibition and parenteral administration of bilirubin 
comparably attenuated oxidative stress and hypertension in an angiotensin 
II-dependent animal model (33). In our opinion, this supports a causal and 
dominant role of bilirubin. A similar approach with parenteral 
administration of bilirubin in humans may provide a definite proof of its 
beneficial impact on cardiovascular disease. 
Finally, HIV protease inhibitors are commonly connoted for their 
contribution to cardiovascular complications in HIV patients (34). In contrast 
to several other protease inhibitors however, atazanavir does not affect 
glucose tolerance, plasma cholesterol level or endothelial function in healthy 
volunteers at a dosage of 400 mg once daily (32). Consistently, we did not 
observe changes in plasma glucose or plasma cholesterol levels at a twice 
daily dosage of 300 mg nor did we find a relation between atazanavir plasma 
levels and the observed improvement of endothelial function. 
In contrast to the promising data on the parenteral use of ascorbate, clinical 
trials with orally administered exogenous anti-oxidants like vitamin C and E 
have been generally disappointing (35, 36). Several explanations have been 
put forward varying from the inability to obtain sufficiently elevated 
intracellular levels by oral dosing regimens, to the inability of vitamin C and 
E to compete with highly reactive molecules like peroxynitrite (16). Notably, 
bilirubin is one of the most potent scavengers of ROS in nature (37). As our 
strategy evidently fortifies an endogenous and physiologically relevant anti-
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oxidant resource, it may overcome the flaws of previous treatment strategies 
with exogenous anti-oxidants. Besides, bilirubin has shown to inhibit 
NADPH oxidase activity in vitro (38). Given the importance of NADPH oxidase 
activity in the pathogenesis of diabetes related endothelial dysfunction, this 
property may contribute to the beneficial effects on endothelial function 
observed in our diabetic subjects too. 
In summary, our study is the first to address the concept of vascular 
protection by experimental hyperbilirubinemia in humans. Given the 
overwhelming preclinical and observational data on bilirubin and 
cardiovascular disease, it is in our opinion very likely that the improvement 
of endothelial function and plasma anti-oxidant capacity observed after 
atazanavir treatment should be attributed to the associated 
hyperbilirubinemia. Indisputable evidence on this should be provided by the 
use of alternative human models for experimental hyperbilirubinemia. 
Finally, optimally protective plasma levels have to be established. If potent at 
only mildly elevated bilirubin levels, long term UGT1A1 inhibition may prove 
a novel pharmacological approach to prevent cardiovascular disease in 
T2DM. 
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Abstract 
 
Inflammation-induced free radical release is considered an important factor 
in the pathogenesis of several diseases, including atherosclerosis and sepsis. 
Unconjugated bilirubin is a powerful anti-oxidant and elevated levels have 
beneficial effects in preclinical models as well as in human cardiovascular 
disease. However, its effects during acute inflammation in humans are 
unknown. 
Following double-blinded four-day treatment with atazanavir 300 mg (or 
placebo) twice daily, twenty healthy male volunteers received 2 ng/kg 
Escherichia coli lipopolysaccharide intravenously. Blood drawn to determine 
bilirubin levels, anti-oxidant capacity and cytokine response demonstrated 
that atazanavir treatment resulted in an increase in total bilirubin 
concentrations to maximum values of 4.67 mg/dL (95%CI 3.91-5.59) 
compared to 0.82 (95%CI 0.64-1.07) mg/dL in the control group (p<0.01). 
Furthermore, anti-oxidant capacity as measured by the ferric reducing 
activity of plasma was significantly increased with 36% in hyperbilirubinemic 
subjects (p<0.0001) and concentrations correlated strongly with bilirubin 
concentrations (R2=0.77, p<0.001). Atazanavir treatment attenuated the 
release of Interleukin (IL)-10 from 377 (95%CI 233-609) to 219 (95%CI 152-
318) pg/mL (p=0.01), whereas release of pro-inflammatory cytokines 
remained unaltered. In the absence of hyperbilirubemia, atazanavir did not 
influence in vitro LPS-induced cytokine release. Endothelial function was 
assessed using forearm venous occlusion plethysmography after intra-
arterial infusion of acetylcholine and nitroglycerin. Experimental 
hyperbilirubinemia resulted in restorement of the inflammation-associated 
blunted vascular reactivity.  
Atazanavir-induced hyperbilirubinemia increases anti-oxidant capacity, 
attenuates IL-10 release and prevents vascular hyporesponsiveness during 
endotoxemia-induced systemic inflammation in humans. 
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Introduction 
 
Inflammation is the common denominator for numerous diseases and among 
them are the most common causes of death in the developed world, 
including ischemic heart disease, stroke (1), and sepsis (2). In cardiovascular 
diseases, chronic inflammation, oxidative stress, and endothelial dysfunction 
contribute to the formation and progression of atherosclerosis (3). Acute 
inflammatory disorders such as the systemic inflammatory response after 
trauma, major surgery, or during sepsis are believed to be driven by the 
same factors: activation of innate immunity and oxidative stress, leading to 
endothelial dysfunction, organ dysfunction, and, ultimately, death (4). 
Therefore, cardiovascular and infectious diseases research has demonstrated 
overlap in recent years with topics such as the use of statins and their anti-
inflammatory and anti-oxidative effects (5, 6).  
While historically considered as a toxic waste product, bilirubin is one of the 
body’s most powerful endogenous anti-oxidants (7). Bilirubin is known to 
inhibit nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (8, 9) 
and lipid peroxidation, which are both considered crucial for the 
development of atherosclerosis (10, 11). Furthermore, it is a known 
scavenger of reactive nitrogen species (RNS) such as nitric oxide and 
peroxynitrite, both considered central players in the development of 
mitochondrial dysfunction in septic shock (10, 12). Indeed, low levels of 
bilirubin are linked to an increased risk for cardiovascular disease (13-16), 
while subjects with a mild lifelong increase in bilirubin concentrations 
because of Gilbert syndrome demonstrate lower oxidative stress levels and 
better endothelium-dependent vasodilation. Results from several studies 
suggest that these individuals are protected from myocardial infarction and 
peripheral artery diseaseas (17-20). However, it should be noted that other 
investigators failed to reproduce these results (21, 22).  
Animal experiments have also demonstrated beneficial effects of bilirubin (or 
biliverdin) administration in endotoxemia, which is considered a model for 
acute inflammatory disorders, like sepsis (23-25). Data from almost 80 years 
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ago alluded to an anti-inflammatory effect of intravenous bilirubin infusion 
in patients with arthritis (26). Furthermore, beneficial effects on endothelial 
function were demonstrated in diabetic patients treated with the bilirubin-
increasing drug atazanavir (27).  Atazanavir is a protease inhibitor for the 
treatment of human immunodeficiency virus (HIV) infection and because of 
its inhibitory effect on uridine diphosphate-5’-glucuronosyltransferase A1 
(UGT1A1) a Gilbert-syndrome is induced pharmacologically. In the absence 
of bilirubin for infusion, we used this effect to create hyperbilirubinemia in 
the healthy volunteers that participated in the present study. We modified 
the dosing regime in agreement with a previous study to create a sufficient 
degree of hyperbilirubinemia (27). The human endotoxemia model is known 
for inducing a predictable inflammatory response and vascular dysfunction 
and, therefore, administration of lipopolysaccharide (LPS) to healthy 
volunteers enables the investigation of possible therapeutical targets in 
inflammatory disorders (28, 29). In the present study we investigated the 
effects of atazanavir-induced hyperbilirubinemia on anti-oxidant capacity, 
systemic inflammation, and endothelial dysfunction elicited by experimental 
human endotoxemia. 
 
 
Methods 
 
All study procedures were approved by the local ethical committee and in 
accordance to the declaration of Helsinki. This study was registered at 
www.clinicaltrials.gov under number NCT00916448. 
 
Subjects 
All participating subjects gave written informed consent prior to inclusion. A 
screening visit within two weeks prior to the experiments included medical 
history, physical examination, routine laboratory tests including HIV and 
hepatitis B screening and an electrocardiogram (ECG). Total bilirubin levels 
below 0.88 mg/dL (15 μmol/L) were obligatory in order to exclude subjects 
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with Gilbert syndrome. Subjects were non-smokers and were excluded in 
case of previous hypertension or cardiovascular disease. Furthermore, use of 
(over the counter or prescribed) drugs was not allowed within two weeks 
before enrollment until the end of the study. Ten hours before the infusion of 
LPS, subjects refrained from the intake of alcohol, caffeine, and food. 
 
Study design  
In this randomized placebo-controlled parallel study, subjects were treated 
in a double-blinded fashion with atazanavir 300 mg or placebo twice daily for 
four consecutive days prior to the LPS infusion. Adopting this dosing 
regimen, previous experiments in T2DM patients resulted in adequate levels 
of experimental hyperbilirubinemia (27). Randomization was performed by 
an independent research nurse using sealed envelopes. Per inclusion 
criterion, all subjects started treatment with bilirubin levels below 0.88 
mg/dL. After two days into the treatment protocol, bilirubin levels were 
checked by the independent research nurse to ensure that total 
concentrations would not exceed desired values. Given the double-blind 
placebo-controlled nature of the study, investigators were not informed 
about bilirubin concentrations, however, when bilirubin concentrations 
exceeded 4.68 mg/dL (equal to 80 μmol/L) the subject was excluded from 
further participation by the research nurse. Excluded subjects were replaced 
in the study protocol without unblinding the involved investigators. After 4 
days of treatment, subjects were admitted to the research unit of the 
Department of Intensive Care of Radboud university medical center. An 
additional ECG was performed to exclude conduction abnormalities as a side 
effect of atazanavir. After local anesthesia (lidocaine 20 mg/mL), the brachial 
artery was cannulated with a 20-gauge catheter connected to an arterial 
pressure monitoring line (Edwards Lifesciences LLC, Irvine CA, USA 
connected to a Philips IntelliVue MP70 monitor, Philips Medical Systems, 
Eindhoven, The Netherlands) to enable the administration of vasodilating 
drugs, blood sampling and the continuous monitoring of blood pressure. A 
second cannula was placed in an antecubital vein to permit infusion of 
prehydration fluid (1.5 L of 2.5% glucose/0.45% saline solution), LPS, and 
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continuous infusion of 150 mL/h 2.5% glucose/0.45% saline. After 
determination of the baseline responses to acetylcholine and nitroglycerin, 
purified LPS (US Standard Reference Endotoxin Escherichia coli O:113) 
obtained from the Pharmaceutical Development Section of the National 
Institutes of Health (Bethesda, MD, USA) was administered at a dose of 2 
ng/kg body weight. Thereafter, blood was sampled serially and body 
temperature was determined every 30 minutes (Firsttemp Genius 2, 
Covidien, Dublin, Ireland). (Figure 5.1) 
 
 
 
Figure 5.1. Flowchart of the study protocol  
After 4 days of taking either placebo (n=10) or atazanavir (n=10), but prior to LPS 
infusion at 0 h, dose-response curves of acetylcholine and nitroglycerine were 
determined. Thereafter, prehydration fluid was infused and blood was sampled 
before LPS administration and serially thereafter. At 4 h after LPS, dose-response 
curves were repeated. FBF indicates forearm blood flow. Dosing range of 
acetylcholine was 0.5-2-8 μg/min/dL forearm volume, and nitroglycerin was dosed 
at 125-250-500 ng/min/dL forearm volume. 
 
 
Laboratory Tests   
All blood samples were drawn from the arterial line, except for samples 
obtained at t=24 hours (h) when blood was sampled by regular vena 
puncture.  
5
105 
 
Bilirubin was determined before and every two hours after LPS infusion in 
lithium heparin plasma using immunologic detection according to the 
instructions of the manufacturer (Aeroset, Abbott Laboratories, Abbott Park, 
IL, U.S.A.). The ferric reducing ability of plasma (FRAP) assay was performed 
in duplicate as described previously (30). Ferric reducing ability of plasma 
values were obtained using a 7-point calibration curve of known amounts of 
Fe2+ and expressed in mmol Fe2+/L. The concentrations of tumor necrosis 
factor (TNF)-α, Interleukin (IL)-6, IL-8, IL-10 and Monocyte Chemotactic 
Protein (MCP)-1, as well as concentrations of endocan, endothelial (E) and 
platelet (P)-selectin and soluble vascular cell and inter-cellular adhesion 
molecules (VCAM-1 and ICAM-1, respectively) were determined in EDTA or 
lithium heparin plasma obtained immediately before LPS administration and 
serially thereafter (see Figure 5.1 for details). Measurements of all cytokines 
and of the soluble adhesion molecules VCAM-1 and ICAM-1 were performed 
by a multiplex assay according to the manufacturer’s instructions (Bio-plex 
cytokine assay, BioRad, Hercules, CA, USA at Luminex 100, Luminex 
Corporation, The Netherlands). E-and P-selectin were determined by 
Enzyme-Linked Immuno Sorbent Assay (ELISA) (R&D systems, Minneapolis, 
USA). Endocan was measured using a sandwich ELISA  (Lunginnov, Lille, 
France). 
C-reactive protein (CRP) levels were measured just before and at 8 and 24 h 
after LPS in lithium heparin plasma (Aeroset, Abbott Laboratories, Abbott 
Park, IL, USA). Leukocyte counts were determined in EDTA anti-coagulated 
blood using flow-cytometry (Sysmex XE-2100, Goffin Meyvis, Etten- Leur, 
The Netherlands) just before and serially after LPS infusion.   
 
In vitro LPS stimulation 
To exclude a direct pro- or anti-inflammatory effect of atazanavir unrelated 
to its induction of hyperbilirubinemia, an in vitro experiment withs whole 
blood in the presence or absence of atazanavir and/or LPS was performed. 
An atazanavir stock solution of 1 mg/mL was prepared as previously 
described (31) and dissolved in dimethyl sulfoxide (DMSO). Further 
dissolution was performed in RPMI 1640 (Sigma-Aldrich, Zwijndrecht, The 
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Netherlands) to reach a final concentration 0.1% DMSO.  Whole blood of 6 
healthy volunteers was incubated with 0, 1, 5 or 10 μmol/L atazanavir and 
0, 1, 10 ng/mL LPS for 24 h at 37°C under 5% CO2. Thereafter, the incubate 
was centrifuged at 20,000 g for 5 minutes. Plasma was aspirated and an 
ELISA was performed for TNF-α and IL-10 (R&D systems, Minneapolis, USA). 
 
Forearm blood flow measurements  
Forearm blood flow (FBF) was determined using venous occlusion 
plethysmography (Filtrass, Domed, Munich, Germany) as previously 
described (32, 33). Briefly, venous occlusion was achieved by inflating the 
upper arm cuff to 45 mmHg. Strain gauges were placed on the forearm and 
connected to plethysmographs to measure changes in forearm volume in 
response to inflation of the venous-congesting cuffs. FBF and drug 
administration were normalized to forearm volume as measured with the 
water displacement method and expressed in milliliters per minute per 
deciliter forearm volume (mL/min/dL). After instrumentation, a resting 
period of 30 minutes was kept to ensure stabile forearm blood flow. 
Thereafter, a dose-response curve to intrabrachial infusion of acetylcholine 
(Miochol, Thea Pharma NV, Zoetermeer, the Netherlands) and nitroglycerin 
(Nitropohl, Pohl-Boskamp, Hoofddorp, The Netherlands) were determined. 
Baseline FBF was determined during five minutes, followed by infusion in 
equal volumes of increasing doses of acetylcholine (0.5, 2, and 8 μg/min/dL 
forearm volume).  Each dose was administered for 5 minutes and 
measurements of FBF were performed in the last 3 minutes. After a washout 
period of 15 minutes and after another baseline measurement, nitroglycerin 
was infused in the same fashion at doses of 125, 250 and 500 ng/min/dL.  
Since infusion of LPS is known to induce vascular hyporeactivity to 
vasodilators after 4 h and until 6 h after administration (34, 35), we repeated 
these measurements at t=4 h to determine the effects of atazanavir-induced 
hyperbilirubinemia on LPS-induced vascular hyporeactivity.  
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Data Analysis and Statistics 
Values are expressed as geometric mean (95% confidence interval (CI)) 
unless described otherwise. Because of the small sample size, log 
transformation was performed to ensure a Gaussian distribution. Thereafter, 
a two-way repeated-measures analysis of variance (ANOVA) was used to test 
variation over time, the variation between interventions, and the interaction 
between time and intervention (IBM SPSS statistics 20 software, Amsterdam, 
The Netherlands). Changes over time alone were analyzed by One-way 
ANOVA (GraphPad Prism version 5.03 for Windows, GraphPad Software, San 
Diego California USA). To compare differences in baseline parameters 
between groups and the difference between baseline and peak values we 
used Student’s t test (Graphpad) on log-transformed data. A p-value < 0.05 
was considered to indicate significance. 
 
 
Results 
 
Demographic data and safety 
Baseline characteristics are presented in Table 5.1. There were no 
differences between the groups. The study drugs were well tolerated and no 
side effects were reported by the subjects. A total of 30 subjects were 
included, of which 10 could not complete the study protocol for different 
reasons. Five of them were excluded because of a too steep rise in bilirubin 
following intake of study medication, as measured two days before the 
planned LPS administration. Two subjects experienced a vagal response 
during the placement of the cannulas, 1 subject was unable to plan the 
experiment, 1 subject made errors in medication intake, and 1 subject had a 
new first-degree atrioventricular block at the morning of the experiment.  All 
subjects excluded after the start of the study medication were replaced to 
ensure equal distribution in the two treatment arms. 
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Table 5.1 Baseline Characteristics 
Placebo (n=10) Atazanavir (n=10) 
Height, cm 182 (177-190)  182 (173-195) 
Weight, kg 73.7 (61.0-87.0) 76.7 (65-93.5) 
Body mass index, kg/m2 22.3 (18.8-25.1) 23.2 (19.4-27.5) 
Age, years 23.0 (20-27) 21.7 (19-28) 
Heart rate, bpm 60 (51-75) 63 (53-79) 
Systolic blood pressure, mmHg 121 (100-144) 125 (110-132) 
Diastolic blood pressure, mmHg 74 (65-85) 77 (65-88)  
Forearm Volume, mL 1401 (1300-1650) 1415 (1200-1750) 
Total cholesterol, mmol/L 3.3 (2.4-4.4)  3.2 (2.5-4.4) 
LDL cholesterol, mmol/L 1.9 (1.2-2.9) 1.7 (0.97-2.76) 
HDL cholesterol, mmol/L 0.97 (0.65-1.18) 1.00 (0.68-1.19) 
Non-HDL cholesterol, mmol/L 2.3 (1.6-3.3) 2.1 (1.5-3.4) 
Triglycerides, mmol/L 0.8 (0.52-1.68) 1.0 (0.57-1.64) 
All data are expressed as geometric mean followed in brackets by range. 
 
 
Bilirubin and anti-oxidant capacity 
Before the start of atazanavir/placebo treatment, bilirubin averaged 0.54 
(95%CI: 0.49-0.58) mg/dL in subjects using atazanavir versus 0.57 (95%CI: 
0.50-0.65) mg/dL in the placebo group (p=0.5). After 4 days of treatment, 
bilirubin concentration averaged 3.08 (95%CI: 2.62-3.61) mg/dL in subjects 
treated with atazanavir versus 0.48 (95%CI: 0.37-0.52) mg/dL in subjects 
treated with placebo (p<0.01). During experimental endotoxemia, a further 
increase in bilirubin was observed in both groups. In subjects treated with 
atazanavir, levels peaked after 6 h to an average maximum concentration of 
4.67 (95%CI: 3.91-5.59) mg/dL while in the placebo group, a maximum 
value of 0.82 (95%CI: 0.64-1.07) was reached at 4 h after LPS infusion (over 
time both p<0.001, between groups p=0.001). (Figure 5.2A) The total anti-
oxidant capacity was assessed by measurement of FRAP and was 
significantly increased in subjects treated with atazanavir averaging 1.09 
(95%CI: 1.01-1.18) mmol Fe2+/L compared to 0.80 (95%CI: 0.72-0.89) mmol 
Fe2+/L in subjects treated with placebo (p<0.0001), and did not change 
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following LPS administration (over time p=0.5 in both the atazanavir group 
and the placebo group). Furthermore, there was a strong correlation between 
bilirubin and FRAP concentrations (Spearman R2: 0.77, p<0.001). (Figure 
5.2B) 
 
 
Figure 5.2 
A) Bilirubin concentrations in subjects treated with placebo (●) and atazanavir (ATV) 
(○) before and serially after the administration of 2 ng/kg Escherichia coli LPS. Data 
are represented as geometric mean and 95% confidence interval. P-value was 
obtained by repeated measures analysis of variance on log transformed data of the 
complete curve. B) The correlation between bilirubin and FRAP. Values were 
obtained just before administration of 2 ng/kg Escherichia coli LPS. Correlations 
were determined using Spearman’s rank correlation coefficient 
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Inflammatory effects in vivo and in vitro 
As demonstrated in Figure 5.3, LPS infusion induced an increase in all 
measured cytokines. Maximum concentrations for the pro-inflammatory 
cytokine TNF-α were 578 (95%CI: 443-753) pg/mL in subjects treated with 
atazanavir versus 580 (95%CI: 395-852) pg/mL in subjects treated with 
placebo (p-value over time both <0.001, between groups p=0.7). 
Concentrations of IL-6 peaked at 1082 (95%CI: 914-1280) pg/mL in the 
atazanavir group compared to 890 (95%CI: 683-1160) pg/mL in the placebo 
group (over time both p<0.001, between groups p=0.1). IL-8 and MCP-1 
peaked at maximum values of 693 (95%CI: 583-825) and 5828 (95%CI: 
4183-8063) pg/mL, respectively, in subjects treated with atazanavir versus 
590 (95%CI: 444-784) and 6835 (95%CI: 5224-8943) pg/mL in subjects 
treated with placebo (all: over time p<0.001, between groups IL-8: p=0.2, 
MCP-1: p= 0.6). 
The anti-inflammatory cytokine IL-10 was attenuated in subjects treated 
with atazanavir: 219 (95%CI: 152-318) pg/mL versus 377 (95%CI: 233-609) 
pg/mL in subjects in the placebo group (over time both p<0.001, between 
groups p=0.01). (Figure 5.3) 
Furthermore, CRP was increased at 24 h following LPS infusion, but did not 
differ between groups (average concentration of 39 (95%CI: 33-47) mg/L in 
the atazanavir-group compared to 35 (95%CI: 29-44) mg/L in the placebo 
group, p=0.3).  
Increasing levels of atazanavir did not induce the in vitro release of TNF-α or 
IL-10 during whole blood incubation for 24 hrs, neither did atazanavir 
influence the release of TNF-α or IL-10 with increasing doses of LPS. As 
expected, increasing doses of LPS induced increasing concentrations of TNF-
α and IL-10. (Figure 5.4) 
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Figure 5.3 Cytokine concentrations 
Levels were determined in the absence (n=10 depicted as ●) and presence (n=10, 
depicted as ○) of atazanavir after administration of 2 ng/kg Escherichia coli LPS to 
healthy volunteers at 0 h. TNF-α: tumor necrosis factor-α (A), IL-6: interleukin-6 
(B), IL-10: interleukin -10 (C), IL-8: interleukin-8 (D), MCP-1: monocyte 
chemoattractant protein-1 (E), CRP: C-reactive protein (F). Data are presented as 
geometric mean and 95% confidence interval. P-values were obtained using 
repeated measure analysis of variance on log-transformed data of the complete 
curve. 
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Figure 5.4 In vitro effects of atazanavir and LPS 
A: Concentration of tumor necrosis factor-α (TNF-α) after 24 hrs of whole blood 
incubation (n=6) with rising doses of Escherichia coli LPS and/or atazanavir (ATV). 
Both doses of LPS significantly increased TNF-α concentrations (p<0.001) while 
increasing doses of atazanavir did not affect TNF-α concentrations. B: 
Concentrations of interleukin (IL)-10 after 24 hrs of whole blood incubation (n=6) 
with rising doses of Escherichia coli LPS and/or atazanavir (ATV). Both doses of 
LPS significantly increased IL-10  concentrations (p<0.001), while increasing doses 
of atazanavir did not affect IL-10. Whiskers are depicted as minimum and 
maximum values. P-values were obtained using Student’s t-test on log transformed 
data. 
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Table 5.2 Hemodynamic response, temperature and forearm blood flow after 
2 ng/kg E. coli LPS infusion 
  Before LPS T=4 h p-value  
over 
time 
p-value 
between 
groups 
Heart Rate, 
bpm 
Placebo 
ATV 
70 (62-79) 
73 (65-81) 
92 (85-100) 
95 (87-104) 
<0.001 
<0.001 
0.3 
MAP, mmHg Placebo 
ATV 
93 (87-100) 
96 (91-102) 
78 (73-84) 
77 (72-82) 
<0.001 
<0.001 
0.6 
Temperature,°C Placebo  
ATV 
36.8 (36.7-37.0) 
36.8 (36.6-37.1) 
37.8 (37.4-38.3) 
38.0 (37.2-38.9) 
<0.001 
<0.001 
0.6 
FBF, 
mL/min/dL 
Placebo 
ATV 
3.2 (2.1-4.8) 
4.5 (3.0-6.7) 
8.1 (6.5-10.1) 
6.9 (4.5-10.5) 
<0.001 
0.2 
NS* 
MAP: mean arterial blood pressure, FBF: forearm blood flow. Data are expressed as 
geometric mean and 95% confidence interval. P-values were all calculated on log-
transformed data. Values over time were obtained using one-way analysis of 
variance while p-values between groups were obtained using repeated measures 
analysis of variance or, in case of forearm blood flow using an unpaired Student’s t-
test.*NS: non-significant differences between forearm blood flow in subjects using 
placebo or atazanavir before LPS (p=0.2) and after LPS (p=0.5). 
 
 
Effects on systemic hemodynamic response  
Treatment with atazanavir or placebo did not influence endotoxemia-induced 
changes in mean arterial pressure (MAP) or heart rate. At 4 h after LPS 
infusion, MAP was decreased by 20% in subjects receiving atazanavir versus 
a decrease of 16% in subjects receiving placebo (Table 5.2, over time both 
p<0.001, no significant difference between groups). Heart rate increased by 
30% in hyperbilirubinemic subjects versus 31% in the placebo group. (Table 
5.2, over time both p<0.001, no significant difference between groups).  
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Effects on endothelial dysfunction and activation 
FBF assessed by venous occlusion plethysmography increased in both 
groups after LPS infusion as demonstrated in Table 5.2.  In subjects treated 
with placebo and before the administration of LPS, the highest dose of 
acetylcholine (8 μg/min/dL forearm tissue) increased flow to 304 (95%CI: 
214-430)% compared to baseline. At 4 h after LPS infusion the response was 
attenuated with a maximum response of 183 (95%CI: 136-246)% compared 
to baseline measured at 4 h. (p=0.02, Figure 5.5A) 
In subjects treated with atazanavir, the attenuated vasodilatory response 
following LPS infusion was not observed. After the highest dose of 
acetylcholine and before the administration of LPS, flow increased to 221 
(95%CI: 129-378)% compared to baseline, whereas 4 h after LPS 
administration flow increased to 217 (95%CI: 135-347)% upon 
administration of 8 μg/min/dL acetylcholine.(p=0.8, Figure 5.5B) 
In the placebo group, nitroglycerin at a dose of 500 ng/min/dL increased 
flow to maximum values of 251 (95%CI: 185-340)% compared to baseline, 
whereas at 4 h after LPS the maximum response was 169 (95%CI: 143-
198)% (p=0.01). In hyperbilirubinemic subjects a non-significant attenuation 
of the response following LPS infusion was observed: 226 (95%CI: 162-316) 
% compared to baseline before LPS and 173 (95%CI: 142-211)% after LPS 
infusion. (p=0.2, Figure 5.5C/D) 
Following LPS administration the endothelial biomarkers E-selectin, P-
selectin, VCAM-1, ICAM-1 and endocan were all significantly increased over 
time (p<0.01). No significant differences could be demonstrated between 
subjects treated with atazanavir or placebo (Figure 5.6).  
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Figure 5.5 Forearm blood flow dose-response curves 
Responses to acetylcholine (A,B) and nitroglycerin (C,D) before (●) and 4 h after the 
administration of 2 ng/kg Escherichia coli LPS (○) to healthy subjects in the 
absence (A,C) and presence (B,D) of atazanavir. Data are presented as % compared 
to baseline and expressed as geometric mean and 95% confidence interval. P-values 
were obtained using a repeated measures analysis of variance on log transformed 
data of the complete curve. 
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Figure 5.6. Endothelial biomarkers  
Platelet(P)-selectin (A), endothelial (E)-selectin (B), vascular cell adhesion molecule 
(VCAM)-1 (C), intercellular adhesion molecule (ICAM)-1 (D) and endocan (E) before 
and at peak value after administration of 2 ng/kg Escherichia coli LPS to healthy 
volunteers in the absence (grey bars) and presence (white bars) of atazanavir. In 
both treatment arms, LPS induced an increase for all molecules (p<0.01). Data are 
presented as geometric means and 95% confidence interval. P-values between 
groups were obtained using an unpaired Student’s t-test on log transformed data. 
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Discussion 
 
The present study demonstrates that atazanavir-induced hyperbilirubinemia 
increases anti-oxidative capacity and decreases IL-10 release. Furthermore, 
vascular hyporeactivity during experimental endotoxemia was completely 
prevented in subjects with atazanavir-induced hyperbilirubinemia. These 
data indicate that increases in bilirubin in this range exert relevant effects 
on oxidative stress, inflammation and vascular reactivity in humans in vivo. 
In the human body, bilirubin is present in three forms: the majority is 
albumin-bound unconjugated bilirubin, a very small fraction is free 
unconjugated bilirubin, and the remainder is conjugated bilirubin. By using 
atazanavir, the main form of the increased levels of bilirubin will be albumin 
bound and unconjugated. Its anti-oxidative effects in this form include 
inhibition of NADPH oxidase (8, 9), reduction of lipid-peroxidation, 
scavenging of peroxyl radicals and RNS thereby protecting fatty acids and 
decreasing the oxidative capacity of hydroxyl and superoxide anion radicals, 
and peroxynitrite (extensively described in a review by Stocker (7)). Besides 
beneficial effects in cardiovascular diseases by prevention of vascular 
dysfunction and the formation and progression of atherosclerosis, these 
effects could also benefit septic patients since these substances are related 
to mitochondrial dysfunction, which is considered important in the 
development of organ dysfunction (10, 12).  
Clinical data of the inverse correlation between bilirubin concentration and 
the occurrence of cardiovascular disease are abundant. Subjects with Gilbert 
syndrome have a decreased risk of cardiovascular events and ischemic heart 
disease (17, 18), whereas a relatively low bilirubin concentration is related to 
coronary artery calcification, silent cerebral infarction and coronary heart 
disease (13-17). Endothelial dysfunction is strongly associated with 
atherosclerosis and cardiovascular disease and increased oxidative stress is 
a key factor in its development (36). Our data show that inflammation-
induced endothelial dysfunction abates during experimental 
hyperbilirubinemia associated with atazanavir use. The notion that 
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specifically the anti-oxidant effects of bilirubin account for this observation 
is supported by several other reports elucidating the effects of e.g. the anti-
oxidant vitamin C. Both locally and systemically administered vitamin C was 
associated with an improved endothelial function, using the same 
experimental human endotoxemia model (37, 38). Interestingly, others 
demonstrated that healthy subjects with mild hyperbilirubinemia exhibit a 
significantly enhanced endothelium-dependent vasodilation and flow-
mediated dilation compared to subjects with normal or low bilirubin (20, 39). 
Similar ameliorating effects on endothelium-dependent vasodilation were 
found in type 2 diabetes patients with atazanavir-induced 
hyperbilirubinemia (27). The attenuation of the response to the endothelium-
independent vasodilator nitroglycerin observed in our human endotoxemia 
experiments confirms previous studies (40, 41), but is not always found (35, 
37). It could be speculated that the presence of inducible nitric oxide 
synthase (iNOS)-derived nitric oxide (NO) after endotoxin administration 
induces a mild tolerance to NO donors such as nitroglycerin. Since bilirubin 
is a known iNOS inhibitor (9, 25), it is tempting to speculate that this may 
explain why the effect appears to be less pronounced in subjects with 
atazanavir-induced hyperbilirubinemia. 
Beneficial effects of elevated levels of bilirubin on inflammatory markers were 
demonstrated in various inflammation models. In some studies TNF-α 
secretion was found to be attenuated (23, 25), while in another no effects on 
cytokine concentrations were observed (8). Nevertheless, pretreatment with 
bilirubin prior to LPS administration reduces symptoms, attenuates iNOS 
release and improves survival rates in animal models (23, 25). Of interest, an 
average (lifelong) concentration of 1.14 mg/dL in a human study population 
with Gilbert-syndrome is known to have protective effects on cardiovascular 
disease compared to an average of 0.69 mg/dL in control patients (17). These 
data suggest that relatively small changes in bilirubin concentration could 
already elicit beneficial effects. Others have used much higher 
concentrations in rodents with a single bolus that reached peak 
concentrations of 6 mg/dL (23). Based on previous use of the atazanavir 
model demonstrating improvement of endothelial function in T2DM subjects 
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at a plasma bilirubin concentration of 3.8 mg/dL (27), we aimed for bilirubin 
levels around 4 mg/dL. We cannot exclude that lower bilirubin plasma levels 
suffice and evoke comparable anti-inflammatory or vascular effects in 
human inflammatory disorders. In our study, endotoxemia itself induced a 
modest increase of bilirubin in subjects receiving placebo. Several 
mechanisms may explain this effect. LPS administration results in a 
downregulation of UGT1A1 through nuclear factor (NF)-κB and therefore can 
increase bilirubin slightly (42). In addition, TNF-α and IL-6 appear to reduce 
bilirubin clearance in the liver (43). Furthermore, induction of heme-
oxygenase that breaks down heme to form bilirubin (most likely occurring in 
the tissues rather than in circulating cells (44)) cannot be excluded.  
In the absence of a commercially available bilirubin product for parenteral 
use, we have demonstrated the usability of the atazanavir model in a proof of 
principle study on the effects of bilirubin in acute inflammation. Obviously, 
we cannot exclude the possibility that the effects found in our study were in 
fact provoked by atazanavir instead of bilirubin. Protease inhibitors in HIV 
patients are known for their disadvantageous effects on lipid profiles and 
their negative effects on endothelial function (45, 46) and both are 
considered related to the increased risk for cardiovascular disease in HIV 
patients. However, a study performed in healthy volunteers demonstrated 
that atazanavir treatment did not influence lipid profiles or significantly 
impact the response to endothelium-dependent vasodilator methacholine 
(46). In accordance, we demonstrated that short term treatment with 
atazanavir in our study does not affect the response to acetylcholine before 
LPS administration (data not shown) or lipid profiles demonstrating that 
inflammation is the most likely cause for endothelial dysfunction in our 
study. However, an effect of atazanavir or its metabolites on endothelial 
function or inflammation after LPS cannot be fully excluded. Nevertheless, 
additional in vitro experiments demonstrated that atazanavir does not 
influence the release of TNF-α or IL-10 (in the presence or absence of LPS) 
making it less likely that atazanavir itself interfered with our cytokine 
results. 
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The strength of the present study includes the fact that the effects of 
atazanavir-induced hyperbilirubinemia were investigated in a well explored 
and standardized model for inflammation, thereby gaining insight into the 
effects of bilirubin during acute systemic inflammation in humans. 
Obviously, a proof of principle study is limited by the amount of subjects and 
more importantly the characteristics of the preclinical model used. Future 
studies in alternative models and eventually clinical practice are warranted 
to explore the effects of bilirubin in acute and chronic human inflammatory 
diseases. Such studies might benefit from the development alternative 
pharmacological means to induce a hyperbilirubinemia striving for both a 
maximum ease of use and a minimum of adverse side effects. 
In conclusion, the present study is the first to demonstrate that 
hyperbilirubinemia elicited by atazanavir improves anti-oxidant status, 
reduces IL-10 release and abolishes endothelial dysfunction during 
experimental endotoxemia in humans. Based on these data, further studies 
utilizing possible other techniques to increase bilirubin concentrations are 
warranted to investigate its possible therapeutic applications in patients 
suffering from inflammatory diseases. 
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Abstract 
 
Preclinical results suggest therapeutic potential of mild hyperbilirubinemia 
in T2DM and cardiovascular disease. Translational data are limited, because 
an appropriate bilirubin formulation for parenteral human use is lacking. 
Considering its use in both clinical practice and medical research in the 
past, we explored the feasibility to reintroduce parenteral bilirubin for 
translational experiments.  
We developed a preparation method in accordance with good manufacturing 
practice and evaluated the parenteral applicability in healthy volunteers 
(n=8). Explorative pharmacokinetic and safety data were compared to the 
results from a literature study on the former parenteral use of bilirubin. 
Bilirubin was administered intra-arterially to raise the local plasma 
concentration in the forearm vascular bed (n=4) and intravenously to raise 
the systemic plasma concentration (n=4). Finally pharmacokinetic 
characteristics were studied following a single bolus infusion (n=3). 
During parenteral application no side effects occurred. Adverse events 
mentioned during the two week observation period were in general mild and 
self-limiting. Three more significant adverse events (appendicitis, 
asymptomatic cardiac arrhythmia and atopic eczema) were judged unrelated 
by independent physicians. 
A dose-concentration relationship appeared sufficiently predictable for both 
intra-arterial and intravenous administration. In line with existing 
knowledge, bilirubin pharmacokinetics could be described best according to 
a two-compartment model with a volume of distribution of 9.9 (±2.0) l and a 
total plasma clearance of 36 (±16) ml per minute. 
Supported by previous reports, our data suggest that it is both feasible and 
safe to perform translational experiments with parenteral albumin bound 
bilirubin. 
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Introduction 
 
Though commonly seen as a harmful residual product from the breakdown 
of heme, bilirubin was already demonstrated to possess anti-oxidant 
capacities in 1954 (1). Ever since, a wide variety of in vitro and animal 
studies have been published on the protecting anti-oxidant, anti-
inflammatory and anti-fibrotic effects of both bilirubin and heme oxygenase 
(HO), the rate-limiting enzyme in bilirubin formation (2, 3). Numerous 
observational studies have demonstrated an inverse association between 
bilirubin concentrations and cardiovascular disease in humans (4). 
Therefore, both the induction of a mild hyperbilirubinemia and the 
enhancement of HO activity have been suggested for the treatment of a 
variety of diseases, including type 2 diabetes mellitus and related 
cardiovascular disorders (2, 5, 6). In case of cardiovascular disease 
translational research is enabled by several well established measures of 
endothelium function as surrogate endpoints (7). Using the perfused forearm 
technique, we previously succeeded to improve endothelial function and 
plasma anti-oxidant capacity in subjects with type 2 diabetes mellitus by a 
short-term treatment with the plasma bilirubin-increasing drug atazanavir 
(8). Additional experiments are needed to invigorate these promising findings 
in the atazanavir model. 
Though opportune for translational and clinical studies that require a steady 
elevation of bilirubin plasma levels, in proof of concept studies the use of 
atazanavir hampers the attribution of observed effects to bilirubin as 
atazanavir itself might influence outcome too. In addition, the atazanavir 
model does not enable to investigate the dose-response relationship of 
bilirubin. The availability of a bilirubin formulation that is suitable for 
parenteral human use would significantly facilitate the design of such 
experiments. 
In the past, intravenous administration of bilirubin was commonly applied in 
human research and clinical practice (see table 6.1). After 1981, however, no 
new data on the experimental use of bilirubin in humans was published. 
Subsequent to an extensive literature study on the former preparation and 
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parenteral use of bilirubin, we developed a production method meeting 
current standards of good manufacturing practice (GMP). In addition to the 
intravenous use of the preparation, we also studied its applicability for intra-
arterial administration in the perfused forearm model. Here, we present the 
method of preparation and the first results on its intravenous and intra-
arterial application in healthy volunteers, including data on its 
pharmacokinetics and safety. For their exploratory nature, these data are 
supported by the context of extensive pharmacokinetic and safety data from 
former reports on the parenteral human use of bilirubin. 
 
 
Methods 
 
Preparation 
Bilirubin concentrate for infusion (6 mg/mL, 10 mL vials) for parenteral use 
in the clinical trial was produced compliant with GMP at the department of 
Pharmacy of the Radboudumc. All chemicals were commercially available 
and used as obtained. All materials were approved on the basis of in-house 
quality controls and their suppliers were qualified. The aseptic production 
process was validated by means of media fills. The drug substance was 
acquired from from Sigma Aldrich (Zwijndrecht, The Netherlands) as 
bilirubin ≥98% powder. The drug substance was tested for identity, purity, 
content with spectrophotometric and chemical analysis and endotoxins with 
the Limulus Amoebocyte Lysate (LAL) test. The drug product was prepared 
by dissolving 6 grams of bilirubin and 4 grams of sodiumhydroxide (Spruyt 
Hillen, IJsselstein, The Netherlands) in 1 liter of water for injections. After 
dissolving, the solution was purged with nitrogen, filtered through a 
Sartopore 2 XLI (0.35 + 0.2 μm) sterile filter (Sartorius AG, Goettingen, 
Germany) and, subsequently, sterile vials were filled with 10.2 ml of liquid 
under a continuous flow of nitrogen. This was carried out at the Department 
of Pharmacy at the Erasmus Medical Center in Rotterdam, The Netherlands. 
Quality control and release of the product was performed at the Department 
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of Clinical Pharmacy, Radboudumc, Nijmegen, The Netherlands. The drug 
product was tested for the microbiological aspects bioburden, sterility and 
endotoxins. Furthermore, labelling, volume, pH, identity and content as well 
particulate contamination were assessed compliant with European 
Pharmacopeia requirements for parenteral preparations. The identity and 
content was assessed by means of a validated high performance liquid 
chromatography assay with ultraviolet detection (HPLC-UV). Prospective 
stability studies showed a stability of the product for 12 months at -20 °C. 
The final formulation consisted of bilirubin at 6 mg/ml in 0.1M sodium 
hydroxide with a pH >10. Shortly before administration the product was 
passed through a 0.2 μm filter and diluted with human albumin 200 mg/ml 
intravenous solution (Albuman ®, Sanquin Plasma Products) to a 
concentration of 1.2 mg/ml for intravenous infusion (pH 8.1) and to a 
concentration of 0.6 mg/ml for intra-arterial infusion (pH 7.6). Based on the 
molecular weight of bilirubin (584.66 g/mol) and albumin (66.5 kg/mol) the 
molarity for bilirubin and albumin was 2.05 and 2.41 mmol/L, respectively, 
for the intravenous solution, and 1.03 and 2.71 mmol/L, respectively, for the 
intra-arterial solution. 
 
Study design 
The applicability of our final bilirubin formulation was evaluated in eight 
healthy volunteers and included the exploration of its pharmacokinetics and 
safety to verify the results from our review of former reports. Subjects had to 
be at least 18 and no older than 65 years of age and were not allowed to 
have a positive history of smoking, drug abuse or liver disease. Women of 
child bearing potential were included only if adequate contraceptive 
measures had been taken. Except for contraceptives, any use of medication 
was prohibited. After signing informed consent, all volunteers were screened 
by means of a complete medical history, physical examination and a limited 
laboratory evaluation including blood count, renal function and liver 
enzymes. Subjects with any sign of active disease or laboratory results 
exceeding twice the upper limit of normal range were excluded. To avoid 
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inclusion of subjects with Gilbert syndrome, baseline plasma levels of total 
bilirubin were not allowed to surpass 10 μmol/L (0.58 mg/dL). 
 
Figure 6.1 Study design 
Bilirubin dosage was adjusted to individual forearm volume in phase 1 and body 
weight in phase 2 and 3. Gray bars indicate the time of infusion of bilirubin. 
Venous blood was sampled from the contralateral arm and in phase 1 also from the 
ipsilateral arm. 
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The experimental design is depicted in figure 6.1. For safety reasons, the 
study protocol initially consisted of a two-stage design. Both stages were 
separated by a safety evaluation to enable adjustment of the second stage 
protocol if needed. During the experiment, a third stage was added to explore 
bilirubin plasma kinetics after a short high dose intravenous infusion. Intra-
arterial and intravenous dose schedules were adjusted to forearm volume 
and total body weight, respectively. In all three stages of the protocol, 
subjects were studied in succession with at least one week in between. 
During the first intra-arterial stage of the protocol, we aimed for a local 
increase in bilirubin concentration in the forearm vascular bed without a 
significant rise of systemic levels. Four increasing doses of bilirubin were 
infused in the brachial artery, each during 20 minutes. Based on the 
assumption of an average brachial artery flow of 2 mL/min per dL of forearm 
volume, the lowest intra-arterial dosage of 1.8 μg/min per dL of forearm 
volume was estimated to give an ipsilateral rise of plasma bilirubin 
concentration of 3 μmol/L (0.18 mg/dL). For the highest intra-arterial 
dosage of 30 μg/min per dL of forearm volume we expected an ipsilateral rise 
of plasma bilirubin concentration of 50 μmol/L (2.92 mg/dL). Venous 
plasma samples were taken every 5 minutes from both the ipsilateral and 
the contralateral arm to assess local as well as systemic changes of bilirubin 
plasma concentration.  
During the second stage we aimed for a systemic hyperbilirubinemia. Each 
of the three intravenous bolus injections was administered over a period of 5 
minutes, followed by a 15 minutes pause. As others have reported an 
increase of approximately 30 (range 24 – 38) μmol/L after a single bolus 
injection of 70 mg (9), we estimated that a single bolus of 233 mg bilirubin 
would cause an increase of plasma bilirubin level of 100 μmol/L. For safety 
reasons and the reported range, we lowered this maximum dose to 200 mg 
corresponding to an expected average rise of 88 μmol/L. To enable 
adjustment to body weight we redefined this maximum dose to 2.9 mg/kg 
bodyweight assuming an average body weight of 70 kg. The lowest 
intravenous dosage of 0.086 mg/kg body weight was estimated to cause a 
systemic rise of 2.6 μmol/L (0.15 mg/dL). For the highest intravenous 
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dosage during the second phase, we expected a rise of 26 μmol/L (1.52 
mg/dL). Every 5 minutes, a plasma sample was taken from the contralateral 
arm. 
During the third phase, we explored the pharmacokinetics of bilirubin upon 
a single intravenous bolus of the maximum dosage of 2.9 mg/kg body weight 
administered over 15 minutes. Subsequently, plasma bilirubin 
concentrations were measured frequently over a total period of six hours. 
The length of interval between sampling was increased during observation 
and varied from 5 minutes immediately upon administration to a maximum 
of 30 minutes from the second hour of observation. 
During all three stages, heart rate, blood pressure, respiratory rate and body 
temperature were monitored. All complaints mentioned during participation 
were listed. After treatment, subjects visited the research unit on day 1, 2 
and 7 to check for side effects. Two weeks after participation, subjects 
underwent a complete medical screening. 
Hematological parameters were assessed using an ADVIA 120 Hemalog 
(Bayer Diagnostic, Tarrytown, N.Y., USA) and chemical parameters including 
both direct (i.e. conjugated) and total bilirubin concentrations were 
determined using an Aeroset (Abbott Laboratories, Abbott Park, IL, U.S.A.). 
For bilirubin concentrations above 5 μmol/L, precision of the measurement 
was characterized by a coefficient of variation (CV) of  20% . Below 5 μmol/L, 
which concerned seven samples of total bilirubin, the CV was much higher 
than 20% and therefore these results were excluded. 
The initial study protocol and all interim modifications were approved by the 
local medical research ethics committee (CMO Regio Arnhem-Nijmegen) and 
consistent with the Declaration of Helsinki. In addition, we appointed an 
independent safety monitor and scheduled frequent meetings to discuss all 
safety data. 
 
Statistics   
In general, descriptive data are presented as mean (±SD). All plasma 
concentrations of bilirubin presented are total (conjugated and 
unconjugated) bilirubin plasma concentrations. Changes in plasma 
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concentration of total bilirubin upon intra-arterial or intravenous infusion 
are depicted as delta. For the intra-arterial infusion in the first phase of our 
experiment, the delta reflects the local rise in plasma bilirubin in the forearm 
vascular bed per dose calculated by the difference between the venous 
bilirubin concentration in the forearm of administration and the 
contemporary systemic bilirubin concentration  (i.e. the venous bilirubin 
concentration in the contralateral forearm)  at the end of the 20 minute 
infusion period of the dose concerned. For the intravenous infusion in the 
second phase of our experiment, the delta reflects the systemic rise in 
plasma bilirubin upon each of the three bolus infusions calculated by the 
difference between the highest plasma bilirubin concentration observed after 
each bolus infusion and the baseline concentration observed at the start of 
the 5 minute infusion period of the dose concerned. The individual plasma 
concentration-time profiles obtained during the third phase of our 
experiment are depicted in Figure 6.2.  
For pharmacokinetic analysis, plasma concentration-time data of total 
bilirubin were analyzed with use of WinNonlin (version 6.3; Pharsight, 
Mountain View, CA) by weighted (1/y) nonlinear regression analysis 
according to a two-compartment model with short intravenous infusion, 
first-order elimination, and a constant endogenous baseline concentration of 
bilirubin. The following pharmacokinetic parameters were obtained (Table 
6.3): total area under the curve (AUC), total area under the first moment 
curve (AUMC), volume of the central compartment (V1), half-life of the 
distribution phase (t½,α), half-life of the elimination phase (t½,β), mean 
residence time (MRT = AUMC/AUC – Tinf/2, where Tinf = infusion time), total 
plasma clearance (CL = D/AUC), and volume of distribution at steady-state 
(Vss = CL × MRT). 
A summary of supporting pharmacokinetic and safety information from the 
prior parenteral human use of bilirubin is provided in Table 6.1. 
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Table 6.1 Overview of publications on parenteral human use of bilirubin  
 Author(s) Year NS NI Dose Bilirubin  level AE’
s 
1 Von Bergmann (9, 
10) 
1927 108 120 70 mg 31 (24 – 38) Y‡ 
2 Boshamer (11) 1928 20 > 46 50 mg NR NR 
3 Harrop and 
Barron (12) 
1931 27 27 1  mg/kg NR NR 
4 Stroebe (13) 1932 16 16 50 mg NR NR 
5 Zadek (14) 1932 10 10 50 mg NR NR 
6 Hofbauer (15) 1933 20 20 1 mg/kg NR NR 
7 Dietel (16, 17) 1933 45 45 50 mg NR NR 
8 Binswanger (18) 1933 111 111 50 mg NR NR 
9 Fuge (19) 1933 44 54 50 mg 31 (12 – 63)  NR 
10 Soffer (20) 1933 21 31 1  mg/kg NR N 
11 Nürnberger (21) 1933 25 25 50 mg 15 (9 – 22) NR 
12 Schindel (22) 1934 NR 50 50 mg NR (12 – 44) NR 
13 Sullivan (23) 1934 101 147 1 mg/kg NR N 
14 Bröchner (24) 1935 65 68 50 mg 27 (11 – 48) NR 
15 Bröchner (25) 1935 50 52 50 mg 31 (17 – 45) NR‡ 
16 Ruhbaum (26) 1935 44 44 50 mg NR NR 
17 Fulde (27) 1935 35 36 50 mg NR NR 
18 Lin (28) 1937 26 26 10 
3 
mg mg/kg NR NR 
19 Thompson (29) 1938 10 85 5 – 20 mg/kg 250 (38 – 607) Y‡ 
20 Lyon (30) 1938 20 20 1 mg/kg NR Y‡ 
21 Rawls (31) 1938 NR NR < 3 mg/kg NR NR 
22 Hench (32) 1938 13 > 78 1 – 4 g NR (342 – 599) Y‡ 
23 Weech (33) 1941 35 35 5 mg/kg NR (103 – 151)† N 
24 Kornberg (34) 1942 65 65 1.5 mg/kg 63 (37 – 123) N 
25 With (35) 1943 63 56 
1 
7 
4 
50 
75 
100 
150 
mg 
mg 
mg 
mg 
65 (22 – 380) NR 
26 Arpe (36) 1946 19 19 NR  NR NR 
27 Tisdale (37) 1959 11 11 15 mg/kg 268 (96 – 323)  NR 
28 Billing (38) 1964 38 38 2 mg/kg NR (51 – 68) † NR 
29 Schmidt (39) 1966 8 8 4 – 6 mg 46 (19 – 82) NR 
30 Raymond (40) 1966 10 10 NR  NR NR‡ 
31 Nixon (41) 1967 1 1 2 mg/kg 84 NR 
32 Engstedt (42) 1967 21 21 50 mg NR NR 
33 Barrett (43) 1968 29 29 
8 
< 0.4 
2 
mg 
mg/kg 
NR 
NR 
NR 
34 Berk (44, 45) 1969 - 
1970 
53 53 < 0.4 mg NR NR 
35 Okolicsanyi (46) 1978 119 119 
14 
2 
540 
mg/kg 
mg 
NR 
NR (68 – 154) 
Y‡ 
36 Goresky (47) 1978 11 11 
8 
5 
2 
6 
12 
mg/kg 
mg/kg 
mg/kg 
NR (75 – 91) † 
NR (221 – 275) † 
NR (426 – 559) † 
NR 
37 Okolicsanyi (48) 1981 29 36 2 mg/kg NR NR 
38 Zenerolli (49) 1982 100 100 2 mg/kg NR NR 
 Sum  1423 > 1770     
         
Bilirubin plasma levels are expressed in μmol/L and depicted as average (range). NS: 
number of subjects; NI: number of infusions; AE’s: adverse events; Y: yes; N: no; 
NR: not reported. †: estimated from incompletely published data. ‡: additional 
information on adverse events.  
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Table 6.1 - continuation 
‡ Additional information on adverse events 
  
1 Fever and chills, 30 - 45 min after injection, avoidable by use of freshly prepared 
bilirubin 
15 10 patients died of severe infections 
19 Co-administration of bile salts; 15 reactions in six patients; Local reactions after 
repetitive infusions; Systemic reactions both immediate (flushing, tachycardia 
and head ache) and delayed (nausea, vomiting, chills and fever one hour after 
administration) 
20 Two deaths (day 6 and 32 after administration), likely related to a complicated 
pregnancy 
22 Venous thrombosis; Strong alkaline mixture;6 – 30 infusions per subject 
30 Authors state that “The procedure is safe…” 
35 Well tolerated except from mild soreness in the arm after high dose in a few 
instances 
 
 
Results 
 
Subject screening 
As a result of the interim amendment of our protocol subjects were recruited 
on two occasions prior to both the first and the additional third phase of the 
study. In total, 13 subjects were screened, four of which were excluded 
because of an elevated plasma bilirubin concentration at baseline. The 
remaining nine subjects were all suitable for inclusion in our study. Eight of 
them actually participated in the experiments. Five subjects (2 male, 3 
female) participated in the intra-arterial dosing experiment (phase 1) and 
four of them (1 male, 3 female) also participated in the intravenous dosing 
experiment (phase 2). Subject B (male) was willing but, for logistic reasons, 
unable to participate to phase 2. The course of the plasma concentration of 
bilirubin upon a single intravenous bolus infusion (phase 3) was studied in 
three other subjects (all male). All participating subjects were without any 
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active disease. All three female participants used oral contraceptive 
medication. The average age of the subjects was 21.5 years (range 19 – 27). 
 
Intra-arterial and intravenous dosing studies (phase 1 and 2) 
Although both total and direct bilirubin levels were measured, parenteral 
administration of our formulation consisting of unconjugated bilirubin 
bound to albumin, almost exclusively increased total bilirubin levels and 
hardly affected the plasma levels of direct (conjugated) bilirubin. The local 
rise of plasma total bilirubin concentration in the forearm vascular bed in 
response to intra-arterial administration is depicted in Table 6.2a. During 
the first intra-arterial experiments we experienced technical difficulties. 
Because of unsuccessful cannulation of the brachial artery during the very 
first experiment, we decided to administer bilirubin intravenously instead. 
Consequently, only systemic concentrations and safety data are presented 
for the first subject. Dislocation of the intra-arterial needle (second 
experiment) and temporary obstruction of the sampling system (third 
experiment) accounted for the remainder of missing values. The intra-arterial 
bilirubin dosage needed to increase the local plasma bilirubin concentration 
in the forearm vascular bed by 1 μmol/L amounted 1.44, 0.75, 0.82 and 
0.71 μg/min per dL of forearm tissue on average for the four subsequent 
intra-arterial infusions, respectively. The systemic rise of plasma bilirubin 
concentration in response to intravenous bolus infusion is depicted in Table 
6.2b. The intravenous dosage needed to increase the systemic plasma 
concentration by 1 μmol/L amounted to 0.041 (0.005) mg bilirubin per kg 
body weight on average. 
 
Pharmacokinetic parameters (phase 3) 
The pharmacokinetic characteristics of total bilirubin obtained during the 
third and final phase of our experiments are depicted in Figure 6.2 and Table 
6.3. The plasma concentration-time curves could be described best by an 
open two-compartment model, taking the endogenous baseline concentration 
of total bilirubin into account. Figure 6.2 displays the fitted individual curves 
of total plasma bilirubin concentrations upon the administration of the 
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single intravenous bolus infusion of 2.9 mg bilirubin per kg body weight. 
Maximum total bilirubin plasma concentrations of 72, 76 and 86 μmol/L 
were observed in the three subjects studied, respectively. Pharmacokinetic 
parameters obtained from this analysis are listed in Table 6.3.  
 
Table 6.2a Individual bilirubin plasma concentrations during intra-arterial 
administration 
 Dose 
(μg/min/dL) 
Expected 
rise (μmol/L) 
Delta bilirubin 
concentration (μmol/L) 
Average 
delta 
(SD; μmol/L) 
Increase 
per 1 
μg/min/dL 
Subject   A B C D E   
FAV (dL)   10 13 11 11 10   
Dose 1 1.8 3  1  0 3 1.3 (1.5) 0.7 
Dose 2 6 10    5 11 8.0 (4.2) 1.3 
Dose 3 18 30   23 18 25 22.0 (3.6) 1.2 
Dose 4 30 50   45 27 54 42.0 (13.7) 1.4 
The delta resembles the local rise of plasma bilirubin concentration in the forearm 
per intra-arterial dose and is depicted by the difference between the venous 
bilirubin concentration in the forearm of administration and the contemporary 
systemic bilirubin concentration in the contralateral forearm at the end of the 20 
minute infusion period of the dose concerned. FAV: forearm volume. 
 
Table 6.2b Individual bilirubin plasma concentrations during intravenous 
administration 
 Dose (mg/kg) Expected 
rise (μmol/L) 
Delta bilirubin 
concentration (μmol/L) 
Average 
delta 
(SD, μmol/L) 
Increase 
per 1 
mg/kg 
Subject   A C D E   
BW (kg)   62 63.5 64 61.5   
Dose 1 0.086 2.6 3  2 2 2.3 (0.6) 27.1 
Dose 2 0.29 8.8 8 6 7 7 7.0 (0.8) 24.1 
Dose 3 0.86 26.4 24 21 22 19 21.5 (2.1) 25.0 
The delta resembles the systemic rise of plasma bilirubin per intravenous dose and 
is depicted by the difference between the highest plasma bilirubin concentration 
observed upon each bolus infusion and the baseline bilirubin concentration 
observed prior to the administration of the intravenous bolus infusion concerned. 
BW: body weight.  
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Figure 6.2 Plasma concentration-time curves 
Plasma concentration-time curves of bilirubin after short intravenous infusion of 
2.9 mg/kg in three healthy male subjects. 
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Table 6.3 Pharmacokinetic parameters of bilirubin after a single intravenous 
bolus infusion of 2.9 mg per kg of body weight 
 Individual subjects Mean (SD) 
Subject (all male) F G H  
BW (kg) 82 87 71  
Dosage (μmol) 406 429 351  
Tinf (min) 15 15 12  
Cbaseline (μmol/L) 8 8 8  
AUC (μmol*min/L) 1.17×104 0.97×104 1.19×104 1,11 (0.12) ×104 
AUMC (μmol*min2/L) 11.0×106 2.41×106 3.72×106 5.71(4.63)×106 
V1 (L) 5.8 5.2 4.0 5.0 (0.9) 
t½,α (min) 43 34 42 40 (5) 
t½,β (min) 280 184 343 270 (80) 
MRT (min) 315 204 333 280 (70) 
CL (mL/min) 35 44 29 36 (8) 
Vss (L) 10.9 9.0 9.8 9.9 (1.0) 
Data are presented as mean (SD). BW: body weight; AUC: total area under the 
plasma concentration-time curve, AUMC: total area under the first moment of the 
plasma concentration-time curve, V1: volume of the central compartment, t½,α: 
half-life of the distribution phase, t½,β: half-life of the elimination phase, MRT: 
mean residence time, CL: total plasma clearance, and Vss: volume of distribution at 
steady-state. 
 
Safety 
In general, the administration of bilirubin was well tolerated. None of the 
experiments, including the one that was complicated by displacement of the 
intra-arterial needle and consequent extravasation of bilirubin, was 
associated with side effects during the administration. During the 
observation period, several adverse events were noted. An overview of all 13 
adverse events is provided in the supporting information (Table 6.4). The 
majority of these events was mild, self-limiting and/or clearly unrelated. 
Three events deserve additional attention. First, one of the subjects suffered 
from a necrotizing appendicitis ten days upon the intra-arterial 
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administration of bilirubin. The subject underwent surgery and fully 
recovered. The event was considered unrelated to our study by both the 
safety monitor and the independent surgeon. Although the possibility to 
withdraw informed consent was explicitly discussed, the subject decided to 
continue participation and did not show any adverse event during the 
second phase of the experiments. Second, one of the subjects demonstrated 
an asymptomatic self-limiting atrial rhythm with a right bundle branch block 
during the post infusion observation period in the second phase of the study. 
An independent cardiology consultant considered the arrhythmia to be 
physiologic and unrelated to our study. Additional visits did not reveal any 
sign of side effects. Third, one of the subjects developed a rash 50 hours 
after a single high dose intravenous bolus injection of bilirubin and albumin. 
An independent dermatology consultant considered the eruption due to 
atopic eczema and unrelated to our study. Additional hematological tests 
and clinical chemistry did not show any sign of systemic side effects. The 
rash vanished within days after topical application of corticosteroids and 
symptomatic treatment with cetirizine. 
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Discussion 
 
Promising preclinical and observational human reports on bilirubin 
encourage a reintroduction of its parenteral human use for the purpose of 
translational research (6). Despite a reasonable amount of data on 
pharmacokinetics and safety of parenteral human use of bilirubin from the 
past, the compound is currently not commercially available in a proper 
formulation for human use. Our data demonstrate that it is nevertheless 
feasible to prepare and apply bilirubin solutions for parenteral human use in 
accordance with GMP standards. Due to the exploratory nature of our 
experiments and the associated low number of subjects studied, our 
pharmacokinetics and safety results should be discussed in the context of 
previously reported data. Table 6.1 provides an overview of all available data 
on the former human use of bilirubin. 
 
Production 
The majority of previous publications on the human use of bilirubin report 
the use of sodium carbonate solutions with high alkalinity. In contrast to 
these reports, we dissolved bilirubin in sodium hydroxide and diluted this 
product in a solution with albumin in excess. Similar procedures have been 
published before for animal experiments and a few human studies (44, 50-
57). Apart from the beneficial reduction of alkalinity, this strategy is 
consistent with normal in vivo physiologic conditions in which unconjugated 
bilirubin is tightly bound to albumin (58). In addition, albumin binding has 
shown to augment the anti-oxidant activity of unconjugated bilirubin in vitro 
(59, 60). 
 
Pharmacokinetics 
In preparation of future translational studies on the supposed beneficial 
impact of bilirubin, we aimed to explore the intra-arterial use of 
unconjugated bilirubin and verify the previously reported pharmacokinetic 
characteristics of intravenously administered unconjugated bilirubin. Our 
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data demonstrate a predictable dose-concentration relationship for both 
routes of administration, facilitating the design of future translational 
studies on the therapeutic potential of bilirubin. 
During the third phase of our experiments, we studied the pharmacokinetics 
of unconjugated bilirubin upon a single intravenous bolus infusion. The 
disposition of unconjugated bilirubin is highly determined by its strong 
binding to albumin. Its exchange between albumin in plasma and albumin 
in the interstitial fluid is allowed by a small free fraction, which is estimated 
to amount only 1/50.000 of total serum bilirubin (58). The volume of 
distribution (Vss) found in our experiments (Table 6.3) corresponds to a 
normal albumin space of 9 L (61). The two phases of the two-compartment 
model that was fitted to the plasma concentration-time curve relate to the 
initial distribution within the albumin space and the true bilirubin clearance 
by the liver. The corresponding half-lives are in agreement with values 
recently predicted by a theoretical model based on the consequences of its 
strong albumin binding (58). In the past, multiple studies on the clearance of 
intravenously administered bilirubin have been performed using either small 
trace-labeled amounts (44, 45), larger non-radioactive dosages (35, 38, 46-
49), such as in our experiments, or both (43). Two- and three-compartment 
models with varying pharmacokinetic characteristics have been proposed. 
Comparison of data is complicated by the fact that the interpretation of the 
disappearance curve and selection of the most appropriate compartment 
model in these older reports was hampered by the lack of current insight 
into bilirubin physiology. Most authors falsely assumed the presence of a 
hepatic bilirubin pool (38, 45, 47) and did not consider the importance of the 
small free fraction of unconjugated bilirubin enabling exchange to albumin 
within the interstitial space. Notably, our experiments were not designed to 
gain detailed insight into the pharmacokinetics of bilirubin, but aimed to 
assess the applicability of our formulation for parenteral human use and 
explore its pharmacokinetic characteristics in comparison with existing data. 
  
6
Parenteral bilirubin for translational research
144  
 
Safety 
Whereas the actual administration of bilirubin was well tolerated, several 
adverse events occurred during the subsequent observation including an 
appendicitis, an asymptomatic cardiac arrhythmia and a pruritic rash. 
Although independent expert clinicians considered these events to be 
unrelated to our experiment, it should be stated that we cannot exclude a 
causal association between the events and the combined administration of 
bilirubin and albumin. Moreover, the limited size of our study does not allow 
any definite conclusion on safety issues. We therefore performed an 
extensive review of the literature covering over 1750 individual bilirubin 
infusions during the former century (Table 6.1). The earliest reports on the 
human use of bilirubin mentioned the occurrence of side effects consisting of 
transient chills and fever.(10, 29) Hinting at microbial contamination, these 
effects could be avoided by a switch to the exclusive use of fresh sterile 
solutions (10). Besides, immediate effects like flushing, tachycardia and 
headache have been mentioned upon the combined infusion of bilirubin and 
bile acids (29). The contemporary use of bile acids obviously complicates the 
definite attribution of the side effects reported in this study. Importantly, no 
other study on the human use of bilirubin has mentioned the occurrence of 
these immediate effects. Finally, the use of large amounts of bilirubin 
dissolved in an unbuffered alkaline solution has been associated with the 
frequent occurrence of venous thrombosis (32). These authors reported up to 
thirty infusions per subject and bilirubin plasma concentrations up to 500 
μmol/L. Though less severe, others have reported mild soreness at the 
injection site in a few cases of highly dosed bilirubin infusions (46). Notably, 
the vast majority of reports on the parenteral use of bilirubin have not 
mentioned any side effect related to its infusion. Several of these reports 
explicitly mentioned the absence of side effects, covering a total of 278 
bilirubin infusions with plasma concentrations up to 150 μmol/L (20, 23, 
33, 34, 62). 
In view of the available data, we feel confident to state that parenteral use of 
bilirubin is safe if produced under GMP conditions and applied in its current 
dosage and albumin bound formulation. Obviously, future studies should 
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maintain focus on the early detection of side effects and it should be noted 
that bilirubin pigments currently available on the market are purified from 
either porcine or bovine gallstones. In our opinion only products of porcine 
origin should be used to nullify the theoretical risk of prion transmission. 
 
Limitations  
Several limitations of this study should be mentioned. First, the number of 
subjects included to test the applicability of our formulation is too low to 
permit conclusions on pharmacokinetics and safety characteristics by its 
own. In view of the yet available knowledge from former experiments and a 
recent theoretical model, we felt it was more appropriate to perform a 
thorough review of prior reports than to increase the sample size purely to 
confirm existing knowledge on these topics. 
Second, we adjusted the bilirubin dosage to forearm volume for intra-arterial 
administration and to body weight for intravenous administration in order to 
minimize variability. This strategy resulted in fairly predictable and 
consistent bilirubin plasma concentrations. It should be noted though that 
both the forearm volumes and body weights of our subjects were quite 
similar and within normal range. Additional experiments are needed to 
confirm the applicability of our dose adjustment strategies in a study 
population with a larger inter-individual variability in forearm volume and 
body weight. 
Third, the clearance of bilirubin demonstrates a significant inter-individual 
variability which is related to several genetic polymorphisms (62). Most 
common is the Gilbert Syndrome, which is due to a TA-insertion in the 
UGT1A1 promotor region and accompanied by a significantly reduced 
glucuronidation activity to approximately 30% of normal (63). To avoid 
outliers as a result of the Gilbert Syndrome, we excluded subjects with a 
plasma bilirubin concentration exceeding 10 μmol/L during the screening 
visit. Though less sensitive than the assessment of individual genetic 
polymorphisms, this approach sufficiently excludes subjects with the Gilbert 
syndrome (64). In view of the relatively high prevalence of the Gilbert 
syndrome in the general population, the avoidance of outliers by the 
6
Parenteral bilirubin for translational research
146 
 
exclusion of subjects with high baseline bilirubin concentrations may have 
caused our clearance data to overestimate the average clearance capacity 
within the general population. 
Finally, we did not assess the impact of our formulation on endothelial 
function. Additional experiments in healthy volunteers are needed to 
compare endothelial function during the intra-arterial infusion of bilirubin 
and saline as control. To discern the effect of bilirubin from possible 
interference of co-administered albumin, subsequent proof of concept 
studies in subjects with endothelial dysfunction should ideally be performed 
with an albumin solution as control.  
 
Conclusion 
In conclusion, our study reopens the gate to the human parenteral use of 
bilirubin for the purpose of translational research. Larger studies are needed 
to evaluate the usefulness of adjusting dose regimens to either forearm 
volume or body weight and to study the influence of genetic variation on the 
elimination rate of bilirubin from plasma. Nevertheless, it appears feasible to 
corroborate the promising preclinical and observational data of bilirubin in 
human disease models. As such, our data provide a basis for further 
experiments on the beneficial anti-oxidant and anti-inflammatory effects 
attributed to bilirubin. 
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General discussion 
 
This thesis covers several translational studies on the therapeutic potential 
of HO-1 induction and hyperbilirubinemia in the metabolic syndrome (MetS), 
in type 2 diabetes (T2DM) and in a human endotoxemia model. Our findings 
will be discussed in the context of increasing insight into the pathogenesis of 
MetS, T2DM and atherosclerotic cardiovascular disease (CVD) and the 
intriguing role of heme oxygenase (HO)-1 and bilirubin herein. 
Accumulating evidence indicates a key role for low-grade inflammation in the 
pathogenesis of obesity-related diseases like MetS, T2DM, and CVD. 
Inflammation associated with obesity appears to be the result of a complex 
interplay between metabolism and the immune system and involves 
adipocytes, vascular cells, neural cells, and multiple immune cells (1). In 
adipocytes, nutritional excess is associated with a redox imbalance 
culminating in so-called adipocyte dysfunction and ultimately insulin 
resistance (2). Involvement of endothelial cells in the inflammatory process is 
characterized by endothelial dysfunction, which is known to herald the 
development of atherosclerosis (3). Over the past years, both HO activity and 
bilirubin have been shown to ameliorate insulin resistance as well as 
atherosclerotic disease in a wide variety of experiments (4). Current 
knowledge and resulting future perspectives will be discussed separately for 
both HO-1 and bilirubin. 
 
 
The role of HO-1 
 
Current insights and results from our experiments 
Traditionally, the beneficial impact of HO-1 has been attributed simply and 
solely to the breakdown of pro-oxidant heme and the associated generation 
of anti-oxidant and anti-inflammatory molecules, including CO, bilirubin, 
and ferritin (5). Recent papers, however, demonstrate important additional 
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non-enzymatic actions of HO-1 (6). Besides, the regulation of HO-1 activity 
appears to involve a refined system of posttranslational modifications such 
as phosphorylation and truncation of the enzyme. HO-1 is present and 
enzymatically active in several subcellular compartments including the 
endoplasmatic reticulum, caveolae, and mitochondria. In a truncated form, 
HO-1 is able to enter the nucleus and affect transcription of other enzymes 
in response to well-known stimuli of HO-1 induction. Likewise, a number of 
regulating functions have been ascribed to biliverdin reductase, the enzyme 
that converts biliverdin into bilirubin (7). 
It is important to note that experimentally HO-1 induction does not 
consistently result in an increase of HO-1 activity. Instead, the extent of HO-
1 activity upon induction depends on the type of inducer, metabolic 
circumstances, and the type of cell and tissue involved (4). As a result, the 
impact of natural and pharmacological HO-1 inducers differs between cell 
types, tissues, and species.  
Also, the in vivo effect of HO-1 induction exhibits important cellular 
differences. In contrast to systemic HO-1 induction, which is in general 
associated with amelioration of MetS and endothelial dysfunction (4), animal 
experiments on selective manipulation of HO-1 activity at a cellular level 
have yielded results varying from amelioration to aggravation of insulin 
resistance. Whereas selective adipocyte HO-1 induction in a mouse model of 
obesity has been demonstrated to cause an amelioration of insulin 
resistance, hypertension, and dyslipidemia (8), others have reported that 
under the same conditions insulin resistance induced by a high fat diet was 
not ameliorated (9). Interestingly, knockout of HO-1 in macrophages even 
protects mice against metabolic disease associated with a high fat diet (10). 
Likewise, activity of HO-1 in hepatocytes has been shown to promote insulin 
resistance in several HO-1 transgenic and –KO mouse (10).  
In chapter 2, we examined the impact of short term HO-1 induction upon 
systemic administration of heme arginate in subjects suffering from MetS 
(11). In contrast to previous human experiments with similar dosing 
schedules (12, 13), heme arginate infusion only modestly induced HO-1 
activity. Monitoring of experimental HO-1 induction in humans is, however, 
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hampered by the current lack of a reliable and widely accepted marker of 
HO-1 activity. In contrast to promising preclinical data on the amelioration 
of insulin resistance and endothelial dysfunction upon HO-1 induction (4), 
no improvement of insulin sensitivity or endothelial function was observed in 
our subjects. Instead, the vasodilator response to intra-arterial infusion of 
nitroglycerin was significantly reduced by the administration of heme 
arginate. Apart from interspecies differences, these unexpected results might 
be explained by the design of our experiments, including the timing and the 
level of the heme arginate dosages. Notably, elevated plasma heme levels 
may have interfered with the beneficial effect of concomitant HO-1 induction. 
In summary, recent findings demonstrate a complex regulation of HO-1 
activity and different cellular functions of HO-1. The design of translational 
experiments on the effect of HO-1 induction is complicated, as the observed 
clinical effect appears to be highly variable and influenced by a variety of 
factors including cell type, tissue, and species involved. Dependent on the 
type of HO-1 effect to be investigated, the study setup, including the 
selection of HO-1 inducer and dosing schedule, needs to be designed 
carefully.  
 
Future perspectives 
Human data on the beneficial impact of HO-1 are still scarce, but of vital 
importance to confirm the suggested therapeutic potential from preclinical 
experiments. Prior to the evaluation in clinical studies, an extension and 
validation of both preclinical and translational data is needed. Preclinical 
experiments should further elucidate the complex mechanisms underlying 
the observed specific role in HO-1 induction of the inducing agent, cell type, 
tissue, species, and disease phenotype. Translational experiments should be 
designed carefully accounting for the delicate balance associated with the 
use of inducers such as heme arginate. One should also strive for a dosage 
level and duration that is sufficiently high to achieve clinical efficacy, but 
also not too high to avoid elevated heme levels by the time endpoints are 
assessed. Additional pharmacologic experiments in healthy volunteers might 
provide more effective dosing strategies with respect to the extent of HO-1 
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induction obtained. Long-term exposure for example by a once weekly heme 
arginate infusion might be more closely to the proven treatment regimens in 
animal experiments. Obviously, the experimental evaluation of different 
regimens would benefit from the development of robust and clinically 
relevant (bio)markers of HO-1 activity. 
In view of the limited clinical applicability of current HO-1 inducers, 
additional effort should be put into the development of alternative strategies 
to capitalize the beneficial effects of HO-1 activity in daily clinical practice. 
Apart from new safer and more specific HO-1 inducers, raising systemic 
levels of the HO-1 effector molecules pharmacologically might prove such an 
alternative strategy. Others are currently investigating the therapeutic use of 
CO-releasing molecules (CORMs) (14). Though promising in preclinical 
experiments, CORMs have not yet reached the stage of human application. 
The possible opportunities of therapeutic hyperbilirubinemia will be 
discussed in the next paragraph. 
 
 
The role of bilirubin 
 
Current insights and results of our experiments 
Though not fully understood from a mechanistic point of view, bilirubin was 
recognized for its anti-oxidant capacity a long time ago (15). Besides 
clarification of the underlying powerful bilirubin/biliverdin redox cycle, 
ongoing research in recent years elucidated an impressive variety of 
additional biological effects of bilirubin. As explicated by others in an 
insightful review (7), bilirubin is part of a complex intra-cellular network of 
signaling cascades involved in metabolism and inflammation. Apart from its 
well-known regulation through intracellular levels of RONS, bilirubin for 
example also appears to regulate gene transcription by direct binding of 
transcription factors including the aryl hydrocarbon receptor (AhR). AhR on 
its turn regulates genes involved in bilirubin homeostasis like HMOX1, 
CYP2A6 and UTG1A1, but in an interplay with other transcription factors 
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like Nrf2 it also controls the transcription of many genes involved in 
inflammation and metabolism.       
With respect to its anti-atherogenic impact, bilirubin was initially thought to 
exert anti-atherosclerotic effects mainly by preventing oxidation of LDL 
cholesterol to the atherogenic oxLDL form (16). Later, bilirubin was also 
demonstrated to inhibit the generation of ROS by inhibition of mitochondrial 
NADPH oxidase (17). In the past years, many additional mechanisms have 
been elucidated by which bilirubin might ameliorate the development of 
atherosclerosis and related cardiovascular disease. These mechanisms have 
been reviewed recently (18) and include the improvement of both insulin 
sensitivity and endothelial function and the reduction of high blood 
pressure, endothelial expression of adhesion molecules, and 
proinflammatory cytokine production. Recently, it was found that the 
protection of endothelial function in diabetes after induction of HO-1 activity 
should in fact be attributed to the associated formation of bilirubin (19). 
Whereas the induction of HO-1 either by treatment with hemin or by 
adenoviral transfer of HO-1 improved endothelial-dependent relaxations of 
aortic rings in diabetic db/db mice, this effect was completely abolished by 
simultaneous silencing of biliverdin reductase thus preventing the 
conversion of biliverdin to bilirubin (19). As expected, the administration of 
unconjugated bilirubin resulted in restoration of endothelial function. These 
findings are supported by in vitro data that confirmed the protective role of 
bilirubin production upon endogenous HO-1 induction in endothelial cells 
exposed to high glucose levels (20) and a reduction in insulin resistance was 
observed upon HO-1 induction (19). Again, bilirubin is likely to have a 
crucial rol as others have demonstrated an improvement of insulin 
sensitivity by the administration of bilirubin in the same model (21).  
As described in chapter 3, observational data from the Nijmegen Biomedical 
Study demonstrated an inverse association between plasma bilirubin levels 
and the ankle brachial index. Over the past years, many others have also 
added evidence to the well-known observation that plasma bilirubin levels 
are inversely related to a variety of diseases including T2DM and (markers of) 
CVD (18, 22). Whereas observational data are prone to confounding and by 
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definition do not provide insight into the causation of an observed 
association, the emergence of Mendelian randomization studies over the past 
years has provided interesting new data (23, 24). In contrast to traditional 
observational studies, Mendelian randomization studies are able to verify 
causality by demonstration of an association between germline genetic 
variants known to have a lifelong influence on plasma bilirubin levels and 
the risk of for example T2DM or CVD later in life. The most obvious and 
adopted genetic variant known to affect bilirubin plasma levels is the 
UGT1A1*28 polymorphism, which is associated with Gilbert syndrome (25). 
Using Mendelian randomization, several authors have independently 
demonstrated a consistent causal link between plasma bilirubin levels and 
the risk to develop T2DM (26-28). Their data thus confirm the abundance of 
preclinical data on the beneficial effect of bilirubin on insulin resistance (4). 
Surprisingly, Mendelian randomization studies on the relationship between 
plasma bilirubin levels and cardiovascular risk appear to suggest the 
absence of causality (28-30). Though generally known as a robust method to 
verify causality by epidemiologic research, caution is however warranted 
while interpreting these type of data (31). The reliability of Mendelian 
randomization is based on fundamental assumptions concerning linearity of 
the association and absence of pleiotropy and linkage disequilibrium (24). 
Negative results of studies aiming to demonstrate causality on the 
association between plasma bilirubin levels and cardiovascular risk might 
therefore be related to non-linearity of the relationship (32). However, a 
meta-analysis did suggest linearity and attributed the non-linearity observed 
in some studies to the impact of co-existing liver diseases at high bilirubin 
levels (33). Another possible explanation for the negative results of 
Mendelian randomization studies might be the fact that UTG1A1 is known to 
conjugate several other endogenous substances in addition to bilirubin, like 
for example estrogens (34). Due to this pleiotropy, the reported absence of a 
relationship between UGT1A1 polymorphisms and cardiovascular disease 
might be due to a neutralizing effect of other substances that are conjugated 
by UGT1A1. Notably, the negative results of Mendelian randomization 
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studies are in contradiction with a growing body of preclinical evidence on a 
variety of beneficial effects of bilirubin. 
UGT1A1 can be inhibited pharmacologically by administration of the HIV 
protease inhibitor atazanavir, which results in unconjugated 
hyperbilirubinemia. By exploiting this side effect, we have performed 
translational experiments to investigate the putative beneficial influence of 
bilirubin on vascular function. As described in chapter 4, short-term 
atazanavir treatment was associated with a significant hyperbilirubinemia, 
an increase in the anti-oxidant capacity of plasma, and an improvement of 
endothelial function in subjects suffering from T2DM. Likewise and 
described in chapter 5, atazanavir-induced hyperbilirubinemia was found to 
increase anti-oxidant capacity of plasma, attenuate IL-10 release, and 
prevent vascular hyporesponsiveness during endotoxemia-induced systemic 
inflammation in healthy volunteers. 
In the past years, several other groups studied the impact of atazanavir 
treatment on vascular function (35-39). First, 15 subjects suffering from type 
1 diabetes mellitus (T1DM) did not experience an improvement of flow-
mediated vasodilation after exposure to an identical treatment regimen 
compared to our protocol and consequently similar plasma bilirubin levels 
(39). In contrast to our design, subjects in this study were allowed to 
continue cardiovascular medication including ACE inhibitors and 
angiotensin receptor blockers. Besides, the apparent absence of impact on 
flow-mediated vasodilation in T1DM subjects might be related to a difference 
in incidence of cardiovascular risk factors and thus the related extent of 
baseline endothelial dysfunction. Three other studies evaluated the impact of 
a controlled randomized switch to an atazanavir containing anti-retroviral 
treatment regimen in HIV positive subjects (35-37). In general, these studies 
demonstrated an increase in bilirubin level and an improvement of lipid 
profile, but no significant impact on flow-mediated vasodilation 12 to 24 
weeks after a switch to atazanavir. A substantial part of subjects in these 
experiments were active smokers and on cardiovascular drugs, including 
ACE inhibitors and angiotensin receptor blockers. It should be noted that 
flow-mediated vasodilation reflects endothelial function in conduit arteries, 
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but it is not associated with 5-year risk of cardiovascular disease (40). In 
contrast, such an association has been demonstrated for endothelial 
function in resistance arteries as measured by the invasive forearm 
technique with acetylcholine infusion used in our experiments (40). Finally, 
others compared in healthy volunteers a 4-week treatment with atazanavir 
(n=9) to placebo (n=12) and lopinavir-ritonavir (n=9) and did not observe a 
significant improvement of metacholin-mediated vasodilation (38). Apart 
from a lack of sufficient power and the potential absence of endothelial 
dysfunction, these findings might be related to the observation that 
atazanavir appears to improve plasma anti-oxidant capacity only in the short 
term (35).  
Though elegant in its design, the interpretation of translational studies with 
atazanavir-induced hyperbilirubinemia is limited by the impossibility to 
distinguish the impact of bilirubin from a possible confouding effect of 
atazanavir. Despite recent observational data demonstrating that the 
benefical effect of bilirubin on cardiovascular disease is unrelated to 
atazanavir use (41) and animal experiments in which parenteral 
administration of bilirubin and UGT1A1 inhibition equally attenuate 
angiotension II-dependent hypertension (42), a definite proof requires 
confirmation of our data in alternative translational models of 
hyperbilirubinemia. Ideally, bilirubin is administered parenterally in these 
models. Though frequently administered to humans in the past, bilirubin is 
currently not commercially available for human parenteral use. As discussed 
in chapter 6 we have demonstrated that it is still feasible to produce 
bilirubin for parenteral human use under GMP conditions. Based on an 
extensive literature study and explorative pharmacokinetic experiments in 
healthy volunteers, we consider it safe to perform translational parenteral 
experiments in humans provided that the bilirubin is produced under GMP 
conditions and applied in an albumin bound formulation, aiming for plasma 
concentrations up to 100 μmol/L at most.  
In summary, the beneficial effect of bilirubin on insulin resistance and 
endothelial dysfunction is based on accumulating preclinical evidence and 
mechanistic insight into the biological actions of bilirubin. Furthermore, a 
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large body of traditional observational data support the inverse association 
between plasma bilirubin levels and the risk to develop T2DM and CVD. 
Whereas the effect on insulin resistance was confirmed by Mendelian 
randomization studies, the same approach surprisingly questioned causality 
of the inverse relationship between plasma bilirubin levels and 
cardiovascular disease. Our own translational experiments, however, do 
support the abundance of preclinical data demonstrating a positive influence 
of bilirubin on vascular disease. 
 
Future perspectives 
As mentioned before, the discussion on causality of the observed association 
between plasma bilirubin levels and cardiovascular disease is ongoing. While 
Mendelian randomization studies have confirmed the benificial effect of 
bilirubin on diabetes, they questioned the impact on CVD. Remarkably, this 
intriguing discrepancy remained undiscussed in an influential editorial and 
review (18, 43). More studies are required to gain better insight into the role 
of bilirubin and possibly additional factors in the development of CVD. 
Although in contradiction with convincing preclinical data, the discrepancy 
might be explained by the true absence of causality between bilirubin levels 
and CVD in humans. Most likely, however, the Mendelian randomization 
studies were confounded by false assumptions with regard to linearity of the 
association or the absence of both pleiotropy and linkage disequilibrium of 
the UGT1A1 gene. Therefore, effort should be put in the search for other 
endogenous substances that are conjugated by UGT1A1 and that have 
influence on the risk of CVD, thereby apparently nullifying the impact of 
UGT1A1-related changes in plasma bilirubin level. In addition, settlement of 
the ongoing discussion on causality would greatly benefit from a definite 
understanding of the underlying mechanisms by which bilirubin exerts its 
beneficial effects. 
Apart from fundamental research on the mechanisms of action of bilirubin 
and the questions raised by Mendelian randomization studies, causality and 
thus the therapeutic potential of bilirubin should be demonstrated by 
additional proof-of-concept experiments in humans. First, our translational 
7
163 
 
model with atazanavir-induced hyperbilirubinemia should be used to verify 
the beneficial effect of bilirubin on insulin resistance in subjects suffering 
from MetS or T2DM. Ideally, alternative human models of hyperbilirubinemia 
should be used to reproduce the results of such experiments to exclude the 
theoretic possibility that the findings are due to atazanavir treatment instead 
of the associated hyperbilirubinemia. A human translational model based on 
parenteral administration of bilirubin could serve this goal, although 
additional pharmacokinetic experiments in healthy volunteers are needed to 
refine dose adjustments based on body weight and forearm volume. Finally, 
though still in its infancy, future human models of hyperbilirubinemia may 
also adopt molecular techniques that interfere with UGT1A1 protein 
expression. A striking example of such strategies was published on the use 
of small interfering RNA to facilitate the cleavage and subsequent 
degradation of messenger RNA encoding PCSK9, a protein involved in 
lipoprotein homeostasis (44). Inhibiting the synthesis of PCSK9, a single 300 
mg injection of the RNA interfering agent, resulted in a significant reduction 
of both PCSK9 and LDL cholesterol that lasted for 180 days. 
In the long term, randomized controlled trials are obviously needed to 
confirm the use and additional value of therapeutic hyperbilirubinemia on 
relevant clinical endpoints. Compared to the dosage in HIV treatment, much 
lower doses of atazanavir might be adequate to obtain a long-term 
subclinical hyperbilirubinemia. Additional experiments are nevertheless 
needed to find the optimal dosing regimen. Effort should be also put in a 
search for alternative pharmacologic strategies to induce a long-term but 
limited increase of plasma bilirubin levels with a minimum risk of associated 
side effects. 
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Type 2 diabetes mellitus 
Due to the increasing global population, their growing prosperity and their 
consequent changes in life style and diet, an epidemic of obesity impends. As 
obesity is their key risk factor, this epidemic inevitably will be associated 
with a dramatic rise of the incidence of both the metabolic syndrome (MetS) 
and type 2 diabetes mellitus (T2DM). Worldwide, conservative estimations 
indicate an expected increase in subjects with T2DM from 366 million in 
2011 to 552 million in 2030. T2DM is characterized by hyperglycemia and 
often associated with hypertension and dyslipidema. Compared with T2DM, 
even more people will develop MetS, a prestage of T2DM and defined by a 
combination of classic cardiovascular risk factors. Cardiovascular 
complications associated with MetS and T2DM are the major cause of 
morbidity and mortality. Apart from the traditional risk factors that 
accompany MetS and T2DM, several other risk factors including physical 
inactivity, cigarette smoking, and a positive family history, substantially 
contribute to the individual cardiovascular risk. Current treatment strategies 
therefore focus on change of lifestyle and treatment of individual risk factors 
including hypertension, hyperglycemia, and dyslipidemia. Unfortunately, 
these measures only reduce the increase of cardiovascular risk in T2DM by 
50%. Neither intensification nor earlier initiation of therapy has led to a 
further reduction of cardiovascular risk. In conclusion, there is a need for 
additional treatment strategies. 
 
Role of HO and bilirubin 
Pathophysiologically obesity-related dysfunction of adipocytes and 
consequent adipose tissue inflammation are central in the development of 
MetS, T2DM and their cardiovascular complications. In short, excess of 
nutrients trigger intra-cellular pro-inflammatory signaling cascades in 
adipocytes. In these cascades, reactive oxygen and nitrogen species (RONS) 
fulfill an important role of second messenger. The related surplus of RONS 
observed in MetS and T2DM is termed oxidative stress. One of the main 
consequences of adipose tissue inflammation is insulin resistance. In 
translational designs, therapeutic effects on insulin sensitivity can be 
8
169 
 
evaluated by the euglycemic hyperinsulinemic clamping technique. In the 
vascular system too, MetS and T2DM are associated with inappropriate and 
chronic inflammatory activation. This activation of the endothelium, often 
referred to as endothelial dysfunction, is one of the earliest signs of 
cardiovascular detriment and associated with the development of 
cardiovascular disease. In translational designs, therapeutic impact on 
endothelial function can be evaluated by the vasodilator response to 
acetylcholine measured by venous occlusion forearm plethysmography. 
In view of the important role of chronic inflammation, research on the MetS, 
T2DM and their cardiovascular complications has focused on the 
amelioration of inflammation and oxidative stress. Therapeutic enforcement 
of endogenous anti-inflammatory and anti-oxidant substances might serve 
this goal. Amongst the possible candiates are heme oxygenase (HO) and 
bilirubin. HO is the rate-limiting enzyme in the breakdown of heme that by 
breaking down heme generates biliverdin, carbon monoxide and iron. 
Biliverdin is then directly converted to bilirubin by biliverdin reductase. In 
vitro, both bilirubin and HO-activity have shown to exhibit important anti-
oxidant and anti-inflammatory properties. Besides, animal experiments have 
demonstrated therapeutic efficacy of HO-1 induction and hyperbilirubinemia 
in a variety of diseases including sepsis, MetS, T2DM, and CVD. Suggesting 
clinical relevance in humans, plasma bilirubin levels appear inversely related 
to the risk to develop T2DM and cardiovascular disease. Nevertheless 
translational studies are  needed to provide more insight in causality of this 
association and verify the therapeutic potential of HO-1 induction and 
hyperbilirubinemia in patients with MetS or T2DM. 
 
This thesis 
This thesis aims to corroborate the abovementioned findings from preclinical 
experiments and observational studies in human proof-of-concept 
experiments. In addition to an observational study, we performed several 
translational experiments that pioneer in the field of human models for the 
therapeutic induction of hyperbilirubinemia and HO-1 activity in the context 
of MetS, T2DM and experimental endotoxemia (figure 8.1). 
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Figure 8.1 Overview of chapters and their connection to HO and bilirubin 
CO, carbon monoxide; Fe, iron; HO, heme oxygenase; BVR, biliverdin reductase; 
UGT1A1,UDP glucuronosyltransferase 1A1.  
 
Chapter 2 
In chapter 2, I describe a vehicle-controlled cross-over study in 14 subjects 
with MetS. Aiming to induce HO-1, we treated the subjects with a heme 
arginate infusion on day 1 and 3 and evaluated the impact on parameters of 
HO-1 induction, endothelial function and insulin sensitivity. Forearm blood 
flow in response to acetylcholine and nitroglycerine was measured by venous 
occlusion plethysmography (day 3), insulin sensitivity by a hyperinsulinemic 
clamp procedure (day 5). In contrast with preclinical data, HA did not 
improve endothelial function or insulin sensitivity but significantly reduced 
the vasodilator response to NTG (p<0.01). These observations may be based 
on several things. First, plasma heme levels were markedly elevated at the 
time we performed our experiments. Therefore, the accompanying pro-
oxidant impact of heme may have abolished a potential anti-inflammatory 
benefit of HO-1 induction in our model. Second, the negative results might 
be due to too short-lasting and limited HO-1 induction. For both reasons, 
future studies should pay attention to the delicate balance between sufficient 
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dosing and timely normalization of plasma heme levels. Additional 
pharmacologic experiments in healthy volunteers might provide more 
effective dosing strategies with respect to the extent of HO-1 induction 
obtained. Long-term exposure for example by a once weekly heme arginate 
infusion might be more closely to the proven treatment regimens in animal 
experiments. 
 
Chapter 3 
From chapter 3 our experiments focus on the impact of bilirubin. Chapter 3 
summarizes the findings of an observational study in which we examined the 
relationship between basal plasma bilirubin concentrations and several 
measures of subclinical atherosclerosis in both the general study population 
from the Nijmegen Biomedical Study (NBS; n=1463) and a subpopulation of 
subjects meeting MetS criteria (n=487). The NBS is a large population-based 
survey in which blood was drawn and non-invasive measurements of 
atherosclerosis were performed. We measured bilirubin levels in stored 
serum and divided the population into quartiles of the bilirubin serum levels. 
The outcome of the non-invasive measurements of atherosclerosis in the 
highest quartile was compared with those in the lowest quartile. Our data 
demonstrated an association between plasma bilirubin levels and ABI. 
Adjustment for traditional cardiovascular risk factors hardly interfered with 
these findings. Most likely due to insufficient power, no significant 
associations were found with other parameters of subclinical atherosclerosis. 
Separate analysis of subjects with the metabolic syndrome yielded similar 
results compared to the general population. Finally, both sexes were 
analyzed separately. Although the association between plasma bilirubin 
levels and ankle brachial index in women appeared less pronounced, 
equality of impact in men and women could not be excluded in view of the 
wide confidence intervals. 
Though in line with an abundance of observational data that demonstrate an 
inverse association between plasma bilirubin levels and (measures of) 
cardiovascular disease, the observed association in chapter 3 obviously does 
not automatically imply causality of the relationship. As stated before, 
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causality and thus the therapeutic potential of bilirubin can only be 
demonstrated by human proof-of-concept studies based on models of 
experimental hyperbilirubinemia. One of the options to increase plasma 
bilirubin levels is the inhibition of its excretion. Interesting in this regard is 
the Gilbert syndrome, a common benign condition, that is associated with a 
mild lifelong hyperbilirubinemia due to an impairment of necessary 
conjugation prior to the excretion into the bile. This impairment is the result 
of an inactivating polymorphism in the gene coding for the responsible 
enzyme UDP glucuronosyl transferase 1A1 (UGT1A1). Pharmacologically, 
UTG1A1 activity can be inhibited by the administration of atazanavir, a drug 
normally used for the treatment of the HIV. Atazanavir has been authorized 
for the European market, is administered orally, and causes a quite steady 
increase of plasma bilirubin level. Exploiting this property of atazanavir, we 
have developed a translational model to study the impact of experimental 
hyperbilirubinemia. This human model was used in experiments described 
in chapter 4 and 5. 
 
Chapter 4 
In chapter 4, we describe a double blind placebo-controlled cross-over study 
in sixteen subjects suffering from T2DM in which we evaluated the impact of 
a short term atazanavir-induced hyperbilirubinemia on endothelial function. 
Using venous occlusion plethysmography, endothelium-dependent and 
endothelium-independent vasodilation were assessed by intra-arterial 
infusion of acetylcholine and nitroglycerin respectively. Upon three days of 
atazanavir treatment an increase in average bilirubin levels from 7 μmol/L to 
64 μmol/L was observed with significant improvement of plasma antioxidant 
capacity and endothelium-dependent vasodilation. Our study was thereby 
the first to address the concept of vascular protection by experimental 
hyperbilirubinemia in humans with T2DM. 
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Chapter 5 
In the experiments described in chapter 5, the same model was adopted to 
investigate the effects of atazanavir-induced unconjugated 
hyperbilirubinemia on anti-oxidant capacity, inflammation and endothelial 
dysfunction in human experimental endotoxemia. Again, endothelial 
function was assessed using forearm venous occlusion plethysmography 
after intra-arterial infusion of acetylcholine and nitroglycerin. Compared to 
placebo atazanavir-induced hyperbilirubinemia increased plasma anti-
oxidant capacity, attenuated IL-10 release and prevented vascular 
hyporesponsiveness during endotoxemia-induced systemic inflammation in 
humans. With this study we demonstrated that hyperbilirubinemia elicited 
by atazanavir not only prevents endothelial dysfunction during chronic 
inflammation due to T2DM, but also during experimental endotoxemia in 
humans. 
 
Chapter 6 
From a pragmatic perspective, atazanavir is ideally suited for trials aiming at 
a therapeutic benefit of mild hyperbilirubinemia. Based on preclinical data, 
it is in our opinion likely that the observed beneficial effects of atazanavir-
induced hyperbilirubinemia in our experiments are directly related to the 
increase of bilirubin level. Still, theoretical interference of atazanavir itself 
hinders the ascription of an observed effect in the atazanavir model simply 
and solely to bilirubin in proof-of-concept experiments. Besides, the use of 
atazanavir does not enable to study a dose-response relationship over a wide 
range of bilirubin concentrations. The only study design that truly clarifies 
the exclusive therapeutic effect of bilirubin and accompanying dose-response 
relationship therefore includes the administration of exogenous bilirubin. 
Due to a low biovailability bilirubin cannot be administered orally, but 
numerous human studies yet utilized the parenteral administration of 
bilirubin in the past. In the late sixties of the former century however its 
application fell in disuse. As a result, bilirubin is currently not available for 
parenteral human use. 
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Considering its extensive use in both clinical practice and medical research 
in the past, we explored the feasibility to reintroduce parenteral bilirubin for 
translational experiments in Chapter 6. Supported by an overview of former 
studies on the human parenteral use of bilirubin, we developed a 
preparation method in accordance with good manufacturing practice and 
evaluated the parenteral applicability in healthy volunteers (n=8). Bilirubin 
was administered intra-arterially to raise the local plasma concentration in 
the forearm vascular bed (n=4) and intravenously to raise the systemic 
plasma concentration (n=4). Finally pharmacokinetic characteristics were 
studied following a single bolus infusion (n=3). A dose-concentration 
relationship appeared sufficiently predictable for both intra-arterial and 
intravenous administration. In line with existing knowledge, bilirubin 
pharmacokinetics could be described best according to a two-compartment 
model with a volume of distribution of 9.9 (±2.0) l and a total plasma 
clearance of 36 (±16) ml per minute. During infusion no side effects 
occurred. Adverse events mentioned during the two week observation period 
were in general mild and self-limiting or judged unrelated by independent 
physicians. Supported by previous reports, our data suggest that it is both 
feasible and safe to perform translational experiments with parenteral 
albumin bound bilirubin. Larger studies are needed to evaluate the 
usefulness of adjusting dose regimens to either forearm volume or body 
weight and to study the influence of genetic variation on the elimination rate 
of bilirubin from plasma. Nevertheless, our findings reopen the gate to 
human parenteral use of bilirubin for the purpose of translational studies 
needed to corroborate the promising preclinical, observational and limited 
translational data on bilirubin. 
 
Chapter 7 
In chapter 7, the General discussion and future perspectives, I aggregate our 
findings and relate these findings to the broader context of increasing insight 
into the pathogenesis of MetS, T2DM and atherosclerotic cardiovascular 
disease (CVD) and the intriguing role of heme oxygenase HO-1 and bilirubin 
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herein. Current knowledge and future perspectives are discussed separately 
for both HO-1 and bilirubin. 
For HO-1 recent findings demonstrate a complex regulation of HO-1 activity 
and different cellular functions of HO-1. The observed effect upon HO-1 
induction appears to be highly variable and influenced by a variety of factors 
including cell type, tissue, and species involved. Preclinical experiments 
should further elucidate the complex mechanisms underlying the observed 
specific role in HO-1 induction of the inducing agent, cell type, tissue, 
species, and disease phenotype. As stated, translational experiments should 
be designed carefully accounting for the delicate balance associated with the 
use of inducers such as heme arginate. One should strive for a dosage level 
and duration that is sufficiently high to achieve clinical efficacy, but also not 
too high to avoid elevated heme levels by the time endpoints are assessed. 
Evaluation of different regimens would benefit from the development of 
robust and clinically relevant (bio)markers of HO-1 activity. In view of the 
limited clinical applicability of current HO-1 inducers, additional effort 
should be put into the development of alternative strategies to capitalize the 
beneficial effects of HO-1 activity in daily clinical practice. Apart from new 
safer and more specific HO-1 inducers, raising systemic levels of the HO-1 
effector molecules pharmacologically might prove such an alternative 
strategy. 
For bilirubin ongoing research in recent years elucidated an impressive 
variety of additional biological effects in addition to its well-known anti-
oxidant capacity. First, bilirubin appears part of a complex intra-cellular 
network of signaling cascades involved in metabolism and inflammation. 
Second, bilirubin is able to regulate gene transcription by direct binding of 
transcription factors. Apart from the anti-oxidant effects, bilirubin therefore 
ameliorates the development of atherosclerosis in many other additional 
ways. 
Over the past years, many observational studies added evidence to the well-
known observation that plasma bilirubin levels are inversely related to a 
variety of diseases including T2DM and (markers of) CVD. The simultaneous 
emergence of Mendelian randomization studies provided interesting 
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additional insight in causality of these associations since Mendelian 
randomization studies are able to verify causality by demonstration of an 
association between germline genetic variants known to have a lifelong 
influence on plasma bilirubin levels and the risk of for example T2DM or 
CVD later in life. Using this technique, several authors have independently 
demonstrated a consistent causal link between plasma bilirubin levels and 
the risk to develop T2DM. Surprisingly however and in contrast, Mendelian 
randomization studies on the relationship between plasma bilirubin levels 
and cardiovascular risk appear to suggest the absence of causality. Although 
in contradiction with convincing preclinical data, the true absence of 
causality between bilirubin levels and CVD in humans should be considered. 
Possibly however the Mendelian randomization studies may have been 
confounded by false assumptions with regard to linearity of the association 
or the absence of both pleiotropy and linkage disequilibrium of the UGT1A1 
gene. 
Echoing our papers on atazanavir-induced hyperbilirubinemia besides, 
others have adopted the model and in contrast with our positive findings did 
not find an impact of atazanavir-induced hyperbilirubinemia on vascular 
function in subjects suffering from type 1 diabetes mellitus. In HIV positive 
subjects besides, a randomized controlled switch to an atazanavir containing 
anti-retroviral treatment regimen did not have a significant impact on flow-
mediated vasodilation. The discrepancy with our data might be related to a 
lesser extent of baseline endothelial dysfunction in subjects suffering from 
T1DM and HIV. In contrast to our design besides, subjects were allowed to 
continue smoking and instructed to continue the use of cardiovascular 
medication including ACE inhibitors and angiotensin receptor blockers 
during assessment of endothelial function. 
In general,  causality and thus the therapeutic potential of bilirubin should 
be further demonstrated by additional proof-of-concept experiments in 
humans. In subjects suffering from MetS or T2DM for example, the 
beneficial effect of bilirubin on insulin resistance could be verified by an 
euglycemic hyperinsulinemia clamp procedure in our atazanavir model. 
Ideally, the results from our atazanavir model should be reproduced by the 
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use of alternative human models of hyperbilirubinemia to exclude the 
possible interference of atazanavir itself. Parenteral administration of 
bilirubin or the future application of molecular techniques that interfere with 
for example UGT1A1 protein expression, may serve that goal. 
As stated, the future health burden related to MetS and T2DM is immense 
and current treatment strategies only half the risk of the associated 
morbidity and mortality. Joining the search for new therapies, this thesis 
unites the first steps on the potential benefit of HO induction and 
hyperbilirubinemia in man. The findings are reassuring, but still many steps 
have to be taken. Additional translational experiments are needed and 
should be followed by randomized controlled trials to confirm therapeutic 
efficacy on relevant clinical endpoints. 
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Type 2 diabetes mellitus 
De groei van de wereldbevolking, de toenemende welvaart en de daaruit 
voortvloeiende veranderingen in levensstijl en voeding leiden momenteel tot 
een wereldwijde epidemie van overgewicht. Omdat overgewicht de 
belangrijkste risicofactor is voor het metabool syndroom (MetS) en diabetes 
mellitus type 2 (T2DM), zal deze epidemie van overgewicht onvermijdelijk 
hand in hand gaan met een drastische toename van het aantal mensen met 
MetS of T2DM. Conservatieve schattingen wijzen wereldwijd op een stijging 
van 366 miljoen mensen met T2DM in 2011 tot maar liefst 552 miljoen in 
2030. 
T2DM wordt gekenmerkt door hoge glucosewaarden in het bloed 
(hyperglycemie) en gaat daarnaast vaak gepaard met een hoge bloeddruk 
(hypertensie) en een te hoog cholesterol (dislipidemie). Patienten met MetS 
hebben een combinatie van risicofactoren voor hart- en vaatziekten (HVZ) en 
in feite een voorstadium van T2DM. HVZ kunnen als complicatie optreden en 
vormen voor beide aandoeningen de belangrijkste oorzaak van ziektelast en 
overlijden. Naast de klassieke risicofactoren bij MetS en T2DM 
(hyperglycemie, hypertensie en dislipidemie) dragen ook andere 
risicofactoren zoals lichamelijke inactiviteit, roken en een positieve 
familieanamnese in belangrijke mate bij aan het cardiovasculaire risico. De 
huidige behandeling is dan ook gericht op aanpassing van de leefstijl en 
medicamenteuze behandeling van onder andere hypertensie, hyperglycemie 
en dislipidemie. Helaas leiden deze maatregelen slechts tot een halvering van 
het verhoogde cardiovasculaire risico bij T2DM. Noch striktere behandeling 
noch screening en daarmee vroegere start van de behandeling heeft tot een 
verdere afname van het risico geleid. Er is kortom behoefte aan nieuwe 
behandelopties die het cardiovasculaire risico verder kunnen verlagen. 
 
Chronische ontsteking 
Bij het ontstaan van MetS, T2DM en HVZ speelt disfunctie van vetcellen 
(adipocyten) door overgewicht een cruciale rol. Door een overschot aan 
voedingsstoffen ontstaat er in adipocyten een activatie van signaalketens die 
uiteindelijk leiden tot een laaggradige ontsteking van het vetweefsel. 
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Zuurstof- en stikstofradicalen (RONS) vormen een belangrijke schakel in 
deze ketens. De overmaat aan RONS die door activatie van de signaalketens 
in de vetcel ontstaat wordt oxidatieve stress genoemd. Een van de 
belangrijkste gevolgen van de chronische ontsteking van vetweefsel en 
oxidatieve stress is een verminderde gevoeligheid voor insuline, het hormoon 
dat het verbruik en de opslag van glucose coördineert. Deze verminderde 
gevoeligheid (insulineresistentie) kan in onderzoeksverband gemeten worden 
met de hyperinsulinemische euglycemische clamp test. Daarmee kan op 
kleine schaal onderzocht worden of nieuwe behandelingen de 
insulinegevoeligheid verbeteren. Ook in de bloedvaten gaan MetS en T2DM 
gepaard met een chronisch laaggradig ontstekingsproces. Bloedvaten zijn 
aan de binnenzijde bekleed met endotheelcellen. Activatie van deze 
endotheelcellen bij chronische ontsteking wordt endotheeldisfunctie 
genoemd en is geassocieerd met het ontwikkelen van hart- en vaatziekten. 
Ook deze endotheeldisfunctie kan in onderzoeksverband op verschillende 
manieren worden gemeten, bijvoorbeeld door te bepalen hoe goed bloedvaten 
reageren op acetylcholine, een vaatverwijdende stof. Deze reactie wordt in de 
onderarm gemeten met behulp van plethysmografie. In onderzoeken kan 
daarmee op kleine schaal onderzocht worden of nieuwe behandelingen de 
functie van de vaatwand herstellen en daarmee mogelijk op termijn ook het 
risico op hart- en vaatziekten zouden kunnen verlagen. 
 
Haem-oxygenase en bilirubine 
Aangezien chronische laaggradige ontsteking een belangrijke rol blijkt te 
spelen bij het ontstaan van MetS, T2DM en HVZ, is het niet verrassend dat 
er al veel onderzoek is verricht naar mogelijke nieuwe behandelingen die de 
chronische ontsteking en oxidatieve stress zouden kunnen verminderen. Een 
van de mogelijkheden om dit te bereiken is het versterken van de 
beschermingsmechanismen van het lichaam zelf. Haem-oxygenase (HO) en 
bilirubine zijn in dat opzicht interessante kandidaten. HO is een enzym dat 
de stof haem afbreekt tot biliverdine, koolmonoxide en ijzer. Biliverdine 
wordt meteen daarna door biliverdine-reductase omgezet in bilirubine, een 
oranje pigment. Bij sterk verhoogde concentraties in het lichaam 
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(hyperbilirubinemie) geeft bilirubine aanleiding tot een gele verkleuring van 
het oogwit en de huid. Een ernstige hyperbilirubinemie kan daarnaast bij 
pasgeboren kinderen een kernicterus veroorzaken. Dit ziektebeeld kan 
zonder behandeling met lichttherapie leiden tot schade aan de hersenen. 
Lange tijd is dan ook gedacht dat bilirubine niets meer was dan een 
schadelijke afvalstof van haem. Laboratoriumonderzoeken hebben echter 
inmiddels aangetoond dat zowel bilirubine als activiteit van HO anti-oxidante 
en ontstekingsremmende effecten hebben. In proefdieren bleken 
hyperbilirubinemie en toegenomen HO-activiteit daarnaast te beschermen 
tegen een verscheidenheid aan ziekten, waaronder MetS, T2DM en CVD. Tot 
slot is uit epidemiologisch onderzoek gebleken dat mensen met een hogere 
bilirubineconcentratie over het algemeen een lager risico hebben op zowel 
T2DM als HVZ. Aanvullende experimenten bij mensen zijn desalniettemin 
nodig om te onderzoeken of verhoging van de bilirubineconcentratie of HO-
activiteit inderdaad ook in de mens beschermt tegen MetS, T2DM of de 
daarmee geassocieerde HVZ. 
 
Dit proefschrift 
Het promotietraject dat de basis vormde voor dit proefschrift had tot doel de 
bovengenoemde bevindingen uit laboratoriumonderzoek en proefdierstudies 
te vertalen naar de mens. Naast een epidemiologische studie voerden we 
daarom voor het eerst verschillende experimenten uit in kleine groepen 
gezonde proefpersonen of patienten met MetS of T2DM. Voor deze 
experimenten ontwikkelden we nieuwe humane modellen waarin we voor de 
duur van de experimenten tijdelijk de bilirubineconcentratie of de HO-
activiteit probeerden te verhogen.  
 
Hoofdstuk 1 
Hoofdstuk 1 van dit proefschrift geeft een algemeen overzicht over het 
ontstaansmechanisme van MetS, T2DM en HVZ en gaat daarna in op de 
effecten van HO en bilirubine. 
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Hoofdstuk 2 
In hoofdstuk 2 beschrijf ik een studie bij 14 proefpersonen met MetS. Met 
het doel HO-1 te activeren, behandelden we de patiënten met een haem-
arginaat (HA)-infuus op dag 1 en 3 en evalueerden we het effect op 
verschillende parameters waaronder HO-1-activiteit, endotheelfunctie en 
insulinegevoeligheid. Het vaatverwijdende effect van acetylcholine en 
nitroglycerine werd in de onderarm gemeten door middel van 
plethysmografie op dag 3 en de insulinegevoeligheid werd gemeten met een 
clamp-test op dag 5. Dezelfde onderzoeken werden ook gedaan na een 
behandeling met een arginine-infuus zonder haem, waardoor HO-1 niet 
wordt geactiveerd. In tegenstelling tot onze verwachting op basis van de 
gepubliceerde proefdieronderzoeken verbeterde HA de endotheelfunctie en de 
insulinegevoeligheid niet. Wel was er een – eveneens onverwachte – afname 
van het vaatverwijdende effect van nitroglycerine. Verschillende verklaringen 
zijn mogelijk. Ten eerste hadden onze proefpersonen op het moment dat we 
de metingen uitvoerden nog duidelijk verhoogde haemconcentraties in het 
bloed. Omdat haem zelf oxidatieve stress kan veroorzaken, valt niet uit te 
sluiten dat een ongunstig effect van haem de mogelijk gunstige effecten van 
verhoogde HO-activiteit teniet heeft gedaan. Ten tweede is de toename van 
HO-activiteit die we met onze studie-opzet hebben bereikt mogelijk te 
kortdurend of te gering geweest. Om beide redenen is het voor de toekomst 
belangrijk om bij nieuwe studies aandacht te besteden aan het belang van 
een voldoende hoge dosering enerzijds en een normale haemconcentratie 
tijdens de metingen anderzijds. Aanvullende experimenten bij gezonde 
vrijwilligers kunnen daarbij meer inzicht verschaffen in de meest effectieve 
doseringsstrategie. Zo sluit langduriger blootstelling waarbij proefpersonen 
eens per week een HA-infuus krijgen bijvoorbeeld beter aan bij de opzet van 
de dierproeven waarbij wel een gunstig effect werd gemeten. 
 
Hoofdstuk 3 
Vanaf hoofdstuk 3 concentreren onze experimenten zich op bilirubine. 
Hoofdstuk 3 vat de bevindingen samen van een observationeel onderzoek 
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naar de relatie tussen de bilirubineconcentratie in het bloed en verschillende 
maten van subklinische atherosclerose. Bij subklinische atherosclerose is 
sprake van “aderverkalking zonder HVZ”. Mensen met subklinische 
atherosclerose hebben dus al wel meetbare schade aan de bloedvaten, maar 
(nog) geen klachten. We onderzochten de relatie tussen bilirubine en 
verschillende maten van subklinische atherosclerose in de database van de 
Nijmeegse Biomedische Studie (NBS). De NBS is een groot 
bevolkingsonderzoek waarbij bloed werd afgenomen en niet-invasieve 
metingen van atherosclerose (NIMA) werden verricht. We bepaalden 
bilirubinespiegels in opgeslagen bloedmonsters en verdeelden de groep aan 
de hand van deze bilirubinespiegels op basis van de hoogte van de 
bilirubinespiegel in vier groepen (kwartielen). De uitkomst van de 
verschillende NIMA in het hoogste bilirubine-kwartiel werd vergeleken met 
die in het laagste bilirubine-kwartiel. Onze gegevens van 1463 proefpersonen 
toonden een verband aan tussen de bilirubineconcentratie en de enkel-arm 
index (ABI). Correctie voor een mogelijk verstorend effect van traditionele 
cardiovasculaire risicofactoren veranderde deze uitkomsten vrijwel niet. Voor 
overige NIMA vonden wij geen duidelijke associatie met de bilirubine 
concentratie. Mogelijk was de onderzochte groep daar te klein voor. Naast de 
analyse in de gehele groep, hebben we ook apart gekeken naar de 487 
proefpersonen met MetS. In vergelijking met de gehele groep leidden de 
analyses in deze groep tot vergelijkbare resultaten. Tenslotte voerden we 
onze analyses nog afzonderlijk uit voor mannen en vrouwen. Het verband 
tussen de bilirubineconcentratie en de ABI leek bij vrouwen iets minder 
uitgesproken, maar de betrouwbaarheid van onze gegevens is niet voldoende 
om met zekerheid te kunnen stellen dat mannen en vrouwen in dit opzicht 
verschillen. Alhoewel onze resultaten en een overvloed aan andere 
epidemiologische studies laten zien dat mensen met een hogere 
bilirubineconcentratie een lager risico hebben op HVZ, betekent dit niet 
automatisch dat bilirubine beschermt tegen HVZ. Zo valt zonder aanvullende 
onderzoeken niet uit te sluiten dat de associatie juist is ontstaan doordat 
HVZ andersom de bilirubineconcentratie verlagen. Een andere theoretische 
mogelijkheid is het bestaan van een derde factor die het risico op HVZ 
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verhoogt en tegelijkertijd de concentratie van bilirubine verlaagt. Een 
oorzakelijk verband kan daarom alleen worden aangetoond door aanvullende 
experimenten waarbij wordt onderzocht of kunstmatige verhoging van de 
bilirubineconcentratie inderdaad leidt tot verlaging van de kans om HVZ te 
krijgen. 
 
Hoofdstuk 4 
Een experimentele hyperbilirubinemie kan onder andere worden geïnduceerd 
door de uitscheiding van bilirubine te remmen. Interessant in dit verband is 
het syndroom van Gilbert, een veelvoorkomende goedaardige aandoening, die 
gepaard gaat met een levenslange milde hyperbilirubinemie. Deze 
hyperbilirubinemie is het gevolg van een verminderde omzetting (conjugatie) 
van bilirubine naar een wateroplosbare vorm. Omzetting naar deze 
wateroplosbare vorm is nodig om bilirubine uit te kunnen scheiden in de gal. 
De afname van conjugatie bij het syndroom van Gilbert is het gevolg van een 
klein verschil in het gen dat codeert voor het enzym UDP-
glucuronosyltransferase 1A1 (UGT1A1) waardoor UTG1A1 minder actief is. 
Het eindresultaat daarvan is dat bilirubine minder goed kan worden 
uitgescheiden en daardoor in lichte mate “ophoopt” in het lichaam. UGT1A1-
activiteit kan door toediening van atazanavir ook medicamenteus worden 
geremd. Atazanavir is een protease-remmer die normaliter wordt gebruikt 
voor de behandeling van HIV. Atazanavir is goedgekeurd voor de Europese 
markt, wordt in capsules toegediend en veroorzaakt door remming van 
UGT1A1 als bijwerking een vrij stabiele hyperbilirubinemie. Om de effecten 
van hyperbilirubinemie in de mens te kunnen bestuderen hebben wij deze 
bijwerking van atazanavir benut bij de opzet van een nieuw 
onderzoeksmodel. 
In hoofdstuk 4 beschrijven we een studie bij zestien proefpersonen met 
T2DM. Ze werden tweemaal door ons behandeld; eenmaal met atazanavir en 
eenmaal met een placebo. De volgorde werd bepaald door toeval en niet 
gedeeld met de onderzoekers en de patienten. Na beide behandelingen 
onderzochten we de endotheelfunctie door het vaatverwijdende effect van 
acetylcholine te meten met plethysmografie. In vergelijking met de placebo-
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periode, zagen wij na drie dagen behandeling met atazanavir een toename 
van de bilirubineconcentratie van gemiddeld 7 μmol/L naar gemiddeld 64 
μmol/L. Daarbij verbeterde ook het vaatverwijdende effect van acetylcholine. 
Onze studie was daarmee de eerste die ook in de mens aantoonde dat de 
vaatfunctie bij mensen met T2DM verbetert tijdens een experimentele 
hyperbilirubinemie. 
 
Hoofdstuk 5 
Ook in hoofdstuk 5 gebruikten wij het atazanavirmodel, ditmaal om te 
onderzoeken of experimentele hyperbilirubinemie oxidatieve stress, 
ontsteking en endotheeldisfunctie tijdens een acute ontsteking kan 
verminderen. Deze ontsteking werd uitgelokt door toediening van 
lipopolysaccharide (LPS). LPS bevindt zich normaliter in de wand van 
bacterieen en veroorzaakt wanneer het aan gezonde proefpersonen wordt 
toegediend een hevige afweerreactie die enkele uren aanhoudt. Een van de 
veranderingen die tijdens deze acute ontstekingsreactie optreden is 
endotheeldisfunctie. Twintig gezonde proefpersonen werden op basis van 
toeval verdeeld in twee gelijke groepen. De ene groep kreeg LPS toegediend 
na een placebo-behandeling, de andere groep na een atazanavir-
behandeling. Proefpersonen en onderzoekers waren ook hier niet op de 
hoogte van de behandeling. We onderzochten onder andere het 
vaatverwijdende effect van acetylcholine in de onderarm voor en na 
toediening van LPS. Anders dan na placebo zagen we bij een 
hyperbilirubinemie na behandeling met atazanavir geen afname van de 
vaatverwijding door acetylcholine. Met deze studie toonden we aan dat een 
hyperbilirubinemie door atazanavir niet alleen endotheeldisfunctie bij 
chronische ontsteking door T2DM voorkomt, maar ook bij een acute 
ontstekingsreactie door toediening van LPS. 
 
Hoofdstuk 6 
Uit praktisch oogpunt is atazanavir uitermate geschikt voor studies naar de 
therapeutische meerwaarde van een milde hyperbilirubinemie. Omdat 
187 
 
proefdierstudies ook op andere manieren hebben laten zien dat een 
hyperbilirubinemie beschermend werkt, zijn wij er vrij zeker van dat de 
gunstige effecten na behandeling met atazanavir veroorzaakt worden door de 
hyperbilirubinemie. Toch kunnen we niet uitsluiten dat de effecten niet door 
bilirubine maar door atazanavir zelf zijn veroorzaakt. Daarnaast is het met 
het atazanavir-model niet goed mogelijk om in detail te kijken naar het effect 
van verschillende bilirubine concentraties. Het enige model dat met 
zekerheid de beschermende effecten van bilirubine kan aantonen is een 
model waarbij bilirubine zelf wordt toegediend. Helaas wordt bilirubine niet 
goed opgenomen via het maagdarmkanaal. In de vorige eeuw is bilirubine 
echter in tal van onderzoeken via een infuus (parenteraal) aan mensen 
toegediend. Doordat het gebruik ervan eind jaren zestig is gestopt, is er 
momenteel echter geen bilirubine-product op de markt beschikbaar. Met oog 
op de veelvuldige, succesvolle toepassing in zowel onderzoek als 
patiëntenzorg tijdens de vorige eeuw, hebben we daarom onderzocht of het 
haalbaar was om bilirubine opnieuw in te zetten bij experimenten in de 
mens. De resultaten van dit onderzoek worden beschreven in hoofdstuk 6. 
Ondersteund door een uitgebreide inventarisatie van alle gegevens uit 
beschikbare publicaties over parenterale toediening van bilirubine bij 
mensen, hebben wij een bereidingsmethode ontwikkeld die voldoet aan de 
huidige regelgeving. De toepasbaarheid en veiligheid van het eindproduct 
hebben we vervolgens onderzocht bij acht gezonde vrijwilligers. Allereerst 
dienden we bij vier proefpersonen in oplopende doseringen bilirubine toe via 
een slagader in de onderarm. Deze intra-arteriele toediening leidt tot een 
verhoging van de bilirubineconcentratie in de onderarm maar niet tot 
nauwelijks in de rest van het lichaam. Na deze fase hebben we de bilirubine 
in oplopende doseringen aan vier personen toegediend via een ader in de 
onderarm. Deze intraveneuze toediening leidt tot een gelijkmatige verhoging 
van de bilirubineconcentratie in het gehele lichaam. In de derde en laatste 
fase hebben we aan drie proefpersonen een eenmalige hoge dosis toegediend 
en vervolgens onderzocht hoe snel bilirubine na parenterale toediening door 
het lichaam uit het bloed wordt verwijderd. In alle fasen hebben we de 
proefpersonen tot twee weken na toediening gevraagd om eventuele 
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lichamelijke klachten aan ons te melden. De relatie tussen de dosis en de 
daarmee bereikte concentratie in het bloed bleek goed te voorspellen bij 
zowel intra-arteriële als intraveneuze toediening. Het patroon van de 
uitscheiding van bilirubine kwam bovendien overeen met oude gegevens uit 
de literatuur. Tijdens de toediening van bilirubine traden geen bijwerkingen 
op. Klachten die in de twee weken na toediening optraden waren over het 
algemeen mild of hadden naar het oordeel van onafhankelijke artsen geen 
relatie met ons onderzoek. Onze resultaten laten samen met de samenvatting 
van eerdere publicaties zien dat het haalbaar en veilig is om bilirubine bij 
wetenschappelijk onderzoek met mensen parenteraal toe te dienen. 
 
Hoofdstuk 7 
In hoofdstuk 7 vat ik de resultaten van mijn promotieonderzoek samen. 
Daarnaast ga ik in op recente inzichten in de ontstaanswijze van MetS, 
T2DM en HVZ en op de invloed die HO-activiteit en bilirubine daarop 
hebben. Samengevat is de laatste jaren gebleken dat zowel de activiteit van 
HO als de concentratie van bilirubine via complexe mechanismen worden 
gereguleerd. Ook zijn er meerdere nieuwe mechanismen ontdekt waarmee 
HO en bilirubine direkt invloed hebben op ontstekingsprocessen. Beiden 
blijken onderdeel van complexe signaalnetwerken in cellen. 
Het resultaat van HO-activatie blijkt sterk afhankelijk van de manier waarop 
het geactiveerd wordt en daarnaast ook van het celtype, weefseltype of 
proefdier dat wordt onderzocht. Meer laboratoriumonderzoek is nodig om de 
complexe mechanismen die hieraan ten grondslag liggen verder te 
ontrafelen. Zoals al besproken zal daarnaast bij experimentele studies in 
mensen moet worden gestreefd naar een dosering die qua dosis en duur 
voldoende hoog is om HO-inductie te bereiken, maar tegelijkertijd ook niet te 
hoog waardoor hoge haemconcentraties de uiteindelijke metingen kunnen 
verstoren. Complicerende factor daarbij is het feit dat er momenteel geen 
betrouwbare maat beschikbaar is om HO-activiteit in de mens te meten. Tot 
slot zal ook gezocht moeten worden naar alternatieve manieren om de 
gunstige effecten van HO activiteit te benutten in de patiëntenzorg, omdat de 
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huidige strategieën om HO te activeren niet goed toepasbaar zijn in de 
dagelijkse praktijk. 
Met betrekking tot bilirubine zijn er ook in de afgelopen jaren studies 
gepubliceerd die opnieuw laten zien dat er een omgekeerd verband bestaat 
tussen de bilirubineconcentratie en een verscheidenheid aan ziekten, 
waaronder T2DM en (markers van) HVZ. Interessant in dit opzicht is de 
toepassing van Mendeliaanse randomisatiestudies. Hierbij wordt onderzocht 
of er een relatie bestaat tussen een ziekte en een verschil in genen. Met deze 
methode wordt dus niet onderzocht of er bijvoorbeeld een relatie is tussen 
HVZ en de bilirubineconcentratie, maar in plaats daarvan of er een relatie is 
tussen HVZ en genen die de bilirubineconcentratie beïnvloeden. Omdat deze 
genen vanaf de bevruchting nog voor het ontstaan van HVZ van invloed zijn 
geweest op de bilirubineconcentratie, wijst een eventuele relatie tussen deze 
genen en HVZ wél op een oorzakelijk verband. Met behulp van deze techniek 
hebben verschillende publicaties onafhankelijk van elkaar een consistent 
verband aangetoond tussen T2DM en genen die de bilirubineconcentratie 
beïnvloeden. Bilirubine lijkt op basis van deze studies dus te beschermen 
tegen het optreden van T2DM. Verrassend genoeg lijken sommige 
Mendeliaanse randomisatiestudies naar de relatie met HVZ tégen een 
oorzakelijk verband te pleiten. Deze bevindingen zijn in tegenspraak met de 
resultaten van proefdierstudies en ons eigen onderzoek met atazanavir en 
zijn mogelijk het gevolg van onjuiste, maar - bij de toepassing van 
Mendeliaanse randomisatie - noodzakelijke aannames. Desalniettemin dient 
de afwezigheid van een oorzakelijk verband tussen bilirubineconcentraties en 
HVZ bij de mens op basis van deze uitkomsten uiteraard te worden 
overwogen. 
Naast bovenstaande overwegingen bespreek ik in de discussie ook de 
bevindingen van een onderzoeksgroep die ons atazanavir-model heeft 
overgenomen. In tegenstelling tot onze bevindingen zag deze groep bij 
patiënten met diabetes mellitus type 1 (T1DM) geen verbetering van 
vaatfunctie na een behandeling met atazanavir. Daarnaast zijn er enkele 
publicaties verschenen over studies met atazanavir bij HIV-positieve 
patiënten. Bij deze patienten werd de vaatfunctie gemeten nadat de 
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behandeling was gewijzigd in een schema met of zonder atazanavir. Ook deze 
studies vonden geen verschil in vaatfunctie met of zonder atazanavir. De 
discrepantie met onze bevindingen zou te maken kunnen hebben met de 
mate waarin de endotheelfunctie verstoord was voorafgaand aan de 
behandeling met atazanavir. Mogelijk was er bij de patienten met T1DM en 
HIV sprake van een relatief goede endotheelfunctie en was de meerwaarde 
van een hyperbilirubinemie door atazanavir om deze reden beperkt. 
Daarnaast mochten proefpersonen in onze experimenten niet roken en geen 
medicatie gebruiken die de endotheelfunctiemeting zou kunnen beïnvloeden, 
terwijl deze beperkingen niet golden voor de patiënten met T1DM en HIV. 
Al met al zijn de gunstige effecten van bilirubine in de mens ondanks 
positieve resultaten van proefdierstudies en ons eigen onderzoek nog niet 
onomstotelijk bewezen. Aanvullende, kleinschalige experimenten zijn 
allereerst nodig. Het effect van bilirubine op insulinegevoeligheid bij 
patienten met MetS of T2DM zou bijvoorbeeld met de clamp-test in ons 
atazanavirmodel kunnen worden onderzocht. Idealiter dienen er daarnaast 
alternatieve modellen voor een experimentele hyperbilirubinemie te worden 
ingezet om onze resultaten in het atazanavir-model te reproduceren en 
daarmee een mogelijk effect van atazanavir zelf uit te sluiten. Dat zou 
bijvoorbeeld kunnen met een studieopzet waarbij bilirubine parenteraal 
wordt toegediend. Tot slot kunnen in de toekomst wellicht moleculaire 
technieken worden ingezet om de activiteit van UGT1A1 en daarmee de 
uitscheiding van bilirubine te remmen. 
Samengevat is de ziektelast en sterfte door MetS en T2DM wereldwijd groot, 
waarbij de epidemie van overgewicht in de nabije toekomst zal leiden tot een 
verdere toename. De behandeling ter voorkoming van cardiovasculaire 
complicaties leidt momenteel slechts tot een halvering van het verhoogde 
risico. Dit proefschrift is onderdeel van de zoektocht naar nieuwe 
behandelmethoden, in het bijzonder naar de meerwaarde van HO-activiteit 
en bilirubine. Resultaten van onze eerste experimenten in de mens zijn 
bemoedigend, maar aanvullend onderzoek is nodig. 
  
 
 
Dankwoord  
192  
 
Het is af en dat werd tijd! Intensieve perioden van onderzoek wisselden zich 
af – maar vielen vaak ook samen – met nieuwe uitdagingen in de kliniek, een 
drietal verhuizingen en bovenal de gezellige drukte van een uitdijend gezin 
met inmiddels drie kinderen. Ik kijk terug op een hectische, maar bijzondere 
periode en ben op vele fronten dank verschuldigd. 
 
Promotoren en copromotor 
Prof. dr. P.A.B.M. Smits, prof. dr. F.G.M. Russel, dr. F.A.D.T.G. Wagener. 
Beste Paul, Frans en Frank, ik beschouw het als een voorrecht om door 
jullie drieën te zijn begeleid. Alledrie betrokken met ieder een eigen, 
onmisbare inbreng. Daardoor heb ik ruimte en vertrouwen ervaren om eigen 
keuzes te maken, kon ik moeiteloos de laatste hordes nemen en raakte ik op 
talloze momenten geïnfecteerd met broodnodig optimisme. 
 
Opleiders en leidinggevenden 
Dr. P.M. Netten, prof. dr. C. Kramers, prof. dr. J. de Graaf, prof. dr. J.A. 
Romijn, drs. W.E.M. Schouten, dr. F. Holleman en prof. dr. H.A.H. 
Kaasjager. 
Beste Paetrick, Jacqueline, Kees, Hans, Ineke, Frits en Karin, onder jullie 
leiding ontwikkelde ik me tot medisch specialist. Ik zie mijzelf nog zitten in 
de poli-kamer van Paetrick toen hij mij als co-assistent vroeg of ik internist 
wilde worden en eveneens toen hij mij jaren later als AIOS interne adviseerde 
om “het Groot” voortijdig te verlaten en de uitdagingen van de academie aan 
te gaan. Kees nam het stokje van hem over en wakkerde mijn latente 
enthousiasme voor de klinische farmacologie, de toxicologie en het onderwijs 
verder aan. Jacqueline dacht mee over mijn profiel en raadde me aan om de 
geboden kansen in het OLVG en AMC – buiten haar eigen regio – ten volle te 
benutten. Bij Ineke en Frits kreeg ik de gelegenheid om als eerste fellow de 
differentiatie acute geneeskunde mede vorm te geven. Hans inspireerde en 
maakte in de vele korte gesprekken van the sky the limit. Karin tot slot bood 
mij de unieke kans om als jonge klare mee te bouwen aan een nieuwe 
vakgroep en opleiding acute geneeskunde in het UMC Utrecht. 
193 
 
Partners in onderzoek 
Marielle Verstegen, Anja Rasing-Hoogveld, Karin Saini, Petra van den Broek, 
Ab Bilos, Bas Pennings, drs. Margot Pijnenburg, drs. Simone Timman, prof. 
dr. Martin den Heijer, prof. dr. David Burger, dr. Suzanne Holewijn, drs. 
Daan van Velzen, dr. Suzanne Heemskerk en vele anderen. 
Beste onderzoeksverpleegkundigen, analisten, studenten en mede-
auteurs, het is een cliché maar daarom niet minder waar: zonder jullie had 
dit boekje er niet gelegen…. 
 
Collega promovendi 
Dr. Bas Schouwenberg, dr. Stijn Wouters, dr. Annemarie Thijs, dr. Patrick 
Meijer, dr. Mirrin Dorresteijn en opnieuw vele anderen. 
Beste mede-promovendi, het is al weer enige tijd geleden dat we ons leven 
als promovendus vol successen en frustraties deelden onder routenummer 
149. Inmiddels allemaal uitgewaaierd en met mij als hekkensluiter bíjna 
allemaal gepromoveerd… Het wordt tijd voor een reünie. 
 
Paranimfen 
Lieve Meike, als tweelingzus vanaf het allereerste moment tot op de dag van 
vandaag aan mijn zijde. Verjaardagen, zwemdiploma’s, eindexamens; vele 
mijlpalen vierden we samen. Ben trots op je en blij dat je na jaren eindelijk 
weer ‘ns naast me staat. 
Beste Thomas, in meer dan twintig jaar vriendschap deelden we hilarische 
anekdotes en bespraken we talloze onderwerpen uit ons leven. Een 
terugkerend onderwerp valt vandaag af, het spreekt voor zich dat jij daarvan 
getuige bent. 
 
De ‘koude kant’ 
Lieve Joop en Corrie, afgaande op het gemiddelde dankwoord blijken 
grootouders essentieel voor het voltooien van een proefschrift. Zo ook bij mij. 
Veel dank voor jullie oprechte belangstelling, het frequente bijspringen 
Dankwoord
194 
 
tijdens de concertreizen van Suzanne en de vele kinderexcursies in de 
Drentse natuur. 
 
De bakermat 
Lieve pap en mam, ik prijs me gelukkig met mijn leven. Jullie 
betrokkenheid, onvoorwaardelijke vertrouwen en stimulans om uitdagingen 
zelfkritisch en open-minded aan te gaan hebben het fundament daarvoor 
gelegd. 
 
Het thuisfront 
Lieve Suzanne, velen hebben meegeleefd en ondersteund, maar niemand zo 
intens als jij. Wat een geluk om het leven met jou en de kinderen te kunnen 
delen. LUXUTLS 
  
 
 
List of publications  
196  
 
Isfordink CJ, Dekker D, Monkelbaan JF. Clinical value of serum lactate 
measurement in diagnosing acute mesenteric ischaemia. Neth J Med 76, 60-
64 (2018). 
Dekker D, Dorresteijn MJ, Welzen MEB, Timman S, Pickkers P, Burger DM, 
Smits P, Wagener FADTG, Russel FGM. Parenteral bilirubin in healthy 
volunteers: a reintroduction in translational research. Br J Clin Pharmacol 
84, 268-279 (2018). 
Boersma MN, Nugteren-van Lonkhuyzen JJ, van Maarseveen EM, Kaasjager 
HAH, van Riel AJHP, Dekker D. Intoxication with new psychoactive 
substances: drug unknown, but complications are still treatable. Ned 
Tijdschr Geneeskd 161, D1368 (2017). 
van der Have M, Dekker D, Theunissen EMJ, Snijders C, Kaasjager KAH. It 
is all about the form - adrenaline in anaphylaxis: intravenous or 
intramuscular administration? Ned Tijdschr Geneeskd 161, D1089 (2017). 
Dekker D, Dorresteijn MJ, Peters WH, Bilos A, Pennings SW, Wagener FA, 
Smits P. Vascular and metabolic effects of the haem oxygenase-1 inducer 
haem arginate in subjects with the metabolic syndrome: A translational 
cross-over study. Diab Vasc Dis Res 13, 41-8 (2016).  
de Witte LD, Dekker D, Veraart J, Kromkamp M, Kaasjager K, Vinkers CH. 
Aggression and restlessness following baclofen overdose: the narrow line 
between intoxication and withdrawal symptoms. Ned Tijdschr Geneeskd 160, 
A9604 (2016).  
Dorresteijn MJ, Paine A, Zilian E, Fenten MG, Frenzel E, Janciauskiene S, 
Figueiredo C, Eiz-Vesper B, Blasczyk R, Dekker D, Pennings B, Scharstuhl 
A, Smits P, Larmann J, Theilmeier G, van der Hoeven JG, Wagener FA, 
Pickkers P, Immenschuh S. Cell-type-specific downregulation of heme 
oxygenase-1 by lipopolysaccharide via Bach1 in primary human 
mononuclear cells. Free Radic Biol Med 78, 224-32 (2015). 
  
197 
 
Dekker D, Dorresteijn MJ, Pijnenburg M, Heemskerk S, Rasing-Hoogveld A, 
Burger DM, Wagener FA, Smits P. The bilirubin-increasing drug atazanavir 
improves endothelial function in patients with type 2 diabetes mellitus. 
Arterioscler Thromb Vasc Biol 31, 458-63 (2011).  
Wagener FA, Dekker D, Berden JH, Scharstuhl A, van der Vlag J. The role of 
reactive oxygen species in apoptosis of the diabetic kidney. Apoptosis 14, 
1451-8 (2009).  
Meijer P, Oyen WJ, Dekker D, van den Broek PH, Wouters CW, Boerman 
OC, Scheffer GJ, Smits P, Rongen GA. Rosuvastatin increases extracellular 
adenosine formation in humans in vivo: a new perspective on cardiovascular 
protection. Arterioscler Thromb Vasc Biol 29, 963-8 (2009). 
  
List of publications
  
 
 
Curriculum Vitae 
 
  
200  
 
  
201 
 
Douwe Dekker werd geboren op 29 maart 1978 te Amsterdam en groeide 
vanaf zijn vierde levensjaar op in Beilen. In 1996 behaalde hij zijn VWO-
diploma aan het Menso Alting College in Hoogeveen, waarna hij startte met 
de studie geneeskunde aan de Universiteit van Utrecht. In 2001 behaalde hij 
zijn doctoraaldiploma geneeskunde; in 2002 behaalde hij in afwachting van 
zijn co-schappen zijn propedeuse kunstgeschiedenis. Aansluitend op zijn 
artsexamen in 2004 werd hij aangenomen voor de opleiding interne 
geneeskunde in het Radboudumc te Nijmegen onder opleiderschap van prof. 
dr. J.W.M. van der Meer en later prof. dr. J. de Graaf. Van 2004 tot eind 
2006 werkte hij als AIOS interne geneeskunde in het Jeroen Bosch 
Ziekenhuis in ’s-Hertogenbosch (opleider: dr. P.M. Netten), daarna zette hij 
de opleiding voort in het Radboudumc (opleider: prof. dr. J. de Graaf). Hij 
onderbrak daarbij de opleiding voor onderzoek dat uiteindelijk geresulteerd 
heeft in dit proefschrift. Daarnaast verdiepte hij zich binnen de opleiding tot 
internist in de klinische farmacologie (opleider: prof. dr. C. Kramers). In 2011 
verhuisde hij naar Amsterdam om zich in het OLVG (opleider: drs. W.E.M. 
Schouten) en AMC (opleider: dr. F. Holleman) verder te ontwikkelen in de 
acute geneeskunde. Sinds de afronding van zijn specialisatie op 1 januari 
2014, werkt hij als internist acute geneeskunde – klinisch farmacoloog in het 
UMC Utrecht. 
 
Douwe is getrouwd met Suzanne Verburg en heeft samen met haar drie 
kinderen: Biene (2011), Eeke (2013) en Gosse (2016).      
Curriculum Vitae

